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The mammalian lung supports the transport and diffusion of inspired and expired gasses that are 
critical for aerobic life.   With every inspiration the lung is exposed to environmental agents 
including microbes, virus, and environmental pollutants.  In the event that injury occurs the 
epithelium is repaired by an abundant facultative progenitor pool and a sequestered population of 
adult tissue stem cells.  Chronic lung diseases, such as asthma, chronic obstructive pulmonary 
disease, and bronchopulmonary dysplasia, are characterized by extensive epithelial remodeling 
resulting in a reduction to the number of non-ciliated bronchiolar Clara cells.  Given the 
established role for Clara cells as abundant facultative progenitors, these data suggest that 
epithelial repair has been compromised.  In addition to affects on the epithelium, these diseases 
are also accompanied by extensive subepithelial fibroproliferation, mesenchymal remodeling, 
and elevated extracellular matrix deposition as well as a profound increase to lung inflammation.  
It has been postulated, but never tested in vivo that mesenchymal remodeling and uncontrolled 
deposition of extracellular matrix may be a result of impaired airway epithelial reparative 
capacity.  Moreover, the finding that airway epithelial cells are essential for modulation of innate 
immunity suggests that the enhanced inflammatory response described in chronic lung disease 
may be a result of attenuated airway epithelial cell function.  Therefore, this dissertation tests the 
hypothesis that airway epithelial reparative capacity moderates extracellular matrix deposition 
and innate immunity.  Through the use of in vivo models of injury, inflammation, and attenuated 
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Clara cell function, this dissertation research work identifies a previously uncharacterized 
process in which extracellular matrix is dynamically and reversibly regulated during productive 
epithelial repair and severely disrupted by blocking stem cell mediated repair.   In addition, the 
use of mouse models of decreased Clara cell abundance and secretion demonstrate airway 
epithelium modulates pulmonary innate immunity through regulation of macrophage behavior 
and inhibition of pulmonary inflammation.  This work defines two phenotypes that are the result 
of attenuated epithelial repair and supports the paradigm that epithelial reparative capacity may 
be a principal determinant of lung disease. 
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1.0  INTRODUCTION 
The conducting airway epithelium is a critical component of the mammalian lung, which 
provides a primary barrier between host and environment and facilitates transport of inhaled and 
exhaled gas into and out of the lung.  Recent reports have also highlighted the immunoregulatory 
properties of the airway epithelium.  Therefore, the persistent environmental challenges to the 
conducting airway epithelium pose a significant threat to epithelial function and homeostasis.  
Therefore, it is critical to maintain the structure and function of the airway epithelium.  As such, 
the conducting airway epithelium maintains tremendous reparative capacity through utilization 
of a unique progenitor cell hierarchy.  In the setting of chronic lung disease (CLD), there is 
significant remodeling of the epithelium and underlying mesenchyme leading to attenuated 
epithelial function and aberrant extracellular matrix (ECM) accumulation.  It has been postulated 
that inhibition of epithelial repair through altered progenitor cell behavior may play a critical role 
in initiation or progression of CLD, however, this paradigm has never been tested directly in 
vivo.  Understanding the role that airway epithelial repair may play in the development or 
exacerbation of lung disease will be critical for the development of cell and molecular therapy.  
Therefore, this dissertation deals principally with the fundamental paradigm that epithelial 
reparative capacity moderates ECM dynamics and innate immunity.  However, before this 
paradigm is discussed further, a more thorough review of the relevant literature is warranted. 
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Chapter 2.0 of this dissertation will provide an in depth and focused review of the 
conducting airway epithelium to convey the necessary background information to the reader and 
highlight significant knowledge gaps in the field.  The unique structure and function of the 
epithelium lining the conducting airways, cellular and molecular strategies for repair, and how 
progenitor cell utilization may be altered in the setting of lung disease will be discussed.  At the 
conclusion of the chapter, a rationale for the experiments supportive of this dissertation will be 
formally presented (Figure 5).  Chapter 3.0 will provide experimental insight into roles for the 
epithelium in controlling ECM accumulation.  Specifically, the hypothesis that epithelial 
reparative capacity regulates ECM dynamics is tested.  As discussed above, epithelial function is 
also thought to be attenuated in the setting of CLD.  Chapter 4.0 will focus on elucidating a 
mechanism by which the epithelium may moderate innate immunity.  A mouse model of CLD, in 
which epithelial function has been attenuated, is used to test the hypothesis that Clara cells 
moderate the inflammatory response through regulation of macrophage behavior.  In chapter 5.0, 
the implications of this dissertation will be discussed further, future directions outlined, and 
ongoing work presented. 
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1.1 NOTE TO THE READER 
Figures and figure legends referred to in the text are included immediately following their 
description in the text.  Supplementary materials from chapter 3.0 and 4.0 are included in 
Appendix A and B, respectively.  Appendix C includes publications that are the result of this 
dissertation work.  Appendix D is a list of abbreviated terms. 
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2.0  THE CONDUCTING AIRWAY EPITHELIUM:  STRUCTURE, FUNCTION, 
MAINTENANCE, AND CONTRIBUTION TO DISEASE1 
2.1 INTRODUCTION 
Epithelial branching during the process of lung development establishes distinct functional 
zones, each of which are characterized by a unique cellular composition and repertoire of local 
progenitor cells.  Instrumental to lung homeostasis are the myriad of functions that the airway 
epithelium provide, including host defense and immunoregulation.  Therefore, an essential 
component of lung homeostasis is maintenance of the differentiated properties of the airway 
epithelium at steady-state and restoration following injury.  Significant new insights into cellular 
and molecular mechanisms of epithelial maintenance have been made in recent years that 
provide insights into the pathophysiology of lung disease.  This chapter focuses on the complex 
structure-function relationship in the airway epithelium as it relates to host defense and 
immunoregulatory roles of the airway epithelium.  A detailed review of the cellular mechanisms 
that are utilized to maintain the airway at steady-state and repair following injury is also 
included.  Deregulation of this process may contribute to airway disease including perturbations 
to epithelial function and mesenchymal remodeling.  At the conclusion of the chapter a brief 
section outlining the experimental rationale that is designed to test this concept is included and is 
the basis for this dissertation research project. 
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2.2 LUNG STRUCTURE 
The conducting airway epithelium is a dynamic structure that is essential for delivery of inhaled 
gases to the distal alveolar epithelium where gas exchange takes place.  In order to supply 
sufficient oxygen rich gas to the alveolus, the conducting airway epithelium is highly branched 
with an abundant number of small airways lined by bronchiolar epithelium.  The branching 
pattern becomes increasing complex near the distal alveolar epithelium.  The terminal 
bronchioles in larger mammalian species branch further into respiratory bronchioles, which in 
turn branch into alveolar ducts, and terminate in the alveolus.  One terminal bronchiole alone can 
give rise to 14 respiratory bronchioles, from which 1,500 alveolar ducts can branch, terminating 
in approximately 4,500 alveolar sacs, with 20,000 alveoli2.  The complexity is especially evident 
when considering that that there are on average 38, 883 terminal bronchioles in the upper right 
lobe of human lung alone3.  In addition, with each successive branch airway diameter continues 
to decrease.  The diameter of the trachea is approximately 16mm while diameters of terminal and 
respiratory bronchioles are almost two orders of magnitude smaller, 0.6 and 0.4 mm in diameter, 
respectively.  Equally important functions of the epithelium are regulation of host defense and 
intrinsic reparative capacity following microbial or xenobiotic initiated tissue damage.  To 
accomplish these dynamic functions the epithelium of the mammalian lung is compartmentally 
organized along the proximal to distal axis, distinct regions of which are defined by their unique 
cellular composition4.  The normal human tracheal and bronchial epithelium is a pseudostratified 
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epithelium predominantly comprised of basal, ciliated, goblet, and serous cells.  More distal 
within intrapulmonary conducting airways is a simplified columnar epithelium defining the 
bronchiolar airway epithelium.  The bronchiolar epithelium of humans is comprised of ciliated 
cells, nonciliated secretory Clara cells, relatively few basal cells, and devoid of goblet cells5-7.  
Conducting airways of the human lung terminate in a transitional zone of respiratory epithelium 
referred to as the respiratory bronchiole.  Respiratory bronchioles include conducting portions 
lined by cuboidal bronchiolar epithelium that branch from the terminal bronchioles, comprised of 
Clara and ciliated cells in addition to frequent alveoli that bud from the airway wall2,7. 
 
Despite functional conservation of epithelial compartments between species, their relative 
size and cellular composition varies.  The most dramatic anatomical difference between species 
is evidenced by the number of intrapulmonary conducting airway branches and the relative 
abundance of bronchial versus bronchiolar epithelium.  Multiple generations of intrapulmonary 
bronchi observed in humans and non-human primates are limited to one or two generations in 
mice, in which bronchioles predominate8.  Moreover, bronchioles in mouse airways transition 
directly into alveolar ducts implying the transitional respiratory bronchiolar zone typical of larger 
mammalian species is severely attenuated or altogether absent9,10.  Corresponding differences are 
observed in cell types lining airways of the mouse lung.  Basal cells are restricted to the tracheal 
epithelium while ciliated cell abundance diminishes significantly along the proximal to distal 
axis and Clara cells become particularly abundant within bronchiolar airways11.  Cell types of the 
alveolar epithelium show minimal differences between species12.  A schematic depicting the 
overall structure of the conducting airway and alveolar epithelium of mouse is presented in 
Figure 1. 
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The complex anatomical organization of these cellular components is regulated by a 
highly coordinated and stereotypic developmental program, as assessed by interrogation of 
mouse models.  Lung development initiates following fate specification within the ventral 
foregut endoderm and can be defined by NKX2.1 expression13.  Recent data indicate that 
branching occurs through a combination of three geometric branch types in a combination with 3 
stereotypical series. The timing and order of these branching modes are genetically regulated14.  
Regulation of cell proliferation and fate are tightly linked to this process, as signaling 
perturbations impacting these processes lead to a variety of defects in lung branching and 
specification of epithelial lineages13,15,16.  These signaling events involve reciprocal interactions 
between epithelial and mesenchymal cell types resulting in coordinated growth and 
differentiation17-19.  In particular, WNT/CATNNB1 signaling has been shown to be a critical 
mediator of proximal to distal patterning of the lung epithelium during embryonic 
development20-22.  Even though far less is known of signaling axes that contribute to epithelial 
behavior in the adult lung, it is clear that the epithelial-mesenchymal signaling axis is retained 
and its regulation critical to tissue homeostasis23,24. 
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Figure 1. Cellular composition and function of the airway epithelium. 
The epithelium lining mammalian airways is compartmentalized along the proximal to distal axis into four 
distinct zones, which can be further subdivided based upon cellular composition, structure, and function.  The 
schematic represents changes in cellular composition and function according to airway location in the mouse lung 
(proximal to the left, distal to the right).  The pseudostratified tracheobronchial epithelium is characterized by an 
abundance of ciliated and basal cells and a lower incidence of non-mucus secretory cells. Secretory cells in proximal 
airways of larger mammalian species tend to be of more varied phenotype and include serous and goblet cells.  
Basal cells are less abundant within mouse bronchial airways relative to bronchi of larger mammalian species. The 
epithelium of bronchi is largely composed of columnar ciliated and secretory cells.  Secretory cells of both tracheal 
and bronchial airways in mice share some molecular properties of bronchiolar Clara cells, but differ in their 
mechanism of replacement and responsiveness to airway inflammation.  Bronchiolar airways are the most distal 
conducting airway and are composed of ciliated cells and Clara cells.  Other cell types of the conducting airway  
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Figure 1 Continued.   
include rare pulmonary neuroendocrine cells that when organized into clusters are commonly referred to as 
neuroepithelial bodies (NEB’s) and are often located at or near airway branchpoints.  The conducting airway 
epithelium of the rodent lung terminates abruptly at the bronchoalveolar duct junction where airways open into 
alveolar ducts and clusters of alveoli composed of squamated Type I (AT1) cells and cuboidal type II cells (AT2).  
AT1 cells have a greatly attenuated structure and are essential for gas transfer25 while AT2 cells produce surfactants 
essential for regulation of lung compliance and innate immunity26.  Larger mammalian species have a transitional 
respiratory bronchiole that includes bronchiolar epithelium with frequent alveolar buds that protrude from the 
bronchiolar wall (not shown).  Epithelial compartmentalization plays a vital role in protecting the lung from 
microbial infection and inhaled pollutants through two major mechanisms:  (1)  Particles and microbes adsorbed to 
the viscous mucus layer are cleared through concerted ciliary beating within the subtending periciliary layer (PCL), 
resulting in effective clearance with minimal need for an immunologic response.  This process is referred to as 
mucociliary clearance.  (2)  If mucociliary clearance is overwhelmed or evaded, both innate and adaptive arms of the 
host immune response are activated.  Recent work has demonstrated the importance of epithelial and macrophage 
cross-talk in innate immunity27,28. 
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2.3 EPITHELIAL FUNCTION:  MUCOCILIARY CLEARANCE AND 
IMMUNOREGULATION 
2.3.1 Mucociliary Clearance 
The complex cellular composition of the airway epithelium provides key defensive properties for 
the lung (Figure 1).  As reviewed extensively by Knowles and Boucher29, the first line of defense 
to inhaled particulates, oxidants, and biological flora is the airway surface fluid (ASF).  The ASF 
is comprised of the mucus layer, of which the predominant protein components are MUC5AC 
and MUC5AB, and a subtending periciliary liquid layer (PCL) that provides an unrestricted 
media for ciliary beating and effective mucus transport.  Inhaled micro-organisms and 
environmental stimuli are immediately ensnared in the dense mucus of the ASF preventing 
further entry to the more susceptible distal conducting and alveolar compartments.  Through 
precise regulation of PCL height, ciliated cells coordinately regulate mucociliary clearance.  
Effective mucociliary clearance is estimated to take six hours, implying that this mechanism 
alone is not enough to protect from infection29.  As such, the ASF also includes several anti-
microbial proteins that inhibit bacterial proliferation to allow for effective removal through 
mucociliary clearance without infection thus minimizing the need for a massive inflammatory 
response30.  Defects to mucociliary clearance can have devastating effects, as is the case in cystic 
fibrosis (CF).  In CF, mutations to the chloride channel CFTR, most notably a deletion of 
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phenylalanine 50831, result in impaired chloride transport and electrolytic and fluid imbalance.  
This results in decreased viscosity of the PCL, reduced ciliary beating, and decreased 
mucociliary clearance, ultimately leading to chronic infection, mucus plugging, and lung 
disease32. 
2.3.2 Immunoregulatory Properties of the Lung Epithelium 
An abundance of literature exists investigating the role of the hematopoietic derived 
resident lung macrophage in regulation of the inflammatory response.  In an elegant study, Koay 
and colleagues demonstrated the critical role that resident lung macrophages play in lung 
inflammation.  The resident lung macrophage population was ablated through intratracheal 
instillation of clodronate liposomes.  This resulted in a blunted response to LPS as measured by 
neutrophil recruitment to the lung, TNF-α production, and NF-kB activity in the lung33.  In 
addition to elucidating the role for macrophages in LPS elicited inflammation, this study also 
implicated the lung epithelium as a downstream target of the macrophage. 
To formally test the immunoregulatory properties of the lung epithelium several methods 
have been utilized, including sophisticated transgenic manipulation of various components of the 
NF-kB signaling cascade as well as chemically compromising epithelial function.  A critical 
regulator or NF-kB signaling is the IkB complex which binds to NF-kB thus inhibiting the 
pathway by preventing NF-kB translocation into the nucleus.  Upon activation of TLR4 signaling 
by LPS, IkB proteins, specifically IkBα are targeted for proteosomal degradation through 
phosphorylation at Ser32/36 by IkB kinases (IKK1 and IKK2) allowing for NF-kB translocation 
into the nucleus and transcription of target genes34.  The first study to look at the role for lung 
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epithelial cells focused on the alveolar epithelium.  In this study, a dominant negative form of 
IkBα, which is resistant to degradation due to alanine substitutions at Ser32/36 and therefore 
inhibits Nf-KB signal transduction, was constitutively expressed in alveolar type 2 cells under 
the regulation of the SPC promoter.  These mice displayed a blunted response to LPS induced 
inflammation in the lung as measured by a reduction in nuclear NF-kB, recruited PMNs, total 
inflammatory cells, and the production of the CXC chemokine KC.35  A more recent study 
suggests that the airway epithelium participates in regulating the inflammatory response.  In this 
study, adenoviruses expressing either a dominant negative IkBα or a RelA (p65) subunit of Nf-
KB were instilled intratracheally in mice expressing an NF-kB reporter and exposed to LPS.  
Mice instilled with virus expressing dominant negative IkBα or RelA inhibited and potentiated 
lung inflammation, respectively, as measured by NF-kB reporter activity in the airway 
epithelium and chemokine/cytokine production36.  Evidence that the principal airway epithelial 
component of the inflammatory response, came from a study in which constitutively active 
IkBkinase 2 (IKK2) or dominant negative IkBα were placed under doxycycline regulated 
expression in Clara cells.  This study demonstrated that constitutive NF-kB signaling in Clara 
cells promotes lung inflammation.  In contrast, inhibition of NF-kB signaling in Clara cells can 
revert the action of constitutive IKK2 activity and markedly inhibit LPS induced inflammation.37  
Additional work has highlighted the importance of Clara cells by selectively injuring this 
population through administration of naphthalene (for a mechanism of action please refer to 
section 2.5.2).  This study indicated that transient ablation of Clara cells inhibit the inflammatory 
response to LPS27.  Additional work has suggested that the Clara cell and macrophage signaling 
axis is critical for the response to LPS as measured by production of epithelial and macrophage 
specific chemokines and cytokines.   This process is initiated by secretion of paracrine signaling 
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molecules from macrophages, such as TNF-α, that target the airway epithelium as an 
intermediate signaling cell type required for production of neutrophilic chemotactic factors28.  
Collectively, these results indicate that the distal airway and respiratory epithelial cells play a 
prominent role in providing important immunoregulatory properties essential for the regulation 
of innate immunity (Figure 1).  Despite these studies very little is known regarding possible 
signaling molecules secreted by Clara cells that may regulate macrophage cross-talk. 
2.3.3 Clara cell secretory protein (CCSP) 
Among the many functions of Clara cells, the most prominent is secretion.  The principal 
secreted protein product of the Clara cell38,39 and founding member of the secretoglobin class of 
proteins, Clara cell secretory protein (CCSP, Scgb1a1), is the predominant protein product of 
ASF whose expression precipitously declines in chronic lung disease40-44.  These data suggest 
that epithelial secretion has been compromised as a result of the epithelial remodeling and Clara 
cell injury in the setting of CLD.  CCSP is a 16 kDa homodimer with a small internal 
hydrophobic binding pocket that binds to progesterone45, metabolites of PCB46, calcium47,48, and 
phospholipids49.  Previous studies suggested that CCSP may directly regulate phopholipase A2 
activity, however, it is now known that this is through an indirect mechanism in which CCSP 
sequesters Calcium through chelation at Asp48.48  To study the effects of CCSP deficiency on 
lung function, mice homozygous null for CCSP (CCSP-/-) were generated that differ in their 
ability to modulate fibronectin deposition46,50,51.  Exposure of CCSP-/- mice to pulmonary 
irritants, pollutants, and microbes has revealed that Clara cell secretions can moderate 
immunoregulatory aspects of the airway epithelium52-59.  Few studies have demonstrated a robust 
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steady-state phenotype in CCSP-/- mice, despite their altered gene expression profile which 
include increased expression of other secretoglobins (Scgb3a1 and Scgb3a2).56,60   
However, recent work has highlighted the potential for Clara cell modulation of 
macrophage behavior, as naïve CCSP-/- mice display alterations to the macrophage proteome 
compared to wild-type (WT).  Specifically, CCSP deficiency causes an undefined post-
translational modification to AnnexinA1 (ANXA1) resulting in a shift to a more acidic isoform 
as identified by two dimensional difference gel electrophoresis (2D-DIGE61) and peptide 
identification using MALDI-TOF mass spectroscopy62.  This raises the interesting possibility 
that Clara cells may regulate macrophage behavior through a CCSP dependent mechanism.  It 
remains to be determined how CCSP deficiency and attenuated Clara cell function impacts the 
functionality or behavior of lung macrophages and innate immunity.  Therefore this dissertation 
work will seek to assess the direct link between altered Clara cell secretory function and 
macrophage behavior. 
Contrary to initial assumptions, recent work has revealed that the airway epithelium is 
more than an inert barrier to inhaled microbiological flora.  Rather, through precise 
differentiation of cell types organized within distinct functional zones, relative to anatomical 
location, the epithelium plays an active role in host defense.  Collectively, these data indicate that 
airway epithelial specification, effective repair, and maintenance are critical for lung 
homeostasis.  Defects to these processes or significant epithelial remodeling may contribute to 
CLD through altered epithelial function and perturbations to the host defense properties of the 
lung.  The remainder of the chapter reviews the cellular and molecular mechanisms involved in 
epithelial maintenance that are essential for establishing the differentiated properties of the 
epithelium.  An emphasis will be placed on defining the putative stem cell hierarchies 
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endogenous to the conducting airway epithelium, their molecular regulators, and evaluate their 
contribution to lung disease.  Before these issues can be discussed in depth, a brief introduction 
into the classification of a stem cell hierarchy is warranted.  
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2.4 DEFINING A LUNG STEM CELL HIERARCHY 
Identification of the hierarchical organization of progenitor cells into what is commonly referred 
to as a stem cell hierarchy has classically been described in tissues that display a high rate of 
cellular turnover such as the small intestine and skin.  Specifically, the intestinal epithelium, as a 
result of persistent epithelial damage, is in a constant state of regeneration resulting in cellular 
turnover of approximately 5 days63.  Tissue stem cells of this hierarchy have been defined using 
functional assays that interrogate proliferative frequency, self-renewal, and differentiation 
potential.64  Small numbers of intestinal stem cells are thought to reside at or near the base of the 
intestinal crypt and give rise to a more abundant population of highly proliferative transit-
amplifying cells located more proximally within the crypt65,66.  Transit-amplifying cells of the 
intestinal epithelium represent an obligate progenitor cell pool lacking differentiated 
characteristics and are committed to a high rate of proliferation necessary for generation of 
differentiating progeny67.  A model depicting a classical stem cell hierarchy is presented in 
Figure 2. This strategy for rapid tissue replacement is shared by the skin, in which an obligate 
transit-amplifying progenitor cell that is both abundant and broadly distributed within the 
epidermis continuously generates differentiating progeny through a stochastic mode of cell fate 
determination68,69.  In the skin, resting tissue stem cells are maintained in a quiescent state and 
are only activated to proliferate in response to depletion of the transit-amplifying pool, through a 
process thought to be highly regulated by calcineruin, BMP, and NFATc170,71.  The relative  
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Figure 2.  Classical stem cell hierarchy (intestine and skin).  
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Figure 2 Continued. 
In rapidly renewing tissues such as the intestine, a classical stem cell hierarchy maintains epithelial 
heterogeneity and function.  As discussed in depth in the text, stem cells self-renew, (curved solid arrow), give rise 
to an obligate transit-amplifying cell population, and infrequently proliferate.  The obligate transit-amplifying cell 
does not fulfill functions of differentiated cells but instead divides frequently giving rise to terminally differentiated 
post-mitotic cells.  Obligate transit-amplifying cells have limited self-renewal capacity (broken curved arrow) and as 
such are short lived in classical stem cell hierarchies like the gut. (proliferative frequency is depicted in color). 
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quiescence of tissue stem cells in comparison to their more abundant transit-amplifying progeny 
has become a controversial topic in recent studies investigating intestinal stem cells.  However, 
the property of DNA label retention remains a commonly used assay for the identification and 
localization of resident tissue stem cells64. 
The epithelium lining pulmonary airways turns over slowly during the normal process of 
tissue maintenance.  Methods used to calculate the rate of epithelial turnover rely on indirect 
approaches that are based upon measurements of cell proliferation and lineage tagging.  
Measurements of cell proliferation have principally relied upon stable incorporation of labeled 
DNA precursors such as bromodeoxyuridine (BrdU) or [H3]-thymidine into the DNA of cells 
traversing S-phase.  Using this approach, estimates of the steady state instantaneous proliferative 
fraction were determined to be 1.3% in tracheal epithelium72 and 0.06% in bronchiolar 
epithelium73.  Data generated from continuous labeling of the steady-state bronchiolar epithelium 
further demonstrated that the frequency of proliferation within this compartment was 1% per 
day74.  Assuming a direct relationship between the rate of epithelial cell loss and replacement, 
these data suggest that epithelial cells have an average life span of 100 days in bronchioles.  
Direct measurement of ciliated cell half life, as a measure of epithelial turnover, made by 
Rawlins and Hogan indicated that this subpopulation of epithelial cells has an estimated half-life 
of either 6 or 17 months in trachea and bronchioles, respectively75.  Estimates made using either 
approach indicate that the epithelium of the trachea turns over more rapidly than that of 
bronchioles.  While both methods are technically flawed, due to the inability to directly assess 
Clara cell turnover, these studies demonstrate that the frequency with which the airway 
epithelium turns over is similar to that described for the endocrine pancreas and other foregut 
derived tissues76 but differs significantly from the rapid rate of epithelial turnover observed in 
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tissues derived from hindgut endoderm, such as the small intestine64.  These data suggest that 
there are fundamental differences in the regulation of progenitor cells between slowly and 
rapidly renewing tissues77,78. 
Recent work has called into question the existence of stem cells in slowly renewing 
tissues79,80.  As indicated above, the lung epithelium is replaced far more slowly than either the 
gut or the epidermis, a property that is reflected in the functional characteristics of airway 
progenitor cells in resting versus proliferative states.  Therefore, it is not surprising that 
progenitor cell hierarchies of the lung and other slowly renewing tissues do not fit the classical 
stem cell hierarchies described in tissues of rapid turnover77.  In fact, Hu and colleagues, through 
use of in vivo injury models, have recently described the existence of a stem cell capable of 
renewing the endocrine pancreas, a tissue that until recently was thought to be maintained solely 
through self-duplication of differentiated β cells81.  This and previous work in lung to be 
discussed in more detail below, illustrate a deviation from the classical stem cell hierarchy 
marked by lack of an obligate transit-amplifying progenitor cell activity in the steady state.  
Rather, slowly renewing tissues such as lung are maintained at steady state by an abundant 
facultative transit-amplifying progenitor that fulfills characteristics of a differentiated cell type in 
the quiescent state, yet retains proliferative capacity and the ability to generate daughter cells 
capable of generating other specialized lineages.  Therefore, the endogenous stem cell at steady-
state likely remains quiescent.  A proposed model depicting the stem cell hierarchy in the 
conducting airway epithelium and its utilization at steady-state and following injury is presented 
in Figure 3. Studies utilizing in vivo injury models have revealed stem cells do exist in the adult 
lung and can be functionally distinguished from facultative progenitors based upon their 
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resistance to environmental stimuli and spatial localization in the conducting airway (Figure 4).  
These studies are highlighted in detail below. 
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Figure 3.  The stem cell hierarchy of the bronchiolar epithelium. 
Slowly renewing epithelial tissues like the lung are not maintained by a classical stem cell hierarchy at 
steady-state.  The proliferative index of the airway epithelium is low relative to rapidly renewing tissues like the  
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Figure 3 Continued. 
intestine.  (A)  It has been postulated that an abundant facultative transit-amplifying cell maintains the epithelium.  
Clara cells fulfill a variety of differentiated cell functions including secretion of immunoregulatory molecules.  
However, these cells are not post-mitotic.  Rather they have the ability to de-differentiate to a Type A Clara cell 
(facultative transit amplifying cell), proliferate, and differentiate to post-mitotic ciliated cells and differentiated 
Clara cells.  Unpublished observations (Giangreco A., Submitted) indicate that facultative transit amplifying cells 
self-renew (black curved arrow) and maintain cellular diversity of the epithelium at steady-state.  Therefore airway 
epithelial stem cells remain quiescent and do not contribute to steady-state epithelial maintenance.  (B)  However, 
using injury models (yellow lightning bolt) that selectively target the abundant facultative transit-amplifying cells 
and Clara cells, it has been shown that a stem cell population is sequestered to distinct microenvironments within the 
conducting airway epithelium.  This cell type proliferates rapidly following injury and quickly restores the cellular 
diversity of the conducting airway epithelium including the facultative transit amplifying cell.  (proliferative 
frequency is depicted in color). 
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Figure 4.  Progenitor cells of the conducting airway epithelium. 
Using in vivo and in vitro injury models the airway epithelium has demonstrated remarkable reparative 
capacity.  (A)  In the tracheobronchial epithelium, polydocanol or sulfur dioxide injury in mice has revealed the 
existence of a subpopulation of injury resistant label retaining basal cells capable of restoring each cell type of the 
proximal airway epithelium.  Retroviral lineage tracing has also been used to hierarchically organize human 
bronchial epithelial cells according to their clonogenic and differentiation potentials.  Progenitor cells of the 
bronchiolar epithelium include an abundant pool of Clara cells and naphthalene-resistant cells.  Both Clara cells and 
naphthalene resistant cells express CCSP yet only Clara cells are ablated following naphthalene exposure.   
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Figure 4 Continued. 
Naphthalene resistant CCSP expressing cells, termed variant CCSP expressing cells (vCE), localize to 
neuroepithelial bodies (NEB’s) within proximal bronchioles, the bronchoalveolar duct junction (BADJ) of terminal 
bronchioles, and are capable of replenishing the cellular diversity of the epithelium following injury.  Recent data 
have described a cell with similar properties to vCE cells that can be defined based upon their co-expression of 
CCSP and proSP-C.  This cell type has been referred to as a bronchoalveolar stem cell (BASC) based upon the 
ability of fractionated cells to express markers of airway and alveolar lineages in vitro.  The precise relationship 
between BASCs and vCE is not known.  Also depicted is dynamic regulation and turnover of ECM during injury 
and repair.  In other organs such as skin, this is a well known phenomenon that occurs during wound repair, 
however, it remains to be described in the context of airway epithelial repair.  (B)  Representation of cell fate for 
progenitor cell types represented in “A”.   
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2.5 PROGENITOR CELLS IN AIRWAY REPAIR 
2.5.1 Tracheobronchial Epithelium 
Studies investigating progenitor cells of the tracheobronchial epithelium have benefited from a 
combination of in vivo, in vitro, and cellular transplantation models to reveal contributions made 
by distinct cell types of the normal epithelium towards maintenance and renewal.  In vivo models 
have used a variety of agents to injure the epithelium including detergents such as polydocanol,72 
toxic gases such as ozone82, nitrogen dioxide82,83 or sulfur dioxide72 parenterally administered 
toxicants such as naphthalene84, and mechanical wounding of the epithelium85. Using these 
models both basal and nonciliated secretory cells have been shown to exhibit progenitor 
potential.  In this context, the term progenitor cell refers to any proliferative cell defined by 
stable incorporation of [H3]-thymidine or BrdU into its nuclear DNA.  Cell fractionation and 
retroviral lineage tracing coupled with functional analysis in reconstituted tracheal grafts has 
allowed detailed analysis of the differentiation potential and clonogenic capacity of these 
progenitor cells in both mouse and human epithelia. These approaches have revealed 
subpopulations of tracheobronchial basal cells that can be distinguished according to their label 
retention, differentiation potential, clonogenic capacity, and the ability to efflux Hoechst 33342 
dye (termed side population cells)72,86-88.  Recently, related experiments using more sophisticated 
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in vivo lineage tagging approaches have confirmed results from xenograft experiments and 
indicate that a subpopulation of cytokeratin 14 expressing cells exhibit both multipotent 
differentiation potential and significant clonogenic capacity89,90.  Collectively these data reveal a 
number of progenitor cell types that contribute to maintenance and repair of the tracheobronchial 
epithelium, some of which exhibit significant clonogenic potential in vitro or in tracheal grafts 
and is suggestive of the existence of local tissue stem cells in adult proximal airways. 
The observation of a less abundant population of infrequently cycling basal cells within 
intercartilagenous regions of the tracheal epithelium and the ducts of submucosal glands 
provided the first direct evidence suggesting the existence of stem cells within tracheobronchial 
airways.   These cells were found to express high levels of cytokeratin 5 and when isolated were 
greatly enriched for in vitro clone-forming cells.  Among the clone forming cells approximately 
5% had the capacity to generate large clones analogous to highly clonogenic cells observed in 
vivo and in transplantation experiments91.  These findings reinforce the concept that basal cells 
are a heterogeneous population that includes abundant transit-amplifying populations in addition 
to a rare subset of cells with properties of resident tissue stem cells which include label retention, 
localization to a defined microenvironment, and clonogenic potential (Figure 4). 
2.5.2 Bronchiolar Epithelium 
Cell type selective toxicants have been used extensively to reveal progenitor cell types 
contributing to epithelial repair.  Seminal work by Evans and colleagues used oxidant gases to 
selectively injure ciliated cells and show that airway epithelium is repaired through a non-ciliated 
progenitor82.  They went on to demonstrate that proliferating Clara cells lose ultrastructural 
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features typical of the quiescent state, giving rise to a cell type that was termed the type A Clara 
cell.  Based upon this analysis, type A Clara cells were distinguished from their mature quiescent 
counterparts based upon lack of secretory granules and smooth endoplasmic reticulum, and their 
ability to incorporate labeled DNA precursors.  Type A cells contribute to repair by actively 
proliferating and differentiating into mature Clara cells and terminally differentiated ciliated 
cells.  These studies identified Clara cells as an abundant facultative transit-amplifying 
progenitor cell with the capacity for bipotential differentiation and suggested that the normally 
slow rate of epithelial renewal in the steady-state could be dramatically increased in the setting 
of airway injury83 (Figure 3A,B).  Clara cells are analogous to transit-amplifying cells of the gut 
and epidermis, yet have the important distinction of quiescence and other specialized functions in 
the steady-state including immunoregulation and xenobiotic metabolism, thus they are referred to 
as facultative transit amplifying cells rather than obligate transit amplifying cells.   
Experimental demonstration of an airway epithelial pool of putative tissue stem cells was 
made through use of injury models, in which the abundant facultative progenitor cell, the Clara 
cell, was specifically ablated.  Clara cells represent one of the principal sites in the lung at which 
endogenous and xenobiotic lipophilic compounds are metabolized through phase I oxidation 
reactions such as those catalyzed by cytochrome P450 (CyP450) monooxygenases.    This 
function of Clara cells renders them particularly susceptible to injury by xenobiotic chemicals 
that serve as substrates for members of this class of enzymes, and represents the basis for 
selective ablation of Clara cells in mice following exposure to naphthalene92-94.  Specifically, 
cytochrome p450 2F2 is expressed in Clara cells of the conducting airway epithelium and 
bioactivates naphthalene to a stereoselective and highly reactive 1R-2S-Napthalene oxide95.  The 
utilization of high doses of naphthalene overwhelms phase II metabolism, severely depletes 
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glutathione stores, and leads to cellular toxicity due to accumulation of highly reactive epoxides 
and quinones capable of forming protein aducts96.  Use of this injury model in mice allowed 
identification of two putative stem cell niches in bronchioles based upon the resistance to 
naphthalene induced injury and distribution of regenerating epithelial foci containing nascent 
Clara cells (Figure 4).  The first was located predominantly at airway branchpoints found in close 
proximity to neuroepithelial bodies (NEB)84.  NEB associated regenerative foci harbored two 
proliferative populations of nonciliated cells, one expressing Clara cell secretory protein (CCSP) 
and one expressing the pulmonary neuroendocrine cell (PNEC) specific marker, calcitonin gene 
related peptide (CGRP)73,97,98.  A second microenvironment contributing to replacement of 
depleted Clara cells was located in the terminal bronchiolar epithelium adjacent to the 
bronchoalveolar duct junction (BADJ)84.  Chemically resistant proliferative cells located at the 
BADJ express the secretory cell marker CCSP and unlike regenerative foci in more proximal 
airways, lack a restricted association with PNEC’s99.  
The critical role played by NEB and BADJ associated CCSP expressing cells in repair of 
Clara cell depleted airways was demonstrated using a transgenic mouse model allowing 
conditional ablation of naphthalene sensitive and resistant CCSP expressing cells.  In this model, 
airway repair was completely abrogated through directed expression of the suicide gene herpes 
simplex virus thymidine kinase (HSV-tk) in all CCSP expressing cells.  These data suggested 
that CGRP (+) PNECs are not the progenitors of the airway epithelium74.  These studies clearly 
identified up to two distinct populations of CCSP expressing cells that are sequestered within the 
bronchiole of normal adult mice.  Of these populations, rare NEB and BADJ associated CCSP 
expressing cells share the property of infrequent proliferation relative to their more differentiated 
Clara cell counterparts74,99.  Similarities between rare naphthalene resistant CCSP expressing 
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cells and tissue stem cells of other organs form the basis for their designation as a putative 
bronchiolar stem cell that is sometimes referred to as either the variant Clara cell (vClara) or 
variant CCSP expressing cell (vCE)74.  Further distinctions were made between bronchiolar stem 
and Clara cells based upon the observation of rare CCSP expressing cells that co-express the 
alveolar type 2 cell marker surfactant protein C (SP-C), that these cells were localized to the 
BADJ, and that they were resistant to naphthalene.  Cells with this molecular phenotype were 
observed in preparations of distal airway/alveolar epithelial cells and could be enriched from this 
crude cell preparation based upon their unique expression of stem cell antigen-1 (SCA-1) and 
CD34.  The observation that in vitro culture of these cells resulted in the expression of aquaporin 
5, a gene commonly associated with AT1 epithelial cells, led to the conclusion that they harbored 
the capacity for both bronchiolar and alveolar differentiation and formed the basis for their 
designation as bronchoalveolarstem cells (BASCs)100.  However, no in vivo data directly 
demonstrate that a BADJ associated CCSP expressing population has the capacity for 
bronchiolar and alveolar differentiation.  As such, the similarity between variant Clara cells and 
BASCs has not been established (Figure 4B).  Moreover, recent studies investigating the cell 
surface phenotype of epithelial cells from mouse conducting airways indicate that although cell 
surface SCA-1 allows for discrimination of conducting airway and alveolar epithelial cells, it 
does not distinguish the local stem cell population residing within distal bronchioles from the 
more abundant population of Clara cells101.  Collectively, these data indicate that the airway 
epithelium harbors a unique stem cell hierarchy that maintains the unique cellular heterogeneity 
required for normal physiological function.  How this progenitor cell hierarchy is deregulated in 
the setting of CLD has yet to be determined.  However, several hypotheses have been suggested 
and are presented in the following section. 
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2.6 ROLES FOR PROGENITOR CELLS IN CHRONIC LUNG DISEASE 
2.6.1 Chronic Lung Disease Pathology 
Chronic lung diseases (CLD), such as obliterative bronchiolitis (OB), chronic obstructive 
pulmonary disease (COPD), and asthma are characterized by remarkable epithelial and 
mesenchymal remodeling that includes but is not limited to:  chronic injury to the airway 
epithelium, decreased abundance of Clara cells, goblet cell hyperplasia, mucus cell metaplasia, 
subepithelial basement membrane thickening, fibrotic nodules causing stenosis of small airways, 
airway smooth muscle hypertrophy, and uncontrolled lymphocytic, neutrophilic, and monocytic 
inflammation102-105.  Accordingly, understanding the etiology and progression of CLD has been 
complicated due to the complex network of cellular cross-talk present in the lung.  Defective 
airway epithelial repair has been proposed as an early event in the initiation of CLD and chronic 
defects in reparative capacity and cellular composition may further contribute to disease 
progression and susceptibility to exacerbation106.  This implies that normal functions for 
facultative progenitor and stem cells are compromised.  Evidence suggesting that this may be the 
case comes from analysis of biomarkers of epithelial remodeling that have been used to follow 
severity and progression of lung disease.  Levels of CCSP in airway lining fluid or serum are 
uniformly reduced in the setting of chronic lung disease as discussed above, suggesting that 
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epithelial remodeling involves altered differentiation or cell death of this critical bronchiolar 
progenitor, as CCSP is a marker for Clara cells lining the conducting airway epithelium6,107.   
2.6.2 Chronic Injury and Defective Epithelial Repair 
Increasing evidence from studies in humans and animal models suggest that chronic 
injury and inflammation inhibits normal epithelial repair and differentiation leading to 
remodeling of the entire epithelial mesenchymal trophic unit (EMTU)105.  Chronic exposure to 
xenobiotic and biological flora has been postulated to play a causative role in the development 
and exacerbation of chronic lung disease.  As an example, cigarette smoke causes extensive 
airway epithelial injury, a robust inflammatory response in the lung, and is the principal 
epigenetic factor contributing to the development of chronic obstructive pulmonary disease108.  
Cigarette smoke can have a variety of detrimental effects on the lung including damage to the 
epithelial, mesenchymal, and endothelial compartments109.  This includes damage to Clara cells 
as indicated by decreased abundance of CCSP protein in asthmatic BAL and lung tissue 
sections110.  In vitro studies have demonstrated that cigarette smoke can severely blunt epithelial 
wound repair by decreasing the rate of cell proliferation, migration, and altering extracellular 
matrix remodeling111,112.  Paradoxically, in another study, in vitro models indicated that low 
levels of cigarette smoke condensate can significantly increase proliferative potential of 
epithelial cells113.  Together, these observations have been extended to in vivo model in which 
chronic cigarette smoke exposure in mice was shown to attenuate epithelial repair following 
naphthalene induced Clara cell injury114.  Epithelial cell injury and persistent inflammation that 
are both associated with cigarette smoking have also been demonstrated to blunt tissue repair in 
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models of epidermal wound healing115.  These studies indicate that proper epithelial repair can be 
severely altered by environmental challenge. 
2.6.3 Extracellular Matrix Deposition and Remodeling 
As discussed above (section 2.2.), the diameter of the conducting airways greatly 
attenuates along the proximal to distal axis.  Therefore, proper epithelial and mesenchymal 
structure is necessary to prevent occlusion of the airways and inhibition of gas transfer.  In fact, 
occlusion of the small airways is often a result of invasion of the airway lumen by fibrotic foci 
generated from aberrant ECM accumulation and fibro-proliferation, over-production of mucus, 
smooth muscle hypertrophy, and excessive cellular exudates 116,117.  Occlusion ultimately leads 
to compromised lung function through declining airflow into and out of the alveolus.  Therefore 
understanding mechanisms leading to uncontrolled epithelial and mesenchymal remodeling of 
the airway is essential for developing strategies for therapeutic intervention in chronic lung 
diseases. 
Mechanisms contributing to tissue remodeling involve changes in the abundance and 
activity of key matrix remodeling enzymes leading to excessive depletion of elastin118 and other 
structural matrix components critical for maintenance of tissue architecture.  However, tissue 
remodeling also includes fibroproliferative responses that lead to inappropriate deposition of 
matrix molecules.  Recent studies have indicated that the proteoglycan hyaluronon (HA), a 
normal component of basement membrane, deposited during epithelial injury and essential for 
restoration of lung homeostasis119.  In fact, recent work has shown that CD44 and TLR4/TL:R2 
are critical for clearance and signaling of HA fragments, respectively120,121.  Mice deficient for 
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CD44 are more susceptible to bleomycin induced lung injury as marked by increased mortality, 
inflammation, and deposition of HA in the lung120.  On the other hand deletion of TLR4 and 
TLR2 negatively impacts mortality rates following bleomycin induced lung injury, as HA can 
also promote epithelial survival121.  These studies demonstrate that ECM deposition following 
lung injury plays an instrumental role in repair.  However, if removal or degradation of this ECM 
protein is inhibited allowing for accumulation of this matrix protein, restoration of lung 
homeostasis is severely impaired.  Despite these studies, little is known regarding the cellular 
cross-talk between injured and repairing epithelium and the underlying mesenchyme.  It has been 
postulated that the epithelial mesenchymal trophic unit (EMTU) is essential for proper epithelial 
repair and that in the context of defective repair this may lead to aberrant and chronic 
mesenchymal remodeling that includes extensive fibroproliferation, ECM deposition, and 
development of fibrosis.  Further studies are warranted to determine the impact on ECM 
deposition and turnover during airway epithelial specific injury and repair, and how this process 
may be affected by inhibiting stem cell mediated repair. 
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2.7 MOLECULAR REGULATION OF THE STEM CELL HIERARCHY 
Defining the molecular regulators of the stem cell hierarchy is critical as defects to progenitor 
cell utilization may result in loss of epithelial cell function and mesenchymal remodeling.  
Currently, investigation into mechanisms regulating the airway stem cell hierarchy have focused 
predominantly on genetic manipulation of candidate signaling pathways and molecules with 
established roles as regulators of lung development or carcinogenesis.  These include canonical 
WNT signaling through stabilization of β-catenin (CATNNB1) in addition to signaling through 
MAP kinase, KRAS, PTEN, GATA-6, and BMI1.  These studies have typically relied upon 
knock-out, ectopic expression strategies, or the use of conditional gene manipulation approaches, 
that lead to altered expression of key regulatory molecules.  Ectopic activation of CATNNB1, 
KRAS signaling, or developmental loss of either GATA-6, PTEN, PI3 kinase and p38α MAP 
kinase, have all been found to result in increases in the abundance of CCSP/Pro-SPC dual 
immuno-positive cells that are believed to represent bronchiolar stem cells23,100,122-127.  Changes 
in the pool size of bronchiolar progenitor cells have been investigated in many of these models 
through analysis of the cell surface phenotype described by Kim and co-workers, including SCA-
1positive/CD34positive cells within the CD45negative/CD31negative viable fraction of dissociated lung 
cells100.  However, even though changes in these signaling pathways result in the expansion of 
putative stem cells based upon the use of these markers, the absence of a comprehensive 
molecular phenotype for bronchiolar stem cells that distinguishes them from other airway 
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progenitor cell types suggests that the impact of altered signaling on stem cells per se can not 
easily be determined.  In this context, functional changes in epithelial repair capacity involving 
use of injury models that are known to result in activation of putative stem cells has the potential 
to provide a more direct means to interrogate changes in progenitor function.  For instance, 
activation of CATNNB1 signaling within the bronchiolar epithelium of the late embryonic 
mouse lung results in an increase in the abundance of naphthalene resistant bronchiolar cells, 
expansion of a Sca-1positive/CD34negative fraction of airway epithelial cells that co-expressed CCSP 
and Pro-SPC, and reduced autofluorescent character of fractionated epithelium, a property 
representative stem cells101.  However, the lack of identified signaling pathways that regulate 
airway epithelial repair continues to prevent more sophisticated analysis of the molecular 
regulation of stem cell mediated repair and therefore warrants a more global and unbiased 
description of the molecular signature of airway epithelial repair.   
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2.8 RATIONALE 
There are only a handful of studies describing the basic mechanisms of airway epithelial 
repair.  The signaling pathways between the epithelium and underlying mesenchyme following 
injury remain equally enigmatic.  The few studies interrogating these mechanisms have focused 
on ex vivo and in vitro model systems calling into question their relevance to the complexity of 
the in vivo environment.  This warrants an unbiased approach to identify novel in vivo molecular 
regulators of airway epithelial repair.  The basic behavior of progenitor cells, their molecular 
regulators, and how each is impacted by disease would provide novel insights into disease 
pathogenesis and reveal new therapeutic targets that may allow modification of disease outcome.  
Furthermore, understanding the effects of abrogating epithelial repair on modulation of the 
EMTU and epithelial function will be equally important, especially as it relates to the initiation 
and progression of CLD.  Therefore, this dissertation work seeks to test the hypothesis that 
Epithelial reparative capacity moderates ECM dynamics and innate immunity (Figure 5).   
The existence of endogenous lung epithelial stem cells remains a controversial issue.  To 
facilitate a more thorough understanding of progenitor cell behavior and the putative stem cell 
hierarchy will require development of novel endpoints to answer the fundamental questions 
outlined above.  Moreover identification of molecular regulators of this hierarchy and how 
alterations to the hierarchy may perturb epithelial and mesenchymal function will be equally 
important.  The studies presented in this dissertation work will bring the scientific community 
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one step closer to the development of cellular and molecular strategies for therapeutic treatment 
of lung disease. 
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Figure 5.  Dissertation research rationale. 
 (1) A significant paradigm that has emerged suggests that airway epithelial repair is essential for 
maintenance of ECM dynamics in the lung.  This implies that the aberrant and excessive accumulation of ECM in 
chronic lung disease may be a result of attenuated epithelial reparative capacity.  Though this is an appealing model, 
there is no in vivo data suggesting that ECM accumulates during conducting airway epithelial injury and repair, nor 
is there evidence to suggest that blocking repair results in uncontrolled ECM deposition.  In chapter 2  this paradigm 
is tested using in vivo models of productive and abortive airway epithelial repair.  (2)  As described in the text and 
presented in Figure 1, the airway epithelium plays an important role in host defense.  Recent work has demonstrated 
that significant cross-talk occurs between Clara cells and resident lung macrophages which directly regulates the 
inflammatory response.  Therefore elucidating the factors secreted by Clara cells will provide significant insight into 
mechanisms regulating host defense.  In addition, the significant remodeling of the airway epithelium observed in 
CLD suggests that epithelial function has been altered (broken arrows).  However, the signaling pathways that have 
been perturbed have yet to be identified.  In chapter 4, using in vivo models of epithelial injury, decreased Clara cell  
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Figure 5 Continued. 
function (note the lack of secretory granules in Clara cells), and inflammation, the hypothesis that Clara cells 
moderate the inflammatory response through regulation of macrophage behavior is tested. 
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3.0  THE REPARATIVE CAPACITY OF AIRWAY EPITHELIUM IMPACTS 
DEPOSITION AND REMODELING OF EXTRACELLULAR MATRIX128. 
3.1 EXPERIMENTAL RATIONALE AND HIGHLIGHTED RESULTS 
Defective epithelial repair in the setting of chronic lung disease has been suggested to contribute 
to uncontrolled extracellular matrix deposition and development of fibrosis.  This hypothesis was 
tested through gene expression profiling of total lung RNA isolated from mouse models of 
selective epithelial cell injury that are associated with either productive or abortive repair.  
Analysis of gene expression in repairing lungs of naphthalene exposed mice revealed prominent 
clusters of up-regulated genes with putative roles in regulation of the extracellular matrix and 
cellular proliferation.  Further analysis of tenascin C, a representative matrix protein, in total 
lung RNA revealed a transient 4.5 fold increase in mRNA abundance 1 day following injury and 
a return to steady-state levels by recovery day 3.  Tenascin C was deposited in the 
peribronchiolar mesenchyme immediately following injury and was remodeled to basement 
membrane subtending the bronchiolar epithelium during epithelial repair.  Epithelial restitution 
was accompanied by a decrease in tenascin C mRNA and protein expression to steady-state 
levels.  In contrast, abortive repair using a transgenic model allowing ablation of all reparative 
cells led to a progressive increase in tenascin C mRNA within lung tissue and accumulation of its 
gene product within the sub-epithelial mesenchyme of both conducting airway and alveolar 
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epithelium.  These data demonstrate that the extracellular matrix is dynamically remodeled in 
response to selective epithelial cell injury and that this process is activated without resolution in 
the setting of defective airway epithelial repair. 
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3.2 INTRODUCTION 
The epithelial-mesenchymal trophic unit (EMTU) is a complex arrangement of epithelial cells, 
fibroblasts, smooth muscle, and extracellular matrix106.  Dynamic interactions between these 
components are critical for the process of lung development and continue into adulthood for 
regulation of normal tissue homeostasis and repair13,129.  Chronic lung injury leads to permanent 
alterations to both cellular and extracellular components of the EMTU that lead to permanent 
declines in lung function.  This is clearly seen in chronic lung diseases such as asthma and 
chronic obstructive pulmonary disease.  Pathological changes to lung tissue that are associated 
with these diseases include fibroproliferation, accumulation and remodeling of extracellular 
matrix components, and altered epithelial cell function which together lead to airway 
obstruction102,104,105.  However, the complexity of these interactions in the intact lung and the 
inability to effectively model these interactions in vitro, have led to difficulties in identifying 
critical factors that initiate the process of pathological tissue remodeling.  Roles for epithelial cell 
dysfunction in the initiation and/or progression of this process have been proposed, although not 
tested in vivo106,130. 
 
The airway epithelium provides both a physical and biological barrier that functions to 
protect the host against invading microorganisms and inhaled pollutants27,36,37,131,132.  The 
epithelium of bronchiolar airways turns over with very slow kinetics and is maintained in the 
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steady-state by the infrequent proliferation of an abundant facultative progenitor cell that is 
commonly referred to as the Clara cell77,78,83,99.  Injury resulting in the depletion of Clara cells, 
such as that resulting from exposure to the aromatic hydrocarbon naphthalene, is repaired 
through the activation of local tissue stem cells residing at airway branch point associated 
neuroepithelial bodies (NEBs) and the bronchoalveolar duct junction (BADJ)73,74,84,99,100.  
Further studies have revealed that stem cells localized at the BADJ, termed bronchoalveolar stem 
cells (BASC)s, can be identified in vivo by co-expression of CCSP and sufactant protein C 
(SPC), isolated according to cell surface phenotype, and may have the in vitro capacity to 
generate cells of both bronchiolar and alveolar lineages100.  Further research is necessary to 
understand the microenvironmental cues that regulate stem cell mediated epithelial repair. 
Roles for matrix remodeling in regulation of airway repair are suggested from studies 
investigating mouse models carrying null alleles for selected matrix metalloproteinases. Matrix 
metalloproteinases (MMP)s are a family of membrane associated or secreted proteases which 
upon activation have the ability to degrade components of the ECM, epithelial cell junctions, and 
liberate tethered growth and chemotactic factors in response to wounding133.  In recent work, 
matrix metalloproteinases have been shown to play key roles in regulating epithelial repair in the 
lung134,135.  Chen and co-workers demonstrated that TIMP1 functions to inhibit airway epithelial 
repair, raising the possibility that increased levels of TIMP1 that are observed  in diseases such 
as obliterative bronchiolitis may both attenuate epithelial reparative capacity and promote 
fibrosis135.  These studies reinforce the concept that epithelial defects within the EMTU may 
initiate uncontrolled fibroproliferation and extracellular matrix (ECM) deposition106.  To date, a 
description of ECM dynamics in the setting of stem cell mediated airway epithelial repair has not 
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been conducted.  Therefore this study will investigate the molecular signature of epithelial repair 
to determine if ECM is a component of the injury and repair response. 
In vitro studies have shown that inhibition of epithelial repair can augment pro-fibrotic 
signaling pathways, thereby supporting the model that epithelial repair can regulate ECM 
dynamics136.  However, this has never been formally tested in vivo.  In addition to providing a 
molecular signature of epithelial repair, this study will test the hypothesis that epithelial 
reparative capacity is a key regulator of extracellular matrix remodeling.  Previously validated in 
vivo models of Clara cell ablation are utilized to demonstrate that ECM deposition, as measured 
by Tenascin C (TNC) mRNA and protein abundance, are dynamically and reversibly regulated 
during repair of epithelial lesions in airways.  In contrast the loss of epithelial reparative capacity 
results in continued deposition of extracellular matrix without resolution.  This study provides 
the first in vivo evidence that ECM deposition is a dynamic component of the EMTU during 
productive airway epithelial repair and suggests that defects to epithelial reparative capacity 
directly leads to matrix deposition through alterations within the EMTU. 
46 
 
3.3 MATERIALS AND METHODS 
3.3.1 Animal Housing 
Mice used in this study were housed in an AAALAC certified institutional vivarium under 
specific pathogen free conditions, 12 hour light/dark cycle, provided food and water ad libitum, 
and sentinels screened quarterly for pathogens.   All mouse experimental procedures were 
approved by Duke and University of Pittsburgh IACUC.   
3.3.2 Models of Airway Injury: 
3.3.2.1 Ganciclovir Administration 
Adult FVB/N CCtk mice were exposed to ganciclovir (GCV) as previously described98,137.  
Cytovene IV (GCV sodium, Hoffman-LaRoche, Inc., Nutley, NJ) was dissolved in pyrogen free 
saline and administered chronically through a 14 day miniosmotic pump (ALZET Osmotic 
Pumps, #2109D, ALZA Corp., Palo Alto, CA) resulting in a dosage of 4.5 mg/kg ganciclovir 
daily.  Body weights were measured to evaluate realtime the extent of injury. 
3.3.2.2 Naphthalene Administration 
Male adult FVB/N (The Jackson Laboratory, Bar Harbor, ME) mice were injected intraperitoneal 
with Naphthalene (Sigma, St. Louis, MO) dissolved in sterile Mazola corn oil as previously 
described73.  In brief, mice were injected with naphthalene (dosage indicated in text) in the 
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morning (8:00-10:00am) to normalize to diurnal fluctuations in glutathione.  Body weights were 
measured to evaluate realtime the extent of injury. 
 
3.3.3 Tissue Processing 
At the time of sacrifice, mice were anesthetized through an intraperitoneal injection of ketamine 
and xylazine.  Following entry into a surgical plane, mice were dissected and thoracic cavity 
opened.  Plasma was collected from the right atrium using a 1ml tuberculin syringe followed by 
separation at 10,000 g for 10 minutes in a BD Microcontainer plasma separator tube (BD 
Microtainer, Becton, Dickinson and Company, Franklin Lakes, NJ).  Mice were exsanguinated 
through scission of the inferior vena cava and trachea cannulated with an I.V. Catheter (BD 
Insyte, Becton Dickinson and Company, Franklin Lakes, NJ).  Bronchoalveolar lavage (BAL) 
fluid was collected in 1 ml of PBS.  The Left lung and accessory lobe were resected and 
homogenized in 2 ml 4M GIC and RIPA buffer with 1mM PMSF for total RNA and protein 
isolation, respectively.  The remaining right lung lobes were inflation fixed at constant pressure 
for 20 minutes in 10% (v/v) buffered formaldehyde (Ricca Chemical Company, Arlington, TX).  
The right cranial lobe was cryopreserved in optimal cutting temperature (OCT) medium, 
sectioned in 5um increments with a cryostat (Microm HM550), and adhered to positively 
charged microscope slides (Ever Scientific, Unifrost Plus Microscopic Slides, EMSC200W+). 
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3.3.4 RNA Isolation and Microarray Analysis 
RNA was isolated from left lung according to protocol by Chomczynski and Sacchi138.  RNA 
quality was determined using a Nanodrop-1000 spectrophotometer (Nanodrop Technologies, 
Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent, Foster City, CA).  All Microarray 
analysis was performed at the University of Pittsburgh Cancer Center Clinical Microarray core 
using Codelink 20K Mouse Bioarrays (Applied Microarrays, Tempe, AZ) according to 
manufacturers’ suggested protocol.  Bioinformatic analysis was conducted as previously 
described139.  Differentially expressed genes were determined using the Scoregenes software 
package (Jerusalem, Israel).  Relative change in gene expression was determined in a pair wise 
comparison of treatment to control.  A significant change in gene expression passed the 
following criteria:  t-test p-value <0.01, threshold number of misclassifications (TNOM) = 0, and 
regulation ≥ 2 fold relative to control.  Genes fulfilling these criteria were hierarchically 
clustered using Scoregenes and visualized as a heat-map in Treeview (Eisen Laboratory, LBL, 
Berkely, CA).   
3.3.5 Realtime PCR 
Determination of relative mRNA abundance in total lung RNA was determined using 
quantitative realtime PCR according to established protocol.  In brief, RNA was reverse-
transcribed using a High-Capacity cDNA Synthesis Kit (Applied Biosystems, Foster City, CA) 
and an Applied Biosystems Veriti Thermocycler (Applied Biosystems, Foster City, CA).  cDNA, 
RealMaster Mix (Qiagen, Valencia, CA), and gene specific Taqman FAM labeled probes and 
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primers (Applied Biosystems, Foster City, CA) were combined into a 96-well optical plate using 
the EpMotion 5070 automated pipeting system (Eppendorf, Hamburg, Germany) to increase 
precision of realtime data.  Realtime PCR was conducted on a Realplex4 EpgradientS 
(Eppendorf, Hamburg, Germany) according to protocol.  The ΔΔCT for realtime PCR was 
calculated to determine relative mRNA abundance140.  An unpaired 1-tailed student’s t-test was 
used to determine statistical significance (p < 0.05; where indicated by asterisk). 
3.3.6 Enzyme Linked Immunosorbant Assay 
CCSP protein in BAL and plasma samples was assayed with a CCSP sandwich ELISA.  In brief, 
IgG purified (Millipore) goat anti rat-CCSP antiserum (capture antibody) was diluted in ELISA 
coating buffer, and incubated in a 96 well polystyrene high binding plate overnight (Costar 
3590).  After sample and rCCSP standard incubation, the plate was probed with rabbit anti rat-
CCSP antiserum (primary detection antibody) and goat anti rabbit-HRP (Biorad).  Absorbance 
was measured at 450nm using a microplate reader (EL808 Ultra Microplate Reader, Bio-tek 
instruments, INC). 
 
3.3.7 Immunofluorescence and Microscopy 
4-color immunofluorescence imaging was conducted using the following primary/secondary 
antibodies and nuclear stains.  Primary antibodies:  goat anti rabbit-CCSP (In House), rabbit anti 
human-tenascin-C (Chemicon), MouseIgG2a anti-α-smooth muscle actin (Sigma), Secondary 
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antibodies: donkey anti-goat-660 (Invitrogen), donkey anti-rabbit-488 (Invitrogen), goat anti-
mouseIgG2a-594 (Invitrogen), Nuclear stain:  DAPI (Sigma).  Tissue sections were post-fixed in 
100% ethanol for 10 minutes and rehydrated with sequential 3 minute washes in 95, 85, and 70% 
ethanol.  The sections were incubated with Trypsin (Cellgro) for 5 minutes at 37°C and blocked 
in 5%BSA/PBS for 30 minutes.  Primary antibody was diluted in 5%BSA/PBS and applied to 
each section overnight at 4°C in a humidified chamber followed by secondary antibody 
incubation in 5%BSA/PBS for 1 hour.  Cross-reactivity of secondary antibodies was eliminated 
by blocking with normal goat serum.  The slides were cover-slipped with DAPI(Sigma) and 
Fluouromont G mounting media (Southern biotech).  Microscopic analysis was conducted using 
a Zeiss Observer.Z1 inverted fluorescent microscope (Carl Zeiss Inc.) and images processed in 
AxioVision Release 4.6.3 (Carl Zeiss Inc.) software. 
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3.4 RESULTS 
3.4.1 Airway epithelial injury and repair regulates pro-mitotic signaling pathways and 
ECM dynamics. 
Naphthalene induced acute Clara cell injury is repaired through activation of endogenous 
bronchiolar stem cells74,99.  During repair both the epithelium, the initial target site of injury, and 
the underlying peri-bronchiolar mesenchyme proliferate74.  To better define the cellular and 
molecular dynamics of the reparative process following naphthalene exposure, genome wide 
mRNA expression profiling was performed. Wildtype FVB/N adult male mice were exposed to 
275mg/kg naphthalene and RNA isolated from total lung homogenate from unexposed control 
and 1, 2, 3, or 6 days after injury and used to screen oligonucleotide microarrays (N = 4/exposure 
group).  Bioinformatic analysis identified a total of 4,751 transcripts with a significant > 2 fold 
change in gene expression.  Genes were hierarchically clustered according to expression and 
displayed in Figure 6A as a heat-map.  Using these selection criteria the gene expression 
signature of the repairing airway was determined to comprise of 3,552 up-regulated and 1,199 
down regulated gene transcripts (Figure 6A, † and ‡, respectively). 
A previous study established that the majority of down-regulated genes directly reflected 
loss of Clara cells and provided new tools to investigate the dynamics of Clara cell loss and 
regeneration139.  This study focused solely on up-regulated gene transcripts, specifically those 
involved in regulation of cell proliferation and matrix remodeling.  The relative mRNA  
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Figure 6.  The gene expression signature of productive repair. 
RNA from control (0) and1, 2, 3, or 6 days after naphthalene induced injury was isolated from whole lung 
homogenate and used for microarray analysis (N = 4/exposure group).  Statistically significant gene expression 
changes relative to control were clustered and presented as a heat map.  Red and green indicate down and up-
regulated gene expression relative to control, respectively.  Heat map representation of (A) all significant gene 
clusters and (B) magnification of the most informative gene clusters.  Annotations for Nodes 89, 176, and 534 are 
included in Appendix A.1 Tables 1-3, respectively.  († and ‡ denote clusters that are up-regulated and down-
regulated relative to control, respectively). 
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abundance of representative genes from nodes 89, 176, and 534 (Figure 6B, Annotations are 
included in Appendix A.1 Supplementary Tables 1-3) were analyzed by realtime PCR to validate 
the bio-informatic process as well as verify gene expression changes to candidate signaling 
pathways (Figure 7 A-F, G, and H respectively).  Genes selected for validation included AKP2, a 
potential marker for tissue stem cells (Figure 7A), pro-mitotic signaling molecules (Figure 7B,C, 
G), ECM modifiers (Figure 7D, E), and ECM (Figure 7F, H). Each of these genes demonstrated 
significant changes in gene expression over the time course of naphthalene induced airway injury 
and repair that were predicted by microarray analysis.  
The expression pattern of selected genes identified by microarray screening throughout 
the processes of airway injury, repair, and resolution was investigated in more detail. Changes in 
the mRNA abundance of amphiregulin (AREG), tumor necrosis factor receptor superfamily 
member TNFSFR12A, and tenascin C (TNC), were interrogated by realtime PCR analysis of 
total lung RNA isolated from unexposed controls, 1, 2.5, 4, 8, and 12 hours or 1, 2, 3, 5, 10, 30 
days after naphthalene (250mg/kg) injury (Figure 8).  Naphthalene induced airway injury 
resulted in a rapid and dramatic increase in the abundance of AREG mRNA which was elevated 
by 3.1 fold 1.0 hour after exposure and reached a maximum increase of 12.8 fold 8.0 hours after 
exposure (Figure 8A). Messenger RNA abundance for AREG remained significantly elevated 
during the reparative phase following naphthalene exposure that included recovery day 5, and 
returned to near steady-state levels by day 10 and 30 (Figure 8A). Expression of TNFSFR12A 
mRNA showed a similar profile of expression to that of AREG, differences being a delay in gene 
induction and more rapid return to baseline levels (Figure 8B). Peak induction of TNFSFR12A 
occurred at the same 8 hour repair time point as observed for AREG, achieving >6-fold the level 
observed in steady-state lung. Expression of TNC mRNA was significantly increased by 2.5-fold  
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Figure 7.  Realtime PCR validation of microarray analysis. 
Messenger RNA abundance in total lung RNA samples from control (0) and 1, 2, 3, or 6 days after 
naphthalene injury was determined by realtime PCR analysis using Taqman probes and primers. Clusters were 
validated by quantifying mRNA abundance of representative genes from (A-F) Node 89, (G) Node 176, (H) Node 
534.  Data are presented as mean ±SEM. 
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Figure 8.  Pro-mitotic signaling pathways and ECM are dynamically regulated during acute Clara cell injury, 
productive repair, and resolution.    
Total lung RNA was isolated from control (0) and 1, 2.5, 4, 8, or 12 hours (Black bars) and 1, 2, 3, 5, 10, or 
30 days (White bars).  Realtime PCR analysis was conducted to measure mRNA abundance of gene transcripts 
representative of (A,B) pro-mitotic signaling pathways and (C) ECM.  Data are presented as mean ±SEM. 
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at 8.0 hours following injury, achieved peak levels of 5.8 fold steady-state levels at 
recovery day 1, and returned to near steady-state levels by 5 days (Figure 8C).  These data 
indicate that robust and transient up-regulation of transcripts encoding pro-mitotic signaling 
molecules and ECM occurs following naphthalene induced Clara cell ablation and the ensuing 
phase of tissue repair.  
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3.4.2 ECM is reversibly and dynamically regulated during airway epithelial repair. 
The kinetics of TNC protein accumulation during airway injury and repair was investigated. 
TNC was localized by immunofluorescence and the relationship to epithelial renewal and 
alterations in peribronchiolar mesenchyme evaluated through colocalization with CCSP (Figure 
9A, D, E) and α-smooth muscle actin (α-SMA; Figure 9 C-E), respectively.  Localization of 
TNC immunoreactivity within the steady-state epithelium revealed a subset of weakly positive 
mesenchymal cells that were positive for the myofibroblast/smooth muscle cell marker α-SMA 
(Figure 9B-D). No TNC immunoreactive protein was detected within other cell types of the 
airway or alveolar compartments. Magnification of panel 9D revealed the intense colocalization 
of TNC and α-SMA (Figure 9E).  Acute Clara cell injury, as assessed by CCSP 
immunolocalization was prominent by day 1 (Figure 9F, I, J).  The distribution and abundance of 
TNC immunoreactivity was dramatically altered during the early phase of repair after 
naphthalene exposure. Analysis of TNC immunoreactivity at 1 day post-exposure, the time point 
showing peak TNC mRNA accumulation, revealed intense up-regulation in the subepithelial 
mesenchyme (Figure 9G, I, and J).  Colocalization with α-SMA revealed that deposition of TNC 
occurred within the underlying mesenchyme showing a broader range of expression than that 
defined by SMA immunoreactivity (Figure 9I, J). 
To further define the dynamics of matrix remodeling that accompanied airway injury and 
repair, TNC, CCSP, and SMA were localized by immunofluorescent staining of lung tissue at 3,  
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Figure 9.   Extracellular matrix is deposited during productive airway epithelial repair.   
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Figure 9 Continued. 
CCSP, TNC, and α-SMA were immuno-localized on formalin fixed and cryo-preserved lung tissue isolated at (A-E) 
control (0) and (F-J) 1 day post naphthalene.  Representative pseudo-colored photomicrographs are shown of DAPI 
(Grey) merged with (A,F) CCSP (Magenta), (B, G) TNC (Green), or (C, H) α-SMA (Red).  (D, I) 4-color merged 
images of control and 1 day post injury.  (E, J) Magnification of areas denoted by a dashed rectangle (D,I).  
(Asterisk denotes co-localization, arrow indicates TNC subtending α-SMA positive cells) Representative images of 
the distal airway epithelium at 400x (scale bar = 50 μm). 
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5, and 30 days after injury (Figure 10 A-E, F-J, K-O, respectively).  Domains of epithelial 
regeneration were defined by small clusters of CCSP(+) cells observed in terminal bronchioles at 
recovery day 3 (Figure 10 A, D, E). These repairing regions showed evidence of expansion at 
recovery day 5 (Figure 10F, I, J), with further expansion noted by recovery day 30 (Figure 10K, 
N, O).  This pattern of repair closely mirrored the kinetics of cell proliferation and renewal 
observed in previous studies99,139.  During this period of epithelial renewal TNC immunoreactive 
protein showed an overall decrease in abundance by day 3, displaying evidence for 
reorganization to the basement membrane immediately subtending the repairing airway 
epithelium (Figure 10E).  A continuing decline in TNC immunoreactive protein was observed by 
day 5, with residual immunoreactivity observed in the sub-epithelial basement membrane (Figure 
10J). The abundance and distribution of TNC immunoreactivity returned to near steady-state 
levels by recovery day 30 (Figure 10K-O).  This pattern of TNC immunolocalization was also 
observed in the subepithelial region of more proximal airways (Appendix A.3 Figure 24).  This 
dynamic pattern of altered TNC immunoreactivity demonstrates that nascent extracellular matrix 
is deposited following injury, reorganized to basement membrane subtending regenerating and 
injured airway epithelium, and returns to steady-state levels upon completion of successful 
airway epithelial repair.  These data indicate that ECM is reversibly and dynamically regulated 
during productive airway epithelial repair. 
3.4.3 Deficiency in epithelial repair leads to persistent matrix deposition.  
Chronic lung injury has been associated with uncontrolled fibro-proliferation and deposition of 
ECM components including TNC141.  Even though defects in epithelial repair have been  
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Figure 10.  Epithelial repair is associated with matrix remodeling leading to restoration of steady-state levels 
and distribution.   
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Figure 10 Continued. 
CCSP, TNC, and α-SMA were immuno-localized on formalin fixed and cryo-preserved lung tissue isolated at (A-E) 
3, (F-J) 5, and (K-O) 30 days post naphthalene injury.  Pseudo-colored images of DAPI (Grey) merged with (A,F,K) 
CCSP (Magenta), (B, G, L) TNC (Green), or (C, H,M) α-SMA (Red) of representative distal airway epithelium.  (D, 
I, N) 4-color merged images of 3, 5, and 30 days post injury.  (E, J, O) Magnification of areas denoted with by a 
dashed rectangle in (D,I, N).  (Asterisk denotes TNC positive basement membrane independent of subtending α-
SMA cells, arrowhead indicates TNC subtending injured epithelium associated with underlying α-SMA cells, arrow 
indicates TNC localized to basement membrane subtending regenerating units).  Representative images of the distal 
airway epithelium at 400x (scale bar = 50 μm). 
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proposed as a contributing factor in fibroproliferation and matrix deposition this has not been 
demonstrated directly.  To determine whether the transient increases in matrix deposition 
observed during productive repair of injured airways would be altered in a model of 
unproductive repair, in which repair was abrogated due to loss of tissue stem/progenitor cells. To 
achieve this, transgenic mice (CCtk) expressing Herpes simplex virus thymidine kinase (HSV-tk) 
in CCSP expressing cells were exposed to ganciclovir (GCV) to injure the airway epithelium and 
abrogate repair74.  This model results in irreversible injury of all CCSP(+) epithelial cells and has 
been shown to result in alveolar dysfunction as well as fibroproliferation 137.  RNA was isolated 
from unexposed control (CCtk(-)) and CCtk (+) mice 3, 6, or 9 days after chronic GCV exposure 
in order to compare the gene expression signatures of injury/productive repair with 
injury/unproductive repair.  Bioinformatic analysis identified 1,729 gene transcripts that were 
regulated by greater than two-fold between GCV injured CCtk mice relative to untreated control 
mice. These genes were hierarchically clustered and are presented as a heat-map in Figure 11A. 
The abortive airway epithelial repair gene signature is comprised of 1,656 genes whose mRNA’s 
were increased by 2-fold or greater and 73 mRNA species showing greater than 50% decreases 
in their abundance (Figure 11A).  Down-regulated gene transcripts were previously used to 
identify new and existing markers for mature Clara cells139.  In an effort to further compare the 
productive and unproductive gene signatures, genes showing a robust pattern of mRNA 
induction were identified and displayed in node 278, which comprised 278 genes (Figure 11B 
and Appendix A.2, Table 4).  The mRNA abundance for selected genes was determined using 
realtime PCR and recapitulated results obtained by microarray analysis (Figure 11 C-J).  A 
difference between productive and abortive repair was observed for AKP2 and ERRFI1 
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(Compare Figure 7 with Figure 11), neither of which showed changes in mRNA abundance with 
abortive repair (Figure 11). 
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Figure 11.  The gene expression signature of unproductive repair. 
RNA from control (0, unexposed CCtk (-)) or CCtk (+) mice exposed to GCV chronically for 3,  6 or 9 
days was isolated from total lung homogenate and mRNA abundance determined using microarray analysis  (N 
=4/exposure group).  Statistically significant gene expression changes relative to control were clustered and 
presented as a heat map.  Red and green indicate down and up-regulated gene expression relative to control, 
respectively.  Heat map representation of (A) all significant gene clusters and (B) magnification of the most 
informative gene clusters (Node 278).  Annotations can be found in Appendix A.2, Table 4.  († and ‡ denote clusters 
that are up-regulated and down-regulated relative to control, respectively).  (C-J)  mRNA abundance of genes 
representative of Node 278 were determined in total lung RNA samples from control (0) and 3, 6, or 9 days of 
chronic GCV exsposure by realtime PCR analysis using taqman probes and primers.  White bar graphs indicate 
genes that were not regulated during chronic GCV exposure and therefore not present in Node278, but were  
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Figure 11 Continued. 
included for comparison to productive repair.  Y-axis scaling was adjusted to Figure 7 graphs to allow for 
comparison of fold-change in productive vs unproductive repair.  Data are presented as mean ±SEM.   
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11 C, I; White Bars). These data support the notion that stem cell amplification and inhibition of 
EGFR signaling has been abrogated with loss of epithelial reparative capacity142,143.  The 
abundance of AREG mRNA was chronically elevated in the abortive repair model compared to 
the transient increase observed in mice displaying productive repair (Figure 11D). In contrast, 
the mRNA for TNFRSF12A was transiently up-regulated in both injury models (Figure 11E).  
Genes whose products participate in remodeling of the extracellular matrix were chronically up-
regulated in mice showing abortive repair, though less abundant (Figure 11F, G), as were those 
for extracellular matrix molecules TNC and LGALS1.  These data indicate that there are 
significant differences in the abortive repair gene signature compared to productive repair that 
have potential to impact tissue remodeling. 
To further explore the dynamics of extracellular matrix remodeling observed during 
abortive airway epithelial repair, the abundance and distribution of TNC expression was 
determined as a function of Clara cell abundance in control and GCV exposed CCtk mice. CCSP 
abundance was measured in total lung RNA, BALF, and serum to assess injury of Clara cells 
using molecular endpoints (Figure 12A-C).  Ganciclovir exposure resulted in a reduction in 
CCSP mRNA abundance to 7.82% and 0.84% of control levels at days 6 and 10, respectively 
(Figure 12A).  This was paralleled by decreases in CCSP content within airway lining fluid, 
which was reduced to 0.52% of control and undetectable levels at exposure days 6 and 10 
(Figure 12B), respectively, as well as reduction in serum (Figure 12C).  Evaluation of TNC 
mRNA abundance by realtime PCR revealed a 3.44 and 9.70 fold up-regulation at exposure days 
6 and 10, respectively (Figure 12D).  These results suggest that ECM, as assessed by TNC 
mRNA abundance, is continually deposited during defective epithelial repair.  To verify that this 
was true at the level of protein accumulation TNC immunoreactive protein was measured by  
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Figure 12.  Multi-compartmental deposition of ECM in lungs of mice with non-repairing conducting airway 
epithelium.  
Control (0, unexposed CCtk (-)) or CCtk (+) mice were administered GCV chronically for 6 or 10 days.  
(A) CCSP mRNA abundance in total lung RNA as measured by realtime PCR.  (B,C)  CCSP protein in BALF and 
serum, respectively, was measured using an ELISA.  (D)  TNC mRNA abundance in total lung RNA as measured by 
realtime PCR.  CCSP, TNC, and α-SMA were immuno-localized on formalin fixed and cryo-preserved lung tissue 
isolated at (E-H) Control (0, unexposed CCtk (-)), (I-L) 6, and (M-P) 10 days following chronic GCV 
administration.  Pseudo-colored images of DAPI (Grey) merged with (E, I, M) CCSP (Magenta), (F, J, N) TNC  
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Figure 12 Continued. 
(Green), or (G, K, O) α-SMA (Red) of representative distal airway epithelium.  (H, L, P) 4-color merged images of 
control, 3 and 10 days GCV treatment, respectively.  (Q-S)  Magnification of areas denoted with dashed rectangle in 
(H, L, K), respectively.  (Asterisk indicates colocalization of TNC and α-SMA, arrow indicates TNC in basement 
membrane subtending injured airway epithelium, arrowhead indicates TNC deposited in the alveolar compartment).  
Representative images of the distal airway epithelium at 400x (scale bar = 50 μm). 
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immunofluorescent colocalization with CCSP and α-SMA. Analysis of control tissue revealed 
abundant CCSP (+) epithelial cells (Figure 12E, H, Q), the stereotypic distribution of TNC 
(Figure 12F, H, Q), and SMA (Figure 12G, H, Q).  CCSP immunoreactive cells were greatly 
diminished 6 days after ganciclovir exposure (Figure 12 I, L, R) and was accompanied by 
increased TNC-immunoreactive protein subtending the airway and alveolar epithelium (Figure 
12J, L, R). The abundance and distribution of α-SMA-immunoreactivity remained unchanged 6 
days after chronic injury (Figure 12K, L, R). A further decrease in the abundance of CCSP-
immunoreactive cells was observed following 10 days of ganciclovir exposure (Figure 12M, P, 
S). This was associated with further accumulation of TNC immunoreactive protein at the 
basement membrane subtending airway epithelium as well as peribronchiolar and alveolar 
mesenchyme (Figure 12N, P, S). No changes in α-SMA-immunoreactivity were observed 
(Figure 12O, P, S).  These results indicate that defective airway epithelial reparative capacity 
results in chronic ECM deposition in airway and alveolar compartments.  These data collectively 
provide the first experimental evidence that defects in epithelial reparative capacity are sufficient 
to drive excessive ECM deposition in vivo. 
71 
 
 
3.5 DISCUSSION 
Defects in epithelial maintenance have been postulated to contribute to uncontrolled ECM 
deposition in fibroproliferative chronic lung diseases 136,144.  However, direct supportive 
evidence is lacking. This problem was addressed through the use of mouse models in which 
selective airway injury is associated with either productive or unproductive repair. Genome wide 
expression profiling identified clusters of regulated genes that included those encoding pro-
mitotic signaling molecules and components of the extracellular matrix. Using tenascin C (TNC) 
as a prototypical matrix protein, this study demonstrates that ECM abundance is transiently up-
regulated during acute injury and productive repair, and that this process continues without 
resolution in the setting of airway injury with unproductive repair. These data are the first to 
provide direct experimental evidence that ECM is dynamically regulated in the repair response to 
selective epithelial cell injury and that epithelial repair defects are sufficient to drive excessive 
matrix deposition typically observed in chronic fibroproliferative lung diseases. 
Increased deposition of TNC has recently been shown to be a marker of chronic fibro-
proliferative lung disease, such as obliterative bronchiolitis (OB)141.  Furthermore gene 
expression analysis of tissue samples from non-smoking COPD patients revealed major 
alterations to gene transcripts involved in ECM deposition145.  The observation that TNC can be 
deposited in response to epithelial cell injury but is only resolved following repair suggests that 
restoration of epithelial homeostasis is a critical factor in resolving otherwise persistent matrix 
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accumulation.  ECM deposition is controlled by the combined regulation of protein synthesis and 
degradation.  Studies in human lung indicate that TNC is expressed in cells of the subepithelial 
mesenchyme during development and in disease146,147.  In vitro studies also indicate that 
fibroblasts are a source of TNC expression148.  It is likely that the increased expression of TNC 
in these studies occurs in the subepithelial mesenchyme as a result of fibroblast activation 
secondary to epithelial cell injury. 
These data demonstrate that transcriptional activation of TNC occurs rapidly after injury 
and is immediately attenuated following initiation of productive repair.  This is paralleled by a 
dramatic increase in TNC immunoreactive protein within the sub-epithelial mesenchyme.  As 
productive repair ensues, TNC pools were initially reduced, resulting in either residual or 
reorganization of TNC protein at the basement membrane.  Basement membrane associated TNC 
was later depleted at the time of epithelial renewal. These data imply that matrix deposition 
following epithelial injury and productive repair occurs in three stages:  1)  transient synthesis of 
nascent TNC during the injury phase, 2)  mesenchymal degradation, and 3)  epithelial associated 
degradation during repair.  In contrast these data demonstrate that TNC mRNA abundance and 
production are chronically elevated in both airway and alveolar compartments in the setting of 
unproductive repair.  Previous studies have shown that chronic defects in airway repair result in 
disruption of alveolar homeostasis, which may provide the basis for the accumulation of TNC in 
this compartment137.  
Repair of acute epithelial lesions in airways is a highly regulated process involving a 
complex interaction between multiple cell types as well as the underlying ECM106,149.  Lesions 
induced by exposure to naphthalene are highly selective for conducting airways due to its 
bioactivation within Clara cells, the abundant pool of facultative progenitors.  The ensuing repair 
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process involves proliferation of naphthalene resistant cells that have been considered to be the 
local population of tissue stem cells99.  Regulation of stem cell activity is likely mediated by 
concerted intrinsic and extrinsic cues derived from the surrounding cellular and a-cellular 
environment, referred to as a stem cell niche 150.  Currently the role of the ECM in regulation of 
niche dynamics and stem cell function has yet to be elucidated in the lung.  This study shows that 
during productive epithelial repair, the ECM molecule TNC is dynamically regulated, including 
reorganization to basement membrane subtending regenerating and injured epithelium.  Several 
studies have focused on the role of TNC in regulation of the stem cell niche, and suggest that 
TNC may regulate both proliferation and developmental progression of neural stem cells in the 
developing central nervous system 151,152.  These data are consistent with those from other studies 
demonstrating a critical role for TNC in regulating hematopoiesis 153.  Recent studies have 
implicated that TNC is upregulated following injury and is required for both proliferation and 
migration of scratch wounded cultured astrocytes 154.  Structural modeling and in vitro models 
have indicated that TNC-EGF domains can bind to EGFR and promote migration independently 
of effects on cell proliferation 155,156.  Together these data suggest that the deposition of TNC and 
reorganization to basement membrane subtending injured and regenerating epithelium may play 
a critical role in niche dynamics through regulation of proliferation and differentiation or 
migration of epithelial progenitors and nascent epithelium, respectively.  Moreover, the chronic 
up-regulation of TNC in the setting of unproductive epithelial repair may also impact fibroblast 
behavior causing increased proliferation and cellular motility, thus exacerbating ECM production 
and remodeling.  Future studies will test these observations in the setting of airway epithelial 
repair using mice deficient for TNC. 
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Since RNA was extracted from total lung homogenates, a caveat to this study is the under 
estimation of changes in gene expression that occurs during the process of airway injury and 
repair. Despite this caveat, other novel findings of the present study included the identification of 
several pro-mitotic signaling pathways regulated during airway epithelial repair.  These included 
amphiregulin (AREG), a ligand for the epidermal growth factor receptor (EGFR), and 
TNFRSF12A, receptor for TWEAK, both of which have been shown to regulate hepatic 
progenitor cells157-159.  Future studies will investigate the contribution made by these signaling 
pathways in regulation of airway repair and remodeling. 
The airway epithelium provides a primary barrier between the host and the environment 
and plays an essential role in immuno-modulation in the lung.  As such, immediate and effective 
repair after injury is required for maintaining lung homeostasis.  Chronic fibroproliferative lung 
diseases are characterized by a remarkable deposition of ECM protein.  In this study, the first 
experimental evidence to suggest that airway epithelial reparative capacity regulates ECM 
dynamics is presented.  Furthermore, this study demonstrates that dynamic regulation of ECM is 
a component of productive airway epithelial repair and may play an essential role in regulation 
of this process. 
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4.0  CLARA CELLS ATTENUATE THE INFLAMMATORY RESPONSE THROUGH 
REGULATION OF MACROPHAGE BEHAVIOR160 
4.1 EXPERIMENTAL RATIONALE AND HIGHLIGHTED RESULTS 
Chronic lung diseases are marked by excessive inflammation and epithelial remodeling.  
Reduced Clara cell secretory function and corresponding decreases in the abundance of the 
major Clara cell secreted protein, CCSP, are characteristically seen in these disease states.  To 
define the impact of Clara cell and CCSP depletion on regulation of the lung inflammatory 
response, chemical and genetic mouse models of Clara cell and CCSP deficiency (CCSP-/-) 
coupled with P. aeruginosa lipopolysaccharide (LPS) elicited inflammation were used.  
Exposure of Clara cell depleted or CCSP-/- mice to LPS resulted in augmented inflammation as 
assessed by polymorphonuclear leukocyte recruitment to the airspace.  Gene expression analysis 
and pathway modeling of the CCSP-/- inflammatory response implicated increased TNF-α 
signaling.  Consistent with this model was the demonstration of significantly elevated TNF-α in 
airway fluid of LPS stimulated CCSP-/- mice compared to similarly exposed wildtype (WT) 
mice.  Increased LPS elicited TNF-α production was also observed in cultured lung macrophages 
from CCSP-/- mice compared to wild type mice.  Moreover, macrophages from Clara cell 
depleted and CCSP-/- mice displayed increased TLR4 surface expression.  These results provide 
evidence that Clara cells can attenuate inflammation through regulation of macrophage behavior 
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and suggest that epithelial remodeling leading to reduced Clara cell secretory function is an 
important factor that increases the intensity of lung inflammation in chronic lung disease. 
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4.2 INTRODUCTION 
Chronic lung diseases (CLD), such as chronic obstructive pulmonary disease (COPD) 
and asthma are a global health problem with COPD expected to be the third leading cause of 
mortality by 2020 and asthma currently affecting 300 million people worldwide161,162.  
Pathological remodeling of the lung in CLD includes changes in the abundance and 
differentiated properties of the airway epithelium, subepithelial fibrosis, increased basement 
membrane thickness, and smooth muscle hypertrophy.  These pathological alterations are 
accompanied by excessive inflammation contributing significantly to declining lung function, 
morbidity, and ultimately mortality 105,163.  The abundance of low molecular weight non-
mucinous secretory proteins in airway lining fluid and serum have been directly correlated with 
severity of CLD 164. Levels of Clara cell secretory protein (CCSP, Scgb1a1) are dramatically 
reduced in either serum or airway lining fluid of patients with COPD, asthma, 
bronchopulmonary dysplasia, silicosis, and post-transplant rejection 41-44,165-168.  More recent 
evidence suggests that the levels of CCSP in serum can also be used as a diagnostic screen for 
acute lung injury (ALI*), acute respiratory distress syndrome (ARDS), and acute pollutant 
exposure169-171.  The loss of CCSP in airways from CLD patients may be due to either decreased 
abundance of Clara cells or a reduction in the de novo synthesis of CCSP.  For instance, a 
guanine to alanine substitution at position 38 of CCSP has been identified.  This position is 
within the minimal promoter region of CCSP and is associated with decreased synthesis of CCSP 
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in asthma and sarcoidosis172-175.  Even though these studies associate epithelial remodeling and 
reduced secretory function with progression of CLD it is not clear if secretory cell dysfunction 
directly contributes to the disease process. 
CCSP is the principal secreted product of the nonciliated bronchiolar Clara cell and the 
founding member of the secretoglobin family of secretory proteins 60,176.  X-ray crystallography 
studies have revealed that mature CCSP forms a homodimeric structure of monomers arranged in 
an anti-parallel orientation that are held in alignment by two di-sulfide bridges.   This structure 
has a small internal hydrophobic binding pocket that is able to bind phospholipids, including 
phosphatidylcholine and phosphatidylinositol177.  CCSP has also been proposed to bind to other 
small lipophilic compounds including:  exogenous ligands such as methylsulfony PCB46 and 
endogenous ligands such and progesterone178,45.  In vitro studies have also revealed that CCSP is 
able to inhibit phospholipase A2 activity, possibly through sequestration of calcium.47  Two 
different lines of CCSP-/- mice have been developed that differ in their steady-state phenotypes, 
but each show evidence for alterations in their susceptibility to environmental agents and injury-
related induction of tissue inflammation 46,50,52,54.  CCSP-/- mice mount an increased 
inflammatory response to live P. aeruginosa administered intra-tracheally as measured by 
increased total inflammatory cell exudates in bronchoalveolar lavage (BAL) as well as secretion 
of pro-inflammatory cytokines, implicating a role for CCSP regulation of innate immunity57.  
However, these studies failed to define molecular mechanisms by which CCSP regulates lung 
inflammatory responses.   The recent demonstration that CCSP deficiency leads to altered post-
translational modification of Annexin A1 (ANXA1) within ciliated cells and macrophages 
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suggests that epithelial and inflammatory cell function may be influenced by Clara cell 
secretions through a paracrine signaling mechanism 62. 
The present study was designed to test the hypothesis that Clara cells moderate the lung 
response to inflammatory stimuli.  Clara cell depletion and CCSP deficiency enhance the LPS 
elicited inflammatory response in vivo.  Furthermore, macrophages from CCSP-/- mice show 
increased LPS-stimulated TNF-α production and cell surface TLR4 relative to macrophages from 
wild type mice. These data suggest that Clara cells can attenuate the inflammatory response 
through regulation of macrophage behavior and that reduced Clara cell secretory function seen in 
patients with CLD may enhance lung inflammation. 
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4.3 MATERIALS AND METHODS 
4.3.1 Animal husbandry 
Inbred CCSP-/- 129J, CCSP-/- C57Bl6/J congenic, and WT FVB/N mice were maintained as in 
house breeding colonies under specific pathogen free conditions in an AAALAC accredited 
vivarium. WT strain 129Sv/Ev and C57Bl/6J mice were purchased directly from the supplier 
(Taconic, Germantown, NY and The Jackson Laboratory, Bar Harbor, ME) and housed for a 
minimum of two weeks prior to experimentation.  Mice were maintained on a 12 hour light/dark 
cycle and provided food and water ad libitum.   Sentinel screening was conducted on a quarterly 
basis to determine pathogen status.  For in vivo exposures male 129Sv/ev mice aged 6-10 weeks 
were used.  All in vitro experiments were conducted with male and female C57Bl/6 WT and 
CCSP(-/-) mice aged 6-12 weeks.  Animal procedures and cell isolations were approved by Duke 
and the University of Pittsburgh’s IACUC. 
4.3.2 Naphthalene and LPS dual exposure 
WT adult male C57Bl/6 mice and FVB/N were exposed to 250mg/kg and 275mg/kg 
naphthalene, respectively.  Naphthalene was dissolved in Mazola corn oil and injected into the 
peritoneal cavity as described previously 84.  Groups that received a dual exposure were aerosol 
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challenged with a 10ng deposited dose of LPS 24 hours after naphthalene injection.  Mice were 
recovered for 2 or 7 days post naphthalene treatment. 
4.3.3 LPS exposure 
WT and CCSP-/- 129Sv/ev mice (6-10wks of age, male) were co-exposed to P. aeruginosa 10 
lipopolysaccharide (Sigma, L8643, St Louis, MO) as previously described, resulting in an 
estimated deposited dose of  10ng 55.  5mg of lipopolysaccharide from P. aeruginosa 10 (Sigma, 
L8643, St Louis, MO) were reconstituted in 4ml of sterile and pyrogen free 0.9%NaCl (Hospira, 
Lake Forest, IL).  Immediately prior to exposures, aliquots of 1.25 mg/ml LPS were diluted to 
62.5µg/ml in sterile 0.9% NaCl.  5ml of the 62.5ug/ml LPS solution were loaded into a jet 
nebulizer (DeVilbiss, Somerset, PA) and nebulized with breathing quality air (Valley Natural 
Gases, Wheeling, WV) at 15psi for 20 minutes.  Animals were sacrificed by administering 
general anesthesia to achieve a surgical plane followed by exsanguination. 
4.3.4 Analysis of polymorphonuclear leukocyte (PMN) recruitment, apoptosis, and 
necrosis 
Inflammatory cells were sampled by total lung lavage.  Briefly, animals were cannulated with a 
20GA BD InsyteTM AutoguardTM I.V. Catheter.  Each animal was lavaged a total of 8 times with 1 
ml of sterile PBS.  Cells were collected by centrifugation at 4°C and resuspended in 1.0 ml PBS.  
Total cell counts were determined in technical triplicates using a Z1 Coulter Particle Counter 
(BeckmanCoulter, Fullerton, CA).  Particles >7um were counted in order to exclude red blood 
82 
 
cells and cellular debris.  Polymorphonuclear leukocyte (PMN) apoptosis was measured using a 
BD FACS CANTO Flow CytometerTM (BD Biosciences).  PMNs were identified by staining 
with Ms-Ly6G/Ly-6C (Gr-1) directly conjugated APC-Cy7 (BD Pharmingen, Cat# 557661) for 
15 minutes 179.  Cells were also stained for AnnexinV-FITC and PI as a measure of apoptosis and 
necrosis, respectively (Biovision, Mountain View, CA).  Appropriate unstained and single 
stained controls were analyzed in order to set compensation voltages.  Apoptotic and necrotic 
PMN were defined as Gr-1pos/annexinV pos/PIneg and Gr-1pos/annexinV pos/PIpos populations, 
respectively.  Unstained total BAL cells were used for microscopic classification of cell types 
using a differential staining kit according to manufacturer’s recommendation (Protocol®, Fisher 
Scientific). 
4.3.5 Gene expression analysis 
RNA was isolated from left lung according to protocol 138.  CodeLink UniSet Mouse 20K I 
Bioarrays (GE Healthcare Bio-Sciences Corp., Piscataway, NJ) were used for gene-expression 
profiling of isolated total RNA.  Determination of RNA integrity, generation of biotin labeled 
cRNA, hybridization to the array, array scanning, and data collection was conducted at the 
University of Pittsburgh Cancer Institute Clinical Genomics Facility.  
4.3.6 Bioinformatic analysis 
Data analysis was conducted in three steps as previously described 180,181.  This included: 1) 
Generation of complete data tables including full annotations, 2) Normalization of raw data and 
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statistical analysis to determine significant changes in gene expression, 3) Identification of 
clusters of similarly expressed genes, and 4) Pathway modeling.  Raw data were annotated using 
the freeware program Source (Stanford University, Stanford, CA).  Data were next imported into 
the ScoreGenes software package (Jerusalem, Israel) for data normalization, statistical analysis, 
and clustering 182.  Raw data were log2 transformed and normalized to the average across all 
groups.  Significant gene expression changes were assessed by fulfilling two criteria:  a 
significant student’s t-test p-value and a threshold number of misclassifications (TNOM) equal to 
0 according to previously established data mining methods 183.  LPS responsive and CCSP 
independent genes were revealed by identifying all genes in WT and CCSP-/- data sets that were 
differentially expressed compared to control (TNOM = 0, t-test p-value <0.1) and not dependent 
upon genotype (TNOM > 0 in a WT vs CCSP-/- comparison). LPS responsive and CCSP 
dependent genes were determined by first identifying all LPS responsive genes.  These genes 
were further evaluated for genotype dependent expression differences by pair-wise comparisons 
of WT and KO data sets (TNOM = 0, and t-test p-value <0.1).  Independent clustering of the 
LPS responsive/CCSP independent and LPS responsive/CCSP dependent genes was conducted 
in the ScoreGenes package using the “pcluster” command.  Data was visualized using Treeview 
software as previously described 184.  Finally, PathwayArchitectTM (Stratagene, La Jolla, CA) was 
used as a means to create biological pathways.  This software package allowed for 
transformation of gene lists into biological pathways based on known functional characteristics 
of the selected genes.  The ontological definitions are based upon the composite of human 
curated databases and analysis of published abstracts through language processing algorithms.  
Microarray analysis was conducted according to MIAME. 
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4.3.7 Protein characterization of bronchoalveolar lavage 
WT and CCSP-/- mice were lavaged twice with 1ml of sterile PBS and centrifuged at 300g for 5 
minutes to remove cells and debris.  Protein enriched supernatants were assayed for cytokine and 
chemokine protein abundance using a Luminex system (Luminex Corp, Austin, Texas) with 
either Mouse-18-plex or Mouse-6-plex chemokine/cytokine detection kits (Biorad, Hercules, 
CA).  CCSP was measured in BAL with a CCSP ELISA that was designed in-house using CCSP 
anti-serum from goat and rabbit. 
4.3.8 Mouse tracheal epithelial cultures 
Primary airway epithelial cultures were established and maintained at the air liquid interface 
(ALI) using the method of You and colleagues  185.  Cultures prepared from WT and CCSP-/- 
mice were exposed to LPS on day 10 of air-liquid culture, as maximal expression of the 
secretory cell marker CCSP occurs at this time.  Epithelial cells were exposed on the basolateral 
surface to 1µg/ml P. aeruginosa lipopolysaccharides (Sigma, St. Louis, MO) in normal growth 
medium.  A basolateral stimulus was conducted, as an apical stimulus can have detrimental 
effects to epithelial integrity 186.  Apical surface fluid was harvested 0, 6, or 24 hours after LPS 
exposure by washing the apical surface of cultures with 500µl sterile PBS and assayed for 
cytokine/chemokine protein expression using a mouse-6-plex assay as outlined above.  RNA was 
extracted from epithelial cells using an SV Total RNA Isolation System (Promega, Madison, WI) 
according to manufacturer’s instructions.  ALI experiments were repeated with three independent 
epithelial cell isolations. 
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4.3.9 Ex vivo LPS exposure of WT and CCSP-/- macrophages 
Lung macrophages were isolated from  naïve WT and CCSP-/- C57Bl/6 (non-sex/age matched) 
mice as previously described by Schurr and colleagues187 and exposed to P. aeruginosa LPS 
(Sigma).  3 WT and 3 CCSP-/- animals were lavaged 8 times with 1ml of PBS.  Cells were 
recovered by centrifugation at 300 x g for 10 minutes and resuspended in media composed of 
DMEM (Cambrex), 10% FBS (ThermoFisher, Waltham, MA), penicillin-streptomycin 
(50IU/ml), and 2mM L-Glutamine (Chemicon).  Cells were incubated for 2 hours to allow for 
adherence to the tissue culture plate.   Media was replaced with LPS spiked media at 
concentrations indicated in figure legends.  Cells were incubated with LPS containing media for 
6 hours and the supernatant collected for further analysis. TNF-α protein concentration was 
determined using a mouse TNF-α cytoset sandwich ELISA according to manufacturer’s 
recommendations (Biosource, Invitrogen, Carlsbad, CA).  The ex vivo macrophage experiments 
were repeated with two independent macrophage isolations.   
4.3.10 Macrophage Gene Expression Analysis 
Alveolar macrophages were isolated from naïve WT and CCSP-/- mice for analysis of TLR4 and 
CD14 mRNA abundance.  WT and CCSP-/- mice were lavaged and cells recovered by 
centrifugation.  3 mice were pooled per group for a total of 3 groups per genotype (N = 3). RNA 
was extracted using an SV total RNA Isolation System (Promega, Madison, WI).  cDNA 
synthesis was performed as described above.  Realtime PCR was conducted to assay for TLR4 
and CD14 mRNA abundance as described below.     
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4.3.11 TLR4 surface distribution on lung macrophages 
Lung macrophages were isolated from WT and CCSP-/- lung and TLR4 distribution analyzed as 
previously described 188.  Briefly, whole lung lavage and centrifugation was performed to obtain 
lung macrophages.  Flow cytometry analysis was performed using a Becton Dickinson FACS 
Calibur (BD BioSciences, San Jose, CA) and analyzed with CELLQuest software (BD 
BioSciences, San Jose, CA).  A laser scanning confocal microscope (LSM 510 UV mounted on 
an Axio Observer microscope, Carl Zeiss, Inc.) was used to obtain the fluorescence and 
transmitted images.  Zeiss LSM510 v4.2 and LSM Image Examiner v3.2 software were used for 
image acquisition and analysis, respectively. 
4.3.12 Realtime PCR 
Taqman realtime PCR was conducted on an Applied Biosystems 7000 RealTime PCR System 
(Applied Biosystems, Foster City, CA).  RNA was analyzed for quantity and quality using a 
Nanodrop 1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE).  Equal amounts 
of RNA were used to generate cDNA using the First strand cDNA synthesis kit according to 
manufacturer’s recommendations (Invitrogen, Carlsbad, CA).  Taqman realtime PCR was 
conducted using validated Taqman probe and primer combinations (Applied Biosystems, 
Applied Biosystems, Foster City, CA).  Relative mRNA abundance was determined by the ΔΔCT 
method for realtime PCR 140. 
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4.3.13 Statistical analysis 
Statistical analysis was conducted in Minitab 15® for Windows®.  Pair-wise comparisons were 
tested for significance using the student’s t-test or a Mann Whitney U test.  The general linear 
model (GLM) and Tukey’s post hoc analysis was used to test multiple pair-wise comparisons. 
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4.4 RESULTS 
4.4.1 Clara Cell Depletion Exacerbates the LPS Induced Inflammatory Response 
To address the contribution of the airway epithelium to the inflammatory response a dual 
exposure mouse model in which Clara cells were specifically ablated by naphthalene exposure 
prior to LPS challenge was utilized.  A critical component of this experiment was to first identify 
the time at which naphthalene induced injury resulted in maximal Clara cell ablation and 
diminished secretory function.   WT FVB/N mice were exposed to naphthalene and recovered 
for 1, 2.5, 4, 8, or 12 hours and 1, 3, 5, 10, or 30 days.  Protein abundance of CCSP was 
measured in the cell free fraction of bronchoalveolar lavage (BAL) as an indicator of both Clara 
cell ablation and secretory capacity.  CCSP protein in BAL increased 1.0 hour after injury 
indicative of Clara cell de-granulation/hyper-secretion, returned to normal levels by 2.5 hours, 
and reached a minima from 8 hours to 5 days suggesting Clara cell ablation and diminished 
secretory capacity had occurred by 24 hours (Figure 13A).  This finding parallels other endpoints 
of Clara cell depletion including depletion of CCSP mRNA within total lung RNA and the loss 
of CCSP immunoreactive cells within lung tissue by immuno-cytochemistry 189. 
To test the physiological impact of Clara cell ablation on the inflammatory response, 
mice were exposed to naphthalene, LPS, or naphthalene and LPS.   The 24 hour recovery time 
point after naphthalene exposure was selected for further LPS challenge as it represented the 
interval showing maximal depletion of Clara cells and their major secretory product, CCSP  
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(Figure 13A).  Naphthalene treatment alone resulted in only a subtle increase in 
lavageable PMNs (Figure 13B, Black).  In contrast, 30% of lavageable cells were classified as 
PMNs one day following treatment with LPS alone (Figure 13B, Grey).  Naphthalene and LPS 
exposure (Dual Exposure, white) resulted in a synergistic increase in PMN recruitment, as 
evidenced by a PMN contribution of 73% of BAL cells (Figure 13B).  As the Clara cell and 
macrophage signaling axis has been shown to be an important regulator of the LPS induced 
inflammatory response, the affects of Clara cell ablation on macrophage behavior was 
investigated 28.  Increased abundance of TLR4 on the surface of lung macrophages has 
previously been correlated with an exacerbated LPS elicited inflammatory response188.  
Therefore, macrophages from control and naphthalene exposed mice were isolated from BAL 
and stained for the macrophage marker F4/80 and TLR4.  TLR4 surface expression was 
evaluated on F4/80 positive macrophages through flow cytometry.  Increased TLR4 surface 
expression and clustering has recently been documented to be a critical determinant of the LPS 
elicited inflammatory response188,190.  Macrophages isolated from naphthalene exposed mice 
demonstrated a robust increase in TLR4 surface expression relative to steady state controls 
(Figure 13C,D).  Even though these data do not rule out indirect effects of injury on modulation 
of the LPS response, they suggest that Clara cells function in an anti-inflammatory capacity 
within airways by modulating macrophage behavior.   
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Figure 13.  The airway epithelium attenuates the inflammatory response. 
WT adult mice were exposed to naphthalene, LPS, or naphthalene and LPS.  The abundance of (A) CCSP 
protein in BALF from 0, 1, 2.5, 4, 8, 12 hours (black, N = 4/group) and 1, 2, 3, 5, 10, 30 days (white, N = 5/group) 
was measured by an ELISA.  (B)  Recruited PMNs were analyzed in BAL from control (N = 3), naphthalene (black, 
N = 3), LPS (grey, N = 3), and naphthalene + LPS exposed (white, Dual Exposure, N = 4) mice.  (C and D)  TLR4 
protein expression was measured on lung macrophages at steady-state (Control, black) and one day after 
naphthalene (Day 1, white) through cytometric analysis and presented as the geometric mean of TLR4 positive 
macrophages and percentage of TLR4 high positive macrophages (C and D, respectively).   Data presented as mean  
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Figure 13 Continued. 
+/- SEM.  (* and  †:  p-value <0.05 for pairwise comparison of exposure group or comparison to control, 
respectively; student’s t-test (panels A, C, and D) and GLM/Tukey’s post hoc analysis was used in panel B ). 
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4.4.2 Increased LPS induced recruitment of PMNs to lungs of CCSP deficient mice 
Based upon these data, a mechanism whereby Clara cells may modulate the inflammatory 
response was investigated.  Clara cells may attenuate the inflammatory response through a 
variety of mechanisms including secretion of paracrine factors.  Previous studies have shown that 
CCSP-/- mice display increased lung inflammation relative to WT mice following exposure to 
inhaled oxidant pollutants 52,54.  Additionally a signaling axis exists between Clara cells and 
macrophages as revealed by changes to ANXA1 post-translational modifications in macrophages 
of CCSP-/- mice 62.  Therefore, to test the hypothesis that Clara cells moderate the inflammatory 
response through a CCSP dependent mechanism, WT and CCSP-/- mice were co-exposed to 10 
ng deposited dose of LPS and recovered for 3 or 24 hours.  Analysis of cell types recovered from 
BAL revealed the expected shift in inflammatory cell profile from >99.5% macrophages in BAL 
of unexposed mice to predominantly recruited PMNs in BAL from both WT and CCSP-/- mice 
either 3 or 24 hours post LPS exposure (Figure 14A).  Even though a similar overall response 
was observed, differences were apparent in the magnitude of PMN recruitment.  PMNs 
represented 44.9  and 74.4 % of WT and CCSP-/- isolated BAL cells 3 hours post LPS exposure 
indicating a statistically significant 65.7% increase in PMNs in airways of CCSP deficient mice 
(Figure 14A).  Furthermore, PMNs represented 70.9 and 81.3% of WT and CCSP-/- BAL 24 
hours post LPS exposure demonstrating a more subtle but 14.6% increase in PMN contribution 
to CCSP-/- BAL.  Corresponding decreases were observed in the fractional contribution of  
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Figure 14.  CCSP deficiency augments the LPS induced inflammatory response.   
WT and CCSP-/- mice were simultaneously challenged with LPS and recovered for 3 or 24 hours.  Control 
(N = 4) mice were unexposed to LPS (0).  Cellular infiltrates were analyzed using a differential cellular stain to 
determine (A) PMN recruitment.  (B)  Total cells were determined in WT and CCSP-/- BAL using a Coulter Particle  
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Figure 14 Continued. 
Counter (Left).  To reveal cell type specific changes to the total cellular infiltrate total macrophages (center) and 
PMNs (right) were calculated by multiplication of total cells by the percentage of macrophage or PMN in BAL as 
determined in differential cell analysis.  Data presented as mean +/- SEM.  (* and  †:  Tukey’s post hoc p-value 
<0.05 in pair-wise comparisons of WT and CCSP-/- or comparison to control, respectively; WT:  Black, CCSP-/-:  
White).   
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macrophages to BAL cells recovered from airways of WT and CCSP-/- mice following LPS 
exposure (data not shown). 
Changes in total cell numbers were also measured to better define CCSP dependent 
differences in inflammatory cell recruitment.  Total BAL cell counts were increased by 68% and 
43% in BAL of CCSP-/- mice compared to WT mice at 3 and 24 hours post LPS exposure, 
respectively (Figure 14B, left). No changes were observed in total macrophages recovered in 
BAL from WT and CCSP-/- mice, despite the decreased fractional abundance in BAL.  (Figure 
14B, middle).  Increased cellular recruitment following LPS exposure could be accounted for by 
recruitment of PMNs. Consistent with differential cell-type analysis in BAL, PMNs were 
recruited to significantly higher levels in BAL of LPS exposed CCSP-/- mice compared to 
similarly exposed WT mice. PMNs in BAL of LPS exposed CCSP-/- mice showed 2.79 fold and 
1.66 fold increase over WT control mice at the 3 hour and 24 hour post-exposure time points, 
respectively (Figure 14B, right). 
Instantaneous measurements of PMN abundance represent the sum of recruitment and 
apoptotic clearance. To determine whether CCSP deficiency was associated with changes in 
either of these parameters, the abundance of apoptotic and necrotic PMN’s was determined 
within BAL of WT and CCSP-/- mice by FACS analysis 24 hours post LPS exposure.  Isolated 
BAL cells were stained with Gr-1179 and the fraction of apoptotic cells determined by relative 
staining for annexin V-FITC and PI.  As was the case with cytological identification of cell 
types, FACS analysis revealed >50% contribution of PMN’s to the total cell fraction of BAL 
from LPS-exposed WT and CCSP-/- mice (Figure 15A, B).  The abundance of cells showing cell 
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surface staining for annexin V and either exclusion or staining with PI indicated no statistically 
significant differences in apoptotic and necrotic PMNs, respectively, in BAL of CCSP-/- mice  
compared to WT (Figure 15C-G).  These data suggest that CCSP deficiency modifies the initial 
response to pro-inflammatory stimuli leading to increased PMN recruitment, but has no impact 
on PMN turnover. 
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Figure 15.  Resolution of the inflammatory response is not impacted by CCSP deficiency. 
BAL Cells from WT and CCSP-/- lung were isolated 24 hours post LPS exposure (N = 4) for determination 
of PMN apoptosis and necrosis.  Appropriate one color controls were used to set compensation voltages (data not 
shown).  (A) Unexposed controls were used to determine the Gr-1 (-) fraction of inflammatory cells.    (B-D)  
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Figure 15 Continued. 
Isolated cells were stained with Gr1-APC-Cy7, AnxV-FITC, and PI to determine PMN specific apoptosis and 
necrosis.  (E)  Scatterplot of PI vs AnxV-FITC Gr-1 (+) cells to determine necrotic and apoptotic PMNS.  Quadrants  
2 [AnxV(+)/PI(+)] and 4 [AnxV(+)/PI(-)] represent necrotic and apoptotic PMNs respectively.  Quantitative analysis 
of the percentage of (F) apoptotic and (G) necrotic PMN (No significance was reached using a 2-sample student’s t-
test).  Data presented as mean +/- SEM.  (WT:  Black, CCSP-/-:  White). 
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4.4.3 Microarray analysis reveals CCSP dependent and CCSP independent affects to the 
LPS response 
To better understand mechanisms by which CCSP impacts LPS induced lung inflammation a 
genome wide expression screen of WT and CCSP-/- lung RNA from mice at 0, 1.5, 6, and 12 
hours post exposure to an estimated deposited dose of 10ng LPS.  A total of 1815 genes were 
identified that demonstrated a similar LPS response in WT and CCSP-/- lung. This gene list was 
designated as CCSP independent and LPS responsive, relevant portions of which are represented 
as a clustered heat-map in Figure 16A.  The representative gene list, fold change relative to WT 
or CCSP-/- controls, and annotations are presented in Appendix B.1 Supplementary Table 5.  A 
second gene set of 267 transcripts was comprised of genes that were differentially LPS 
responsive in a WT and CCSP-/- pair-wise comparison. This gene list was designated as CCSP 
dependent and LPS responsive, relevant portions of which are represented as a clustered heat-
map in Figure 16B.  The representative gene list, fold change relative to WT, and annotations are 
presented in Appendix B.1 Table 6.   To validate the gene expression signatures displayed in 
Figure 16, mRNA abundance for genes from each cluster was determined by quantitative real 
time PCR (data not shown; validated genes indicated in Appendix B.1 Tables 5 and 6).   
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Figure 16.  Hierarchical clustering of genome wide expression analysis to identify CCSP dependent and 
independent components of the LPS induced inflammatory response.   
WT and CCSP-/- mice were coexposed to LPS aerosol for 20 minutes and recovered for 1.5, 3, 6, 9, and 12 
hours (N 4/group, Control mice were not exposed to LPS).  RNA from 0, 1.5, 6, and 12 was screened for total 
message expression using Codelink 20K Bioarrays (N = 3/group).  Hierarchical clustering of gene expression is 
represented in heat maps where columns are experiments and rows are genes (yellow and magenta indicate 
decreased and increased expression, respectively, with respect to the average across all time points).  The heat map 
represents a subset of the clusters from (A)  CCSP independent/LPS responsive and (B)  CCSP dependent /LPS  
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Figure 16 Continued. 
responsive gene signatures.  The rows (genes) are annotated in ascending numerical order.  For complete 
annotations including accession number, gene name, and ontology refer to Apendix B.1. (Tables 5 and 6). 
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4.4.4 Pathway analysis identifies TNF-α and IL-6 as key cytokines involved in the CCSP 
deficient inflammatory response. 
PathwayArchitect™ was used to organize the gene set in silico based upon transcriptional 
regulators and gene product interactions 191-193.  Genes within the LPS responsive CCSP 
dependent gene cluster were organized into an interactive pathway to provide further insights 
into regulatory mechanisms accounting for CCSP dependent regulation of the inflammatory 
response.  In addition to these genes, LPS, CCSP, and two known regulated downstream target 
genes, SCGB3A2 and ANXA1, were included within the gene set to identify evidence of 
involvement in this pathway.  Generation of the in silico pathways are described in the materials 
and methods.  The in silico generated pathway recapitulated the previously established model of 
LPS elicited inflammation, including LPS recognition by CD14 and TLR4.  Included within this 
pathway are key nodes of regulation implicated in the CCSP dependent modulation of LPS 
elicited inflammation. Two key signaling molecules implicated in the CCSP dependent 
component of the inflammatory response were TNF-α and IL-6 as demonstrated by the high 
connectivity between genes whose mRNA’s were significantly altered in a CCSP-dependent, 
LPS-dependent fashion (Figure 17A, Red Asterisk).  Importantly, neither TNF-α nor TLR4 
mRNA abundance were found to be CCSP dependent as indicated by similar responses to LPS 
treatment between WT and CCSP-/- mice and their absence from the corresponding gene list 
used for pathway analysis.  Rather, Pathway Architect’s computational algorithm added TNF-α 
and TLR4 to the pathway as they were both predicted to be key upstream regulators of genes 
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represented within the CCSP dependent and LPS dependent gene list.  This observation suggests 
that increased signaling by TNF-α and IL-6 may contribute to the enhanced LPS elicited 
inflammatory response observed in CCSP-/- mice relative to co-exposed WT mice. 
To determine whether the in silico prediction of increased IL-6 and TNF-α signaling 
could be validated in vivo, protein abundance in WT or CCSP-/- BAL fluid was determined by 
cytokine/chemokine multiplex analysis at 0, 1.5, 3, 6, 9, and 12 hours following LPS stimulation.  
Statistically significant 3.2 and 5.8 fold increases in TNF-α protein abundance were observed in 
BAL fluid isolated from CCSP-/- mice compared to similarly exposed WT mice at either 1.5 or 3 
hours post LPS exposure (Figure 17B).  This was accompanied by a trend towards increased IL-6 
protein in CCSP-/- BAL fluid 3 hours post LPS exposure compared to WT (Figure 17C), a 
finding consistent with an over-abundance of TNF-α194.  These data support the prediction 
generated from microarray data that there exists CCSP dependent changes in LPS elicited TNF-α 
and IL-6 protein production in vivo.   
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Figure 17.  Pathway analysis of the CCSP dependent and LPS responsive gene signature identifies regulatory 
networks that can be biologically validated.   
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Figure 17 Continued. 
Genes that were identified to be LPS responsive and CCSP dependent (Figure 16B) were utilized to construct an 
interaction network as discussed in materials and methods.  Gene products (ellipses) are linked functionally by 
connecting lines in accordance with functional annotation (refer to legend).  Note the high connectivity of TNF-α 
and IL-6 in the proposed pathway.  (Red and black asterisk denote molecules/processes that were added to the 
pathway in either an unsupervised (added by the pathway analysis software) or supervised (manually by the user) 
fashion as discussed in the text.  (B and C)  WT and CCSP-/- mice were simultaneously aerosol exposed to P. 
aeruginosa and sacrificed 1.5, 3, 6, 9, and 12 hours post exposure (N = 4 per group).  Control mice were unexposed 
to LPS (0).  BAL was collected and characterized using a multiplex immunoassay.  (B)  TNF-α (pg/ml) and (C) IL-6 
protein levels are depicted.  Data presented as mean +/- SEM.  (* and  †:  Tukey’s post hoc p-value <0.05 in 
comparison of WT and CCSP-/- or comparison to control, respectively; WT:  Black, CCSP-/-: White).  
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4.4.5 Airway epithelium and lung macrophages are intrinsically hyper-responsive to LPS 
stimulation 
Previous studies have revealed alterations to airway epithelial cells and macrophages as a result 
of CCSP deficiency 56,62. Since each of these cellular compartments play central roles in 
mediating the lung response to inhaled LPS, their intrinsic responsiveness to LPS was 
investigated in WT and CCSP-/- in vitro models. Differentiated airway epithelial cell cultures 
were prepared from WT and CCSP-/- mice.  Expression of cell type-specific marker genes was 
used to verify differentiation status of cultured epithelia and similarity of cultures prepared from 
WT and CCSP-/- mice.  Steady-state analysis of gene expression indicated that in vitro cultures 
of WT and CCSP-/- epithelium were similarly differentiated prior to and throughout the 
exposure as indicated by equivalent expression of the ciliated and secretory cell lineage markers 
FoxJ1 and Cyp2f2, respectively (Figure 18A,B). The expected difference in CCSP gene 
expression was observed between WT and CCSP-/- cultures, with the latter showing no 
detectable CCSP mRNA (Figure 18C).  Interestingly, CCSP mRNA abundance significantly 
decreased following 24 hours of LPS exposure (Figure 18C).  This observation correlates with a 
study by Harrod  and Jaramillo demonstrating that CCSP promoter activity is attenuated by P. 
aeruginosa exposure both in vitro and in vivo 195.    
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Figure 18.  CCSP-/- airway epithelial cells are hyper-responsive to LPS. 
Primary cultures of WT and CCSP-/- epithelium were generated and maintained at the air-liquid interface 
according to established protocol as described in materials in methods (N = 3 per genotype/treatment group).  
Control group is unexposed to LPS (0).  RNA was isolated from each culture for Taqman realtime PCR assessment 
of (A) FoxJ1, (B) CyP450-2f2, and (C) CCSP expression to interrogate the differentiation status of the epithelium.  
(D) IL-6 protein secreted into the apical surface fluid was measured using a multiplex immunoassay.  Data presented 
as mean +/- SEM.  (* and  †:  Tukey’s post hoc p-value <0.05 in comparison of WT and CCSP-/- or comparison to 
control, respectively; WT:  Black, CCSP-/-: White). 
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To determine whether LPS had direct effects on epithelial cytokine production apical 
fluid was recovered from cultures and the abundance of pro-inflammatory cytokines and 
chemokines measured by multiplex immunoassay.  LPS stimulated epithelial secretion of IL-6 
into apical fluid of cultures from WT and CCSP-/- mice.  A trend towards differences between 
WT and CCSP-/- cultures was observed.  Levels of IL-6 present within apical fluid of epithelium 
from CCSP-/- mice was 6.18 fold and 3.5 fold higher at 6 and 24 hours than that of similarly 
exposed cultures from WT mice (Figure 18D).  These differences did not reach significance due 
to variability at the 24 hour time point and stringency of the general linear model (GLM).  
However, a pair-wise comparison using a student’s unpaired t-test yielded a statistically 
significant p-value of 0.001 at the 6 hour timepoint.  Additionally, a similar trend in the 
abundance of KC and RANTES was found (data not shown).  Together these data indicate that 
the CCSP-/- epithelium is intrinsically hyper-responsive to LPS.  However, these changes are 
only weakly associated with the CCSP dependent component of the LPS response.  Therefore, 
the levels of TNF-α secreted into the media were investigated, since this is the most robust 
difference between genotypes following LPS exposure in vivo, as identified by pathway analysis 
and subsequent protein validation.  TNF-α was below the limit of detection in control and LPS 
exposed WT and CCSP-/- epithelial cultures (data not shown), confirming that the cell types 
mediating synthesis and secretion of TNF-α are absent within epithelial cultures. 
In light of the previous finding of biochemical changes to macrophages of CCSP-/- mice 
it was determined if there were functional alterations to macrophages of CCSP-/- mice that might 
account for the observed phenotype described in this study62.  WT and CCSP-/- macrophages 
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were isolated by lavage of steady-state lung and exposed to 0.00, 0.39, 0.78, 1.56, 3.13 6.25, 
12.5, and 25.00 ng/ml LPS and media harvested for analysis of TNF-α release after 6 hours.  
Lung macrophages recovered from CCSP-/- mice displayed a robust increase in LPS-elicited 
TNF-α release compared to similarly exposed macrophages from WT mice (Figure 19A).  Levels 
of TNF-α released into medium of macrophages cultured from CCSP-/- mice was increased over 
that present in macrophages from WT mice by 1.75-2.6 fold when stimulated by LPS 
concentrations of 3.1-12.5 ng/ml (Figure 19A).  These results indicated that CCSP may moderate 
the macrophage elicited LPS response. 
CCSP deficiency may cause alterations to the LPS recognition machinery on lung 
macrophages in parallel to the findings following naphthalene induced Clara cell depletion 
(Figure 13).  Determination of mRNA abundance of TLR4 and CD14 in WT and CCSP-/- 
alveolar macrophages demonstrated no significant difference between genotypes (Figure 19B 
and C, respectively).  As naphthalene induced Clara cell depletion resulted in increased surface 
expression of TLR4 on lung macrophages, macrophages isolated from steady-state CCSP-/- mice 
may have a similar alteration to TLR4 distribution.  Cells were stained with macrophage marker 
F4/80 and TLR4 to determine if trafficking had been affected.  Confocal microscopy of F4/80+ 
WT and CCSP-/- macrophages (Figure 19D and 19F, respectively) revealed increased TLR4 
expression in F480+ CCSP-/- macrophages (Figure 19G) compared to WT (Figure 19E).  In 
order to quantify the observed increase in TLR4 expression on CCSP-/- macrophages flow 
cytometric analysis of WT and CCSP-/- macrophages was performed.  Lavaged WT and CCSP-
/- cells were stained for F4/80 and TLR4.  TLR4 expression was evaluated on F4/80+ 
macrophages and demonstrated that CCSP-/- macrophages have a robust increase in surface  
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Figure 19.  CCSP deficiency augments the macrophage elicited inflammatory response.  
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Figure 19 Continued. 
(A) Primary lung macrophages from WT and CCSP-/- mice were exposed to 0.00, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 
and 25.00 ng/ml P. Aeruginosa derived LPS spiked media for six hours (N = 4 per group).  TNF-α  (pg/ml) was 
determined in media by a mouse TNF-α sandwich ELISA.   (* and  †:  Tukey’s post hoc p-value <0.05 in 
comparison of WT and CCSP-/- or comparison to control, respectively; WT:  Black, CCSP-/-:  White).  (B and C)  
Realtime PCR analysis of TLR4 and CD14 mRNA abundance in isolated lung macrophages indicates no difference 
(t-test p-value >0.05) between WT and CCSP-/- in expression of key components of the LPS signaling machinery 
(N = 3/genotype).  BAL cells from WT (D, E) and CCSP-/- (F, G) lungs were stained for the macrophage marker 
F4/80 (D, F), TLR4 (E, G), and analyzed by confocal microscopy.  Flow cytometric analysis of BAL cells from 
wild-type (Black,  N = 5) and CCSP-/- (White, N = 5) lungs were stained for F4/80 and TLR4.  TLR4 expression on 
F4/80 positive macrophages was quantified and presented as geometric mean fluorescent intensity (H, *t-test p-
value < 0.001) and percentage of macrophages with high TLR4 expression (I, *t-test p-value < 0.001).  Data 
presented as mean +/- SEM. 
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TLR4 surface expression represented by the geometric mean of the fluorescence intensity and % 
of macrophages with high TLR4 surface expression (Figure 19 H and I, respectively).  These 
results confirm that macrophages from CCSP-/- mice are hyper-responsive to LPS and that the 
increased TLR4 surface expression on macrophages was most likely responsible for the observed 
increase in TNF-α production in vivo following delivery of aerosolized LPS. 
To determine if CCSP directly regulates macrophage responsiveness to LPS in cultured 
macrophages, fractionated BAL was prepared from WT and CCSP-/- mice according to a 
previously published protocol196 and used to test the inhibitory effects of CCSP on macrophage 
responsiveness.  These experiments are discussed in detail in Appendix B.2 Figure 25.  Briefly, 
Raw264.7 macrophages were exposed to LPS and TNF-α measured in the supernatant as an 
endpoint for macrophage responsiveness.  The ability of BAL to modulate this response was 
further investigated in two separate experiments.  In the first experiment, no differences in the 
potency of LPS were observed following pre-incubation of LPS with fractionated BAL and 
stimulus of cultured macrophages using BAL/LPS extract.. In the second experiment, pre-
treatment of macrophages with fractionated BAL prior to LPS stimulus also didn’t affect the LPS 
elicited inflammatory response (Appendix B. 2 Figure 25).  These data suggest that neither 
CCSP nor other changes to the acellular fraction of airway lining fluid from CCSP-/- mice 
directly regulate macrophage responsiveness to LPS.  Rather, this data support a model in which 
attenuated Clara cell function results in intrinsic functional differences in the lung macrophage 
population. 
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4.5 DISCUSSION 
This study provides evidence for anti-inflammatory roles of the airway epithelium and 
elucidates a mechanism whereby Clara cells may regulate this process.  Injured airway 
epithelium and mice deficient in expression of Clara cell secretory protein (CCSP) respond more 
robustly to inhaled P. aeurginosa lipopolysaccharide (LPS) leading to increased recruitment of 
PMNs.  Through utilization of micrroarray analysis, pathway modeling, and in vivo validation it 
was demonstrated that TNF-α signaling was robustly increased in the CCSP-/- inflammatory 
response. Functional analysis of macrophages isolated from WT and CCSP-/- lungs revealed a 
robust increase in LPS responsiveness in the CCSP-/- isolated macrophage compared to WT and 
was paralleled by increased TLR4 surface abundance on CCSP-/- macrophages at steady-state.  
The response of cultured macrophages could not be altered in vitro with fractionated CCSP 
enriched BAL indicating that CCSP does not directly regulate macrophage responsiveness.  
Instead, these data argue that CCSP deficiency causes an intrinsic alteration to lung macrophage 
behavior. 
Recent reports have suggested that the airway epithelium provides a pro-inflammatory 
role in the innate immune response through modulation of epithelial NF-kB signaling and 
subsequent secretion of inflammatory cytokines and chemokines 27,35-37.  In contrast, results in 
this study define normal Clara cell secretory function and the production of CCSP as key 
negative regulators of the inflammatory response, providing evidence that the airway epithelium 
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confers anti-inflammatory properties to the lung.  Of particular interest is the apparent 
discrepancy between the findings presented herein and those of Elizur and colleagues describing 
the effects of acute Clara cell injury on the inflammatory response 27.  In their study, Elizur and 
colleagues concluded that Clara cells are pro-inflammatory based upon their observation of 
attenuated TNF-α and KC production in LPS challenged naphthalene injured lung.  In contrast, 
this study demonstrates that Clara cells are anti-inflammatory based upon the observation that 
PMN recruitment is synergistically increased in LPS challenged naphthalene injured lung.  A 
likely explanation can be attributed to differences in the time at which injured mice are 
challenged with LPS.  In the study by Elizur and colleagues, the protocol indicates mice were 
exposed to LPS 2.5 hours after injury, which is preceded 1.5 hours earlier by a supra-maximal 
level of Clara cell secretions in the airway as measured by CCSP protein abundance in BAL 
(Figure 13A). The overabundance of CCSP delivered into the airway before LPS stimulus may 
therefore diminish the inflammatory response.  In contrast, the protracted loss of Clara cell 
secretory function results in altering lung macrophage behavior and exacerbating the response to 
pro-inflammatory stimuli. 
These data have important implications regarding regulation of the inflammatory 
response in normal and diseased airway.  In the normal adult airway, Clara cells function to 
moderate responses to inhaled inflammatory agents, a function that involves paracrine influences 
of Clara cell secretions on lung macrophages 62.  These data suggest that Clara cell secretory 
dysfunction that accompanies airway remodeling results in loss of the intrinsic 
immunosuppressive properties provided by the epithelium leading to exacerbation of the 
inflammatory response.  Furthermore, the exposure of epithelial cells from WT mice to LPS 
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results in a dramatic decrease in expression of CCSP.  This finding is consistent with previous 
reports demonstrating that in vivo exposure of mice to live P. aeurginosa results in decreased 
expression of CCSP.  However, in contrast to the finding of Harrod et al., this study 
demonstrates that decreased CCSP mRNA abundance can occur independently of TNF-α 195. 
When put in the context of these findings from other laboratories these data argue that airway 
inflammation resulting from acute exposure of normal airways to pro-inflammatory bacterial 
products is actively suppressed, but that chronic infection leads to decreased Clara cell secretory 
function and elevated immune-responsiveness that is typical of individuals with chronic lung 
disease. 
The postulated paracrine/endocrine function of CCSP implies recognition by a cell 
surface receptor. A candidate receptor system has previously been described in the proximal 
tubule of the kidney in which receptor mediated endocytosis occurs through a megalin/cubilin 
dependent mechanism.  Receptor mediated uptake of CCSP within the proximal convoluted 
tubule results in its catabolism which has the potential to release bound ligands 197. However, this 
receptor/ligand interaction was shown to be specific to the kidney with no evidence for its 
activity within structural cells or macrophages of the lung.  Other candidate receptors have been 
described previously leading to speculation that CCSP may function as a cytokine 198,199. 
Recently another candidate receptor has been identified that mediates interactions with other 
structurally related members of the secretoglobin family. SCGB3A2 was shown in an expression 
cloning screen to interact with the macrophage receptor with collagenous structure (MARCO) 
200.  Moreover, SCGB3A2 was shown to compete with LPS for interaction with MARCO, 
suggesting an alternative mechanism by which secretoglobin family members may alter the 
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macrophage response to LPS.  However, these data suggest that a similar mechanism does not 
operate in the CCSP dependent moderation of LPS elicited lung inflammation, as the CCSP 
containing fraction of BAL fails to attenuate LPS elicited TNF-α release in cultured 
macrophages. 
The demonstration in the present study that macrophage function is altered in the setting 
of CCSP deficiency is consistent with the previous description of changes in annexin A1 
(ANXA1) post-translational modification (PTM) within macrophages of CCSP-/- mice 62.  
ANXA1 has been shown to play a role in modulation of innate immunity through 
phosphorylation dependent modulation of the subcellular partitioning in phagosomes.  However 
mechanisms by which post-translational modification of ANXA1 modulate this process remains 
unknown 201,202.   Studies aimed at understanding mechanisms of TNF-α release from 
macrophages have revealed that secretion occurs exclusively from the phagocytic cup, a 
subcellular location where TNF-α is brought into close apposition with its activating protease, 
TNF-α converting enzyme (TACE)  203.  It is possible that the increased surface expression of 
TLR4 and resultant increase in TNF-α secretion following LPS stimulus may be dependent upon 
CCSP dependent changes to ANXA1.    
The inability of fractionated BAL to modulate macrophage responsiveness to LPS 
suggests that CCSP does not directly regulate this process.  A reasonable explanation is that the 
macrophage population in the Clara cell depleted and CCSP deficient lung is intrinsically altered 
compared to the steady-state and WT populations, respectively.  A possible explanation is that 
CCSP-/- results in altered steady-state monocyte/macrophage populations within the lung.  
Recently, a subpopulation of monocytes has been identified, termed inflammatory monocytes.  
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These cells can be distinguished based upon the expression of several genetic markers, including 
ANXA1, and their pro-inflammatory gene signature204.  Moreover, these cells are required for a 
robust neutrophilic response to LPS205.  More recently, Kim and colleagues demonstrated 
alterations to macrophage subsets in the setting of chronic lung disease.  In particular, they 
identified an increased abundance of alternatively activated macrophages in CLD, in both mouse 
models as well as patients.  These cells contributed directly to the progression of mucus cell 
metaplasia and epithelial remodeling that is typical of CLD206.  Additional studies will be 
necessary to determine if altered Clara cell secretory function impacts the monocyte/macrophage 
populations within the lungs of CCSP-/- mice. 
Chronic lung disease and associated inflammatory exacerbations are a result of complex 
interactions between the host and environment207.  This study identifies a mechanism of 
epithelial:macrophage cross-talk which when perturbed, as in the setting of chronic lung disease, 
results in an augmented innate inflammatory response to inhaled environmental agents.  The 
precise molecular mechanism by which CCSP or other unidentified Clara cell secreted proteins 
mediate these immunomodulatory effects will be the subject of future studies. 
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5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 EPITHELIAL REPARATIVE CAPACITY REGULATES ECM DYNAMICS 
5.1.1 Conclusions 
In Chapter 3, the hypothesis that airway epithelial reparative capacity moderates ECM 
dynamics was tested.  This hypothesis had long been suggested though it had never been tested 
in vivo.  This study demonstrated that airway epithelial injury initiated a robust response from the 
underlying mesenchyme.  Within 4.0 hours of injury mRNA abundance of ECM gene product 
TNC accumulated in total lung RNA and reached a maximum by 1 day.  When repair initiated, 
TNC mRNA abundance quickly returned to baseline.  Immuno-localization of TNC protein 
during injury and repair indicated an equally dynamic process.  TNC quickly accumulated in the 
subepithelial mesenchyme 1 day after injury and returned to baseline during productive epithelial 
repair.  In contrast, in the setting of unproductive epithelial repair, TNC mRNA and protein 
abundance aberrantly and chronically accumulate in the lung.  These data clearly indicated that 
mesenchymal remodeling in CLD may be a direct result of attenuated epithelial reparative 
capacity. 
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5.1.2 Future Directions 
The finding that airway epithelial repair can moderate ECM dynamics illustrates the need to 
define the molecular pathways regulating proper airway epithelial repair.  Currently, few 
pathways are known that regulate this process, however, recent work has indicated that 
WNT/CATNNB1122, TIMP-1208, MMP-7209 or STAT3210 may be regulators of this process.  
Chapter 3 defines several additional signaling pathways with potential for regulating epithelial 
repair.  TNC has previously been shown to regulate aspects of wound repair including epithelial 
migration and differentiation154.  Therefore TNC may play an active role in regulating epithelial 
repair as an important niche derived protein factor.  To test this hypothesis mice deficient for 
TNC (TNC-/-) will be injured with naphthalene and repair assessed.  TNC-/- mice have been 
imported and breeding initiated to establish an in house experimental colony.  Additionally, the 
mRNA abundance of AREG, a ligand for EGFR shown to mediate repair of injured liver 
hepatocytes211,212, was immediately up-regulated following lung injury.  This suggests that 
AREG/EGFR may regulate airway epithelial repair.  To test this hypothesis mice deficient for 
AREG (AREG-/-) will be injured with naphthalene and reparative capacity assessed.  AREG-/- 
mice have been imported and breeding initiated to establish an in house experimental colony.  
Additionally mice with a floxed allele of EGFR are in the process of being imported.  By 
crossing these mice to a transgenic line in which the CCSP promoter drives expression of CRE, 
EGFR can be deleted in all CCSP expressing cells of the conducting airway epithelium.  These 
mice will also be injured and repair evaluated.  The future studies outlined here will help to 
define additional regulators of epithelial repair.  Given the importance of epithelial repair in 
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moderating ECM dynamics, these pathways may prove to be useful points of therapeutic 
intervention in the setting of CLD. 
5.2 CLARA CELLS MODERATE THE INFLAMMATORY RESPONSE THROUGH 
REGULATION OF MACROPHAGE BEHAVIOR 
5.2.1 Conclusions 
Clara cells are the most abundant secretory cell lining the conducting airway epithelium in mice 
and an abundant cellular component of bronchiolar airways in human6,7.  In recent years their 
role in airway homeostasis has been studied, including epithelial repair and secretion.  More 
recently, studies have sought to determine the role that Clara cells play in regulation of innate 
immunity and have identified an essential role in transduction of pro-inflammatory signals28.  
Proper moderation of innate immunity and the inflammatory response are critical to lung 
function due to persistent exposures to environmental agents.  As discussed, Clara cell 
abundance and secretory capacity are severely diminished in the setting of chronic lung disease.  
Given their role in innate immunity, the persistent inflammation present in CLD, and decreased 
abundance in inflammatory lung disease, these data suggest that Clara cells may moderate the 
inflammatory response.  This study was designed to test this hypothesis.  Results of this study 
indicated that injury to Clara cells potentiates the inflammatory response.  In addition, a mouse 
model of attenuated Clara cell secretory function (CCSP-/- mice) also demonstrated that Clara 
cells have immunosuppressive properties.  These data implied that Clara cells serve a paracrine 
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signaling function in the lung to regulate this process.  Previous studies indicated that CCSP 
deficiency caused alterations to the macrophage proteome62.  Therefore, inflammation and 
macrophage behavior were assessed in models of diminished Clara cell abundance and secretion.  
These data indicated that macrophage behavior is altered resulting in increased surface 
expression of TLR4 and corresponding increased responsiveness to LPS. 
5.2.2 Future Directions 
Future studies will be directed at elucidating the mechanism by which lung macrophage behavior 
is altered.  There are likely two reasonable mechanisms through which macrophages may have 
increased surface expression of TLR4 and increased responsiveness to LPS.  Clara cells may 
either 1) directly regulate TLR4 trafficking or 2) regulate the trafficking or differentiation of 
monocyte and macrophage subpopulations in the lung.  The former mechanism is not likely 
given the inability to affect the responsiveness of macrophages to LPS treated with WT or 
CCSP-/- lavage.  Therefore, the latter represents a more plausible mechanism.  Recent data 
indicate that monocyte populations can be fractionated on cell surface phenotype and their pro-
inflammatory gene signature204.  More recently, alternatively activated macrophages were shown 
to be increased in the setting of CLD and a driving force for mucus cell metaplasia and epithelial 
remodeling206.  Therefore, future studies will be aimed at evaluating the monocyte/macrophage 
populations in the CCSP-/- lung more thoroughly.  This will include microarray analysis of WT 
and CCSP-/- lung macrophages for comparison to previously published gene signatures of 
monocyte/macrophage populations as well as FACS analysis using previously identified markers 
of monocyte/macrophage subsets213. 
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5.3 WORK IN PROGRESS 
5.3.1 Basic studies to define the behavior of airway progenitor cells in normal and 
diseased states     
Epithelial maintenance is dependent upon a balance between turnover and renewal.  If the rate of 
epithelial turnover is held constant, maintenance is purely a function of progenitor cell self-
renewal versus differentiation.  There is currently no information in the existing literature that 
describes the probability with which different progenitor cell types are maintained through self-
renewal or whether this property is impacted by divergence from the steady state such as might 
be the case with acute or chronic lung disease.  The existence of multiple progenitor cell types 
that can be hierarchically organized, such as those of the bronchiolar epithelium, increase the 
complexity of this question.  It is possible, for example, that bronchiolar stem cells are 
maintained through a highly regulated process involving extrinsic signals from the stem cell 
niche to ensure long-term maintenance of a stem cell pool of a defined size.  The likelihood that 
stem cells are activated to participate in epithelial maintenance would inevitably be related to 
longevity of the transit-amplifying progenitor cell pool.  For example, if TA cell maintenance 
occurs through a stochastic mechanism as proposed by Jones and co-workers68,69, the probability 
of which is influenced by extrinsic factors such as injury and/or inflammation, the contribution 
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of stem cells towards epithelial maintenance will be strongly influenced by disease.  Major 
knowledge gaps and experimental rationale are outlined below. 
5.3.2 Analysis of airway progenitor cell behavior during normal epithelial maintenance 
and repair 
The utilization of airway epithelial progenitors during normal epithelial maintenance and repair 
following injury is underappreciated.  The most intriguing and fundamental questions are 
outlined below: 
1) How does progenitor cell utilization differ between steady-state maintenance and repair 
following injury? 
2) Are naphthalene resistant cells (vCE, vClara) sequestered through a stochastic 
mechanism? 
3) What is the proliferative latency of the vCE/vClara, and do they contribute to steady-state 
epithelial maintenance? 
4) How does disease state impact progenitor cell utilization and proliferative latency? 
 
To answer these questions, a labeling strategy has been developed in the lab according to a 
previously published manuscript by Teta and co-workers80.  Using this approach, successive 
rounds of proliferation can be monitored by incorporation of halogenated thymidine analogues 
into DNA when cells traverse S-phase of the cell cycle and immuno-localized with antibodies 
specific to each thymidine derivative.  Antibody/antigen specificity and evaluation of labeling 
efficiency are presented in figures 20 and 21, respectively.  Preliminary evidence does indicate 
the airway epithelial progenitor cell utilization differs greatly compared to the intestine at steady-
state (Figures 22 and 23).  At steady-state, epithelial proliferation is randomly distributed 
throughout the airway and does not utilize an obligate progenitor population.  This is 
demonstrated by the lack of cells undergoing repeated rounds of proliferation.  Interestingly, 
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activation of the stem cell compartment following airway epithelial injury does indicate that 
progenitor cells lining the conducting airway epithelium do have the capacity for successive 
rounds of proliferation with a marked reduction in the latency period.  These preliminary data 
indicate that the airway epithelium is maintained and repaired through two different modes of 
progenitor cell utilization.  Experiments are ongoing to more thoroughly investigate the 
questions outlined above and are expected to reach completion by June 2009. 
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Figure 20.  Determination of antibody immunoreactivity and specificity in intestinal and airway epithelium 
labeled with halogenated thymidine derivatives. 
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Figure 20 Continued. 
WT mice were injected with 0.25 mg of CldU (A, B, E, F) or IdU (C, D, G, H) reconstituted in sterile pyrogenic free 
saline in the intraperitoneal cavity and sacrificed following a 2.0 hour chase.  (A-D)  The intestinal epithelium was 
formalin fixed, cryo-preserved, sectioned at 5um, and stained with antibodies raised against CldU (A,C) or IdU (B, 
D) (pseudo-colored red or green, respectively, and DAPI nuclear dye pseudo-colored blue).  Note both (A) CldU 
and (D) IdU injections and immuno-staining revealed extensive epithelial proliferation in the intestinal crypts.  IdU 
immunoreactivity in CldU injected mice (B) and CldU immunoreactivity in IdU injected mice (C) was 
unremarkable, indicating the specificity of the antibody/antigen complex.  (E-H)  To test the specificity in lung, 
mice were first exposed to naphthalene to increase the proliferative fraction of airway epithelium.  Lungs were 
harvested 3 days after injury, inflation fixed, cryopreserved, sectioned at 5um, and stained with antibodies raised 
against CldU (E,G) or IdU (F, H) (pseudo-colored red or green, respectively; and DAPI nuclear dye, blue).  Note 
both (E) CldU and (E) IdU injections and immuno-staining revealed extensive airway and alveolar epithelial 
proliferation as well as proliferation in the underlying mesenchyme.  IdU immunoreactivity in CldU injected mice 
(F) and CldU immunoreactivity in IdU injected mice (G) was unremarkable, indicating the specificity of the 
antibody/antigen complex.  Representative images at 200X. 
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Figure 21.  IdU and CldU label equivalent populations of proliferative intestinal or lung epithelial cells. 
WT mice were injected with 0.25 mg of CldU and IdU reconstituted in sterile pyrogenic free saline in the 
intraperitoneal cavity and sacrificed following a 2.0 hour chase.  (A-C)  Intestine was formalin fixed, cryopreserved,  
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Figure 21 Continued. 
sectioned at 5um, and immuno-stained for CldU and IdU.  (A)  CldU pseudo-colored red, (B) IdU pseudo-colored 
green, and (C) merged image pseudo-colored yellow demonstrate that CldU and IdU label equivalent populations of 
intestinal crypt epithelial cells traversing the S-phase of the cell cycle.  (D-F)  Mice were exposed to naphthalene to 
increase the proliferative pool of the epithelium, injected with 0.25mg  CldU and IdU 3 days after injury, and 
sacrificed following a 2.0 hour chase.  The lung was harvested,  formalin fixed, cryopreserved, sectioned at 5um, 
and immuno-stained for CldU and IdU.  (D)  CldU pseudo-colored red, (E) IdU pseudo-colored green, and (F) 
merged image pseudo-colored yellow demonstrate that CldU and IdU label equivalent populations of airway 
epithelial cells, alveolar epithelial cells, and mesenchymal cells traversing the S-phase of the cell cycle.  
Representative images at 200X. 
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Figure 22.  Proliferative latency of progenitor cells in the intestinal epithelium. 
Mice were injected with 0.25 mg of CldU, chased for 2 days, injected with 0.25mg of IdU, and sacrificed 
after a 2 hour chase.  Intestine was harvested, formalin fixed, cryopreserved, sectioned at 5um, and immuno-stained 
for CldU (A, D; pseudo-colored red), IdU (B, E; pseudo-colored green).  Merged images are presented in panels C  
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Figure 22 Continued. 
and F.  Representative images at 200X (A-C) and 400X (D-F).  Note the high degree of proliferation throughout the 
intestinal crypt and villus.  This approach clearly demonstrates that cells proliferate in the intestinal crypt, and 
migrate up the intestinal villus where they continue to proliferate (note the label dilution that occurs between the 
migrating tip of the CldU positive epithelial cells and the intestinal crypt).  The highly proliferative population of 
epithelial cells migrating up the intestinal villus is referred to as an obligate transit-amplifying cell.  Additionally a 
subset of cells in the crypt proliferates rapidly, located near the +4 position of the crypt (F, marked by arrow).  This 
is a putative stem cell location within the crypt characterized by Lgr5 expression and short proliferative latency.  
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Figure 23.  Utilization of progenitor cells in the conducting airway epithelium during steady-state 
maintenance and repair. 
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Figure 23 Continued. 
(A)  WT mice were injected every 12 hours with 0.25mg CldU for 3 days followed by IdU injections every 12 hours 
for an additional 3 days.  Lungs were harvested, formalin fixed, cryopreserved, sectioned at 5um, and immuno-
stained for CldU (pseudo-colored red) and IdU (pseudo-colored green).  A merged image is presented and 
representative at 400X.  Note the low levels of proliferation in the airway epithelium, and high degree of 
proliferative latency (lack of cells undergoing proliferation >1, as indicated by a lack of CldU/IdU positive 
epithelium).  Also, proliferation is not defined to a specific region of the airway epithelium.  This is in stark contrast 
to the intestinal epithelium (Figure 22).  To test if this mode of progenitor cell utilization changes as a function of 
injury, WT mice were injected with naphthalene and (B) CldU for 3 days every 12 hours followed by IdU for 1 day 
every 12 hours or (C) CldU for 3 days every 12 hours followed by IdU for 3 days every 12 hours.  Lung tissue was 
harvested, formalin fixed, cryopreserved, sectioned at 5um, and immuno-stained for CldU (pseudo-colored red), IdU 
(pseudo-colored green), and CCSP (pseudo-colored magenta).  Sections were also stained with the nuclear dye 
DAPI (pseudo-colored (B) blue, and (C) grey).  Merged images are presented and representative of 400X fields.  In 
panel B, note the increased proliferation of the airway epithelial cells that are located at the BADJ and have 
undergone successive rounds of proliferation as indicated by their immuno-reactivity to both CldU and IdU (yellow, 
arrow).  In panel C, epithelial repair has advanced as evidenced by the appearance of epithelial cells immuno-
reactive for the Clara cell specific antigen CCSP and dilution of CldU.    Collectively, these data demonstrate that 
airway epithelial progenitor cell utilization differs markedly from steady-state maintenance both in the latency 
period between successive rounds of proliferation and the organization of highly proliferative cells to defined 
microenvironments within the airway. 
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5.4 FINAL THOUGHTS 
The conducting airway epithelium fulfills a myriad of important functions that serve to 
modulate and maintain lung homeostasis.  In order to develop successful treatment strategies for 
CLD, studies designed to elucidate the mechanisms underlying development and progression of 
CLD are necessary.  In this dissertation, cellular and molecular mechanisms are identified that 
affect aspects of CLD including uncontrolled ECM deposition, mesenchymal remodeling, and 
lung inflammation.  This work significantly advances the current views of the airway epithelium 
and the role it plays in normal lung homeostasis and disease. 
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APPENDIX A 
CHAPTER 2 SUPPLEMENTARY MATERIAL 
A.1 SUPPLEMENTARY TABLES:  PRODUCTIVE REPAIR GENE SIGNATURE 
Table 1. Productive Repair Gene Signature (Node 89) 
Fold Change Relative to Control (0) 
LLID  Symbol  Name  0  1  2  3  6 
17750  Mt2  Metallothionein 2  1.0  42.8  11.4  7.4  6.5 
16156  Il11  Interleukin 11  1.0  17.7  6.1  4.4  2.4 
55948  Sfn  Stratifin  1.0  11.7  4.4  3.4  2.5 
12740  Cldn4  Claudin 4  1.0  12.2  5.3  2.9  2.9 
57875  Angptl4  Angiopoietin‐like 4  1.0  7.5  3.6  2.4  1.7 
12575  Cyclin‐dependent kinase inhibitor 1A (P21)  1.0  9.7  2.8  2.7  2.4 
20698  Sphk1  Sphingosine kinase 1  1.0  10.9  3.7  3.7  2.7 
*27279  Tnfrsf12a 
Tumor necrosis factor receptor superfamily, 
member 12a  1.0  9.6  4.4  3.5  2.9 
23886  Gdf15  Growth differentiation factor 15  1.0  8.5  3.2  2.3  2.8 
20648  Snta1  Syntrophin, acidic 1  1.0  3.6  3.0  3.5  2.8 
170706  Tmem37  Transmembrane protein 37  1.0  5.1  3.2  3.4  2.6 
17869  Myc  Myelocytomatosis oncogene  1.0  5.5  4.2  3.6  3.1 
66166  S100a14  S100 calcium binding protein A14  1.0  6.9  4.2  4.3  3.2 
20361  Sema7a 
Sema domain, immunoglobulin domain (Ig), and GPI 
membrane anchor, (semaphorin) 7A  1.0  5.6  3.5  3.5  2.4 
66214  1190002H23Rik  RIKEN cDNA 1190002H23 gene  1.0  6.2  3.5  3.4  2.0 
104009  Qsox1  Quiescin Q6 sulfhydryl oxidase 1  1.0  6.5  3.5  3.2  2.2 
214855  Arid5a  AT rich interactive domain 5A (Mrf1 like)  1.0  5.5  3.0  2.8  2.6 
18654  Pgf  Placental growth factor  1.0  5.2  3.2  2.7  1.9 
*18791  Plat  Plasminogen activator, tissue  1.0  5.5  2.8  2.7  1.8 
15368  Hmox1  Heme oxygenase (decycling) 1  1.0  4.6  2.8  2.7  2.3 
*11647  Alpl  Alkaline phosphatase, liver/bone/kidney  1.0  5.1  2.4  2.4  1.9 
57266  Cxcl14  Chemokine (C‐X‐C motif) ligand 14  1.0  7.4  3.2  3.1  1.8 
22223  Uchl1  Ubiquitin carboxy‐terminal hydrolase L1  1.0  7.0  3.4  3.0  1.9 
*18793  Plaur  Plasminogen activator, urokinase receptor  1.0  7.1  3.6  3.1  2.4 
94242  Tinagl  Tubulointerstitial nephritis antigen‐like  1.0  8.2  3.7  3.5  2.8 
20295  Ccl17  Chemokine (C‐C motif) ligand 17  1.0  9.0  3.2  5.2  2.6 
14229  Fkbp5  FK506 binding protein 5  1.0  6.9  3.3  4.0  1.6 
20296  Ccl2  Chemokine (C‐C motif) ligand 2  1.0  6.6  4.9  5.5  1.9 
19288  Ptx3  Pentraxin related gene  1.0  9.3  7.4  4.9  2.7 
12642  Ch25h  Cholesterol 25‐hydroxylase  1.0  10.8  8.0  5.5  3.6 
21816  Tgm1  Transglutaminase 1, K polypeptide  1.0  8.8  7.4  6.3  4.0 
67951  Tubb6  Tubulin, beta 6  1.0  5.0  5.0  4.4  2.3 
20293  Ccl12  Chemokine (C‐C motif) ligand 12  1.0  6.3  5.3  4.4  2.3 
20716 
Serine (or cysteine) peptidase inhibitor, clade A, 
member 3N  1.0  8.6  7.2  4.8  2.7 
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18212  Ntrk2  Neurotrophic tyrosine kinase, receptor, type 2  1.0  4.3  6.2  3.4  1.6 
*21923  TNC  Tenascin C  1.0  3.8  4.8  2.9  1.8 
18405  Orm1  Orosomucoid 1  1.0  3.7  5.0  3.9  1.8 
20308  Ccl9  Chemokine (C‐C motif) ligand 9  1.0  2.9  3.9  3.8  1.8 
11813  Apolipoprotein C‐II  1.0  3.3  3.8  4.5  2.3 
11847  Arg2  Arginase type II  1.0  2.8  3.3  3.8  1.6 
11846  Arg1  Arginase 1, liver  1.0  2.3  3.6  3.4  1.4 
76574  Mfsd2  Major facilitator superfamily domain containing 2  1.0  2.3  2.7  3.5  3.4 
12796  Camp  Cathelicidin antimicrobial peptide  1.0  3.5  2.0  3.0  3.3 
59083  Fetub  Fetuin beta  1.0  2.5  3.2  2.9  2.4 
234199  Fgl1  Fibrinogen‐like protein 1  1.0  2.9  3.6  2.7  2.0 
57814  Kcne4 
Potassium voltage‐gated channel, Isk‐related 
subfamily, gene 4  1.0  3.1  3.2  3.1  1.7 
11486  Ada  Adenosine deaminase  1.0  4.7  2.5  2.9  1.6 
11625  Ahsg  Alpha‐2‐HS‐glycoprotein  1.0  6.9  4.0  3.1  2.4 
14121  Fbp1  Fructose bisphosphatase 1  1.0  5.9  3.6  3.0  3.5 
14325  Ferritin light chain 1  1.0  3.1  3.0  2.5  2.8 
20302  Ccl3  Chemokine (C‐C motif) ligand 3  1.0  3.6  3.3  2.7  2.3 
116903  Calcb  Calcitonin‐related polypeptide, beta  1.0  4.7  2.9  2.1  1.7 
13654  Egr2  Early growth response 2  1.0  3.6  3.3  2.4  1.9 
23882  Gadd45g 
Growth arrest and DNA‐damage‐inducible 45 
gamma  1.0  3.9  2.5  2.7  2.1 
17395  Mmp9  Matrix metallopeptidase 9  1.0  4.0  2.1  2.9  1.9 
16012  Igfbp6  Insulin‐like growth factor binding protein 6  1.0  3.4  2.3  2.9  2.1 
14622  Gjb5  Gap junction protein, beta 5  1.0  4.3  3.9  3.9  1.9 
21930  Tnfaip6  Tumor necrosis factor alpha induced protein 6  1.0  4.4  3.2  3.7  2.0 
26366  Ceacam10  CEA‐related cell adhesion molecule 10  1.0  3.0  1.8  3.5  2.8 
14204  Interleukin 4 induced 1  1.0  3.0  2.1  3.3  2.8 
66277  Klf15  Kruppel‐like factor 15  1.0  3.2  1.8  3.1  2.2 
15945  Cxcl10  Chemokine (C‐X‐C motif) ligand 10  1.0  2.7  2.0  3.8  2.1 
20568  Slpi  Secretory leukocyte peptidase inhibitor  1.0  4.1  3.4  5.2  3.1 
74747  Ddit4  DNA‐damage‐inducible transcript 4  1.0  3.5  3.2  4.3  3.2 
18029  Nfic  Nuclear factor I/C  1.0  2.2  2.3  2.8  2.3 
69665  2310043J07Rik  RIKEN cDNA 2310043J07 gene  1.0  2.6  2.5  2.6  2.2 
224619  Traf7  Tnf receptor‐associated factor 7  1.0  3.3  2.7  3.1  3.0 
19229  Ptk2b  PTK2 protein tyrosine kinase 2 beta  1.0  2.0  1.9  1.5  2.1 
76905  Lrg1  Leucine‐rich alpha‐2‐glycoprotein 1  1.0  7.5  7.4  7.9  8.1 
19152  Prtn3  Proteinase 3  1.0  4.3  4.4  8.2  3.2 
70835  Prss22  Protease, serine, 22  1.0  3.8  4.7  4.1  2.5 
14620  Gjb3  Gap junction protein, beta 3  1.0  5.4  5.5  5.6  3.8 
19734  Rgs16  Regulator of G‐protein signaling 16  1.0  5.4  4.9  5.4  4.3 
16000  Igf1  Insulin‐like growth factor 1  1.0  1.7  5.7  4.9  1.2 
18406  Orm2  Orosomucoid 2  1.0  3.9  8.0  8.0  2.9 
13717  Eln  Elastin  1.0  3.0  5.6  9.6  3.6 
20202  S100a9  S100 calcium binding protein A9 (calgranulin B)  1.0  4.5  2.3  4.5  1.7 
76770  2010005H15Rik  RIKEN cDNA 2010005H15 gene  1.0  5.0  3.6  5.0  2.1 
20201  S100a8  S100 calcium binding protein A8 (calgranulin A)  1.0  7.0  3.6  5.1  2.7 
53608  Map3k6  Mitogen‐activated protein kinase kinase kinase 6  1.0  7.6  2.6  3.7  1.6 
85031  Pla1a  Phospholipase A1 member A  1.0  8.9  6.2  3.0  1.4 
20306  Ccl7  Chemokine (C‐C motif) ligand 7  1.0  7.2  5.5  6.0  1.3 
20753  Sprr1a  Small proline‐rich protein 1A  1.0  13.7  10.4  10.7  3.1 
20310  Cxcl2  Chemokine (C‐X‐C motif) ligand 2  1.0  12.6  8.2  13.7  5.3 
14825  Cxcl1  Chemokine (C‐X‐C motif) ligand 1  1.0  10.5  7.9  9.8  3.8 
*11839  AREG  Amphiregulin  1.0  5.6  9.9  8.6  6.4 
68891  Cd177  CD177 antigen  1.0  2.3  3.5  10.7  32.5 
17840  Major urinary protein 1  1.0  81.6  5.1  9.4  4.9 
21857  Timp1  Tissue inhibitor of metalloproteinase 1  1.0  23.7  36.0  23.1  5.6 
20210  Saa3  Serum amyloid A 3  1.0  30.5  39.7  71.1  11.3 
*Denotes realtime validation. 
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Table 2. Productive Repair Gene Signature (Node 176) 
.                
Fold Change Relative to Control (0) 
LLID  Symbol  Name  0  1  2  3  6 
107585  Dio3  Deiodinase, iodothyronine type III  1.0  3.7  3.1  2.3  1.2 
16948  Lox  Lysyl oxidase  1.0  4.4  2.5  2.2  1.0 
20700  Serine (or cysteine) peptidase inhibitor, clade A, member 1a  1.0  4.9  2.3  1.8  1.2 
14066  F3  Coagulation factor III  1.0  4.1  2.2  2.0  1.1 
20700  Serine (or cysteine) peptidase inhibitor, clade A, member 1a  1.0  3.7  2.3  2.1  1.5 
11815  Apod  Apolipoprotein D  1.0  5.0  1.4  1.7  1.2 
70544  5730437N04Rik  RIKEN cDNA 5730437N04 gene  1.0  3.9  1.7  1.7  1.5 
271424  Ihpk3  Inositol hexaphosphate kinase 3  1.0  3.3  1.7  1.7  1.4 
21859  Timp3  Tissue inhibitor of metalloproteinase 3  1.0  3.2  1.9  1.7  1.3 
171531  Mlph  Melanophilin  1.0  2.8  1.7  1.5  1.3 
69863  1810054D07Rik  RIKEN cDNA 1810054D07 gene  1.0  4.5  2.4  1.8  1.5 
240913  Adamts4 
A disintegrin‐like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 4  1.0  5.4  2.8  2.0  1.4 
17454  Mov10  Moloney leukemia virus 10  1.0  4.1  1.9  2.1  3.0 
14469  Gbp2  Guanylate binding protein 2  1.0  3.0  1.3  1.2  1.7 
17932  Myt1  Myelin transcription factor 1  1.0  2.9  1.4  1.3  1.8 
11606  Agt  Angiotensinogen (serpin peptidase inhibitor, clade A, member 8)  1.0  3.5  1.3  1.7  2.0 
11536  Gpr182  G protein‐coupled receptor 182  1.0  3.4  1.5  1.5  2.3 
13614  Edn1  Endothelin 1  1.0  4.2  1.7  1.6  2.2 
71839  Osgin1  Oxidative stress induced growth inhibitor 1  1.0  5.4  1.5  1.6  1.7 
18787  Serpine1  Serine (or cysteine) peptidase inhibitor, clade E, member 1  1.0  7.3  2.7  1.9  2.5 
433772  Hypothetical LOC433772  1.0  5.5  2.0  1.6  2.8 
75146  Tmem180  Transmembrane protein 180  1.0  7.3  2.4  2.0  4.3 
18784  Pla2g5  Phospholipase A2, group V  1.0  5.3  1.3  1.2  1.4 
20209  Saa2  Serum amyloid A 2  1.0  5.7  1.2  1.3  1.1 
14411  Slc6a12 
Solute carrier family 6 (neurotransmitter transporter, betaine/GABA), 
member 12  1.0  6.0  1.3  1.1  1.2 
23801  Aloxe3  Arachidonate lipoxygenase 3  1.0  2.5  1.3  1.1  1.2 
73679  Tex19.1  Testis expressed gene 19.1  1.0  3.3  1.3  1.1  1.3 
78593  Nrip3  Nuclear receptor interacting protein 3  1.0  3.1  1.7  1.2  1.2 
18491  Pappa  Pregnancy‐associated plasma protein A  1.0  2.8  1.8  1.4  1.4 
17133  Maff 
V‐maf musculoaponeurotic fibrosarcoma oncogene family, protein F 
(avian)  1.0  3.2  1.5  1.6  1.5 
68760  Synpo2l  Synaptopodin 2‐like  1.0  3.3  1.0  1.6  1.7 
58522  Trim54  Tripartite motif‐containing 54  1.0  3.6  0.9  1.3  1.3 
17067  Ly6c1  Lymphocyte antigen 6 complex, locus C1  1.0  3.1  1.6  1.5  1.3 
15547  Htf9c  HpaII tiny fragments locus 9c  1.0  2.4  1.2  1.0  1.4 
328801  Zfp414  Zinc finger protein 414  1.0  1.5  1.1  1.0  1.5 
70617  5730508B09Rik  RIKEN cDNA 5730508B09 gene  1.0  1.7  1.8  1.2  1.2 
76714  RIKEN cDNA 1700040G22 gene  1.0  2.2  1.8  1.2  1.3 
104174  Gldc  Glycine decarboxylase  1.0  2.6  1.6  1.2  1.3 
213393  8430408G22Rik  RIKEN cDNA 8430408G22 gene  1.0  4.0  2.1  1.4  1.5 
17071  Ly6f  Lymphocyte antigen 6 complex, locus F  1.0  3.5  1.9  1.5  1.0 
228765  Sdcbp2  Syndecan binding protein (syntenin) 2  1.0  4.0  2.2  1.5  1.2 
20717  Serine (or cysteine) peptidase inhibitor, clade A, member 3M  1.0  3.4  2.4  1.7  1.2 
69852  Tcf23  Transcription factor 23  1.0  8.2  2.6  1.5  1.3 
193740  Hspa1a  Heat shock protein 1A  1.0  7.6  1.0  1.2  2.5 
81702  Ankrd17  Ankyrin repeat domain 17  1.0  1.0  0.6  0.6  1.0 
11426  Macf1  Microtubule‐actin crosslinking factor 1  1.0  1.2  0.7  0.7  0.9 
56542  Ick  Intestinal cell kinase  1.0  1.6  0.9  0.7  0.7 
67118  Bfar  RIKEN cDNA 3110001I22 gene  1.0  3.0  1.2  0.8  0.9 
16009  Igfbp3  Insulin‐like growth factor binding protein 3  1.0  3.7  0.9  0.9  0.9 
70422  Ints2  Integrator complex subunit 2  1.0  1.9  1.1  0.8  1.1 
66743  4931406I20Rik  RIKEN cDNA 4931406I20 gene  1.0  2.0  1.1  0.9  1.2 
16535  Potassium voltage‐gated channel, subfamily Q, member 1  1.0  1.6  1.4  1.0  1.5 
27643  Ubl4  Ubiquitin‐like 4  1.0  1.7  1.4  1.1  1.4 
57248  Ly6i  Lymphocyte antigen 6 complex, locus I  1.0  2.3  1.6  1.0  1.0 
85031  Pla1a  Phospholipase A1 member A  1.0  2.3  1.6  1.1  1.0 
18049  Ngf  Nerve growth factor  1.0  2.3  1.3  1.1  1.1 
56365  Clcnkb  Chloride channel Kb  1.0  2.2  1.2  1.0  1.0 
14724  Gp1bb  Glycoprotein Ib, beta polypeptide  1.0  2.1  0.8  1.2  1.5 
16399  Itga2b  Integrin alpha 2b  1.0  2.1  1.1  1.6  1.4 
69573  2310016C08Rik  RIKEN cDNA 2310016C08 gene  1.0  2.7  1.3  1.7  1.3 
93960  Nkd1  Naked cuticle 1 homolog (Drosophila)  1.0  2.6  1.4  1.7  1.5 
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56744  Pf4  Platelet factor 4  1.0  2.4  1.2  1.5  1.4 
15476  Hs3st1  Heparan sulfate (glucosamine) 3‐O‐sulfotransferase 1  1.0  2.6  1.4  1.6  1.6 
66922  Rras2  Related RAS viral (r‐ras) oncogene homolog 2  1.0  2.7  1.8  2.0  1.2 
110454  Ly6a  Lymphocyte antigen 6 complex, locus A  1.0  2.2  1.6  1.6  1.0 
66871  Cpne8  Copine VIII  1.0  2.1  1.7  2.2  1.5 
13388  Dll1  Delta‐like 1 (Drosophila)  1.0  2.5  1.7  2.2  1.5 
80981  ADP‐ribosylation factor‐like 4D  1.0  2.8  1.6  2.1  1.7 
30933  Tor2a  Torsin family 2, member A  1.0  2.4  1.7  1.8  1.6 
20393  Sgk1  Serum/glucocorticoid regulated kinase 1  1.0  2.3  2.0  1.9  1.4 
434325  BC033932  CDNA sequence BC033932  1.0  2.6  2.2  2.3  1.7 
*74155  Errfi1  ERBB receptor feedback inhibitor 1  1.0  2.3  2.0  2.1  1.6 
16007  Cyr61  Cysteine rich protein 61  1.0  2.8  2.0  2.0  2.2 
170776  Cd209c  CD209c antigen  1.0  2.8  2.1  1.9  2.1 
19252  Dusp1  Dual specificity phosphatase 1  1.0  2.5  1.6  2.0  2.5 
11910  Atf3  Activating transcription factor 3  1.0  3.2  2.0  2.1  2.3 
15511  Hspa1b  Heat shock protein 1B  1.0  3.6  1.1  1.4  2.8 
18212  Ntrk2  Neurotrophic tyrosine kinase, receptor, type 2  1.0  3.2  1.6  1.1  2.5 
17169  Mark3  MAP/microtubule affinity‐regulating kinase 3  1.0  1.9  0.9  0.7  1.8 
17169  Mark3  MAP/microtubule affinity‐regulating kinase 3  1.0  1.9  0.9  0.9  1.9 
68724  Arl8a  ADP‐ribosylation factor‐like 8A  1.0  1.8  1.0  0.8  2.0 
20658  Son  Son cell proliferation protein  1.0  2.0  1.1  1.1  2.3 
12739  Cldn3  Claudin 3  1.0  2.5  1.7  1.5  2.9 
18491  Pappa  Pregnancy‐associated plasma protein A  1.0  1.6  1.2  0.9  1.7 
231532  Arhgap24  Rho GTPase activating protein 24  1.0  1.8  1.1  0.9  1.8 
232449  Dera  2‐deoxyribose‐5‐phosphate aldolase homolog (C. elegans)  1.0  1.4  1.0  0.8  1.7 
100689  Spon2  Spondin 2, extracellular matrix protein  1.0  1.7  1.3  1.0  2.2 
14760  Gpr19  G protein‐coupled receptor 19  1.0  1.5  1.6  1.0  2.0 
*Denotes realtime 
validation. 
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Table 3. Productive Repair Gene Signature (Node 534) 
Fold Change Relative to Control (0) 
LLID  Symbol  Name  0  1  2  3  6 
18111  Neuronatin  1.0  1.2  2.5  3.7  2.6 
93721  Cpn1  Carboxypeptidase N, polypeptide 1  1.0  0.9  2.2  2.9  2.2 
15223  Foxj1  Forkhead box J1  1.0  1.3  2.6  3.8  3.5 
12654  Chi3l1  Chitinase 3‐like 1  1.0  1.5  3.3  4.8  4.3 
64136  Sdf2l1  Stromal cell‐derived factor 2‐like 1  1.0  2.1  3.7  4.5  2.9 
100689  Spon2  Spondin 2, extracellular matrix protein  1.0  2.1  2.8  4.4  2.6 
77914  Krtap17‐1  Keratin associated protein 17‐1  1.0  2.4  1.9  4.8  3.2 
81007  Defb5  Defensin beta 5  1.0  2.4  2.5  3.5  2.8 
76507  Abp1 
Amiloride binding protein 1 (amine oxidase, copper‐
containing)  1.0  1.4  2.9  3.3  4.6 
71780  Isyna1  Myo‐inositol 1‐phosphate synthase A1  1.0  1.8  3.3  4.9  3.9 
12709  Ckb  Creatine kinase, brain  1.0  1.5  3.5  4.2  3.3 
26561  Mmp23  Matrix metallopeptidase 23  1.0  1.3  3.2  4.9  3.3 
67305  Gpx7  Glutathione peroxidase 7  1.0  1.5  2.6  4.3  2.5 
52377  Rcn3  Reticulocalbin 3, EF‐hand calcium binding domain  1.0  1.0  2.8  3.8  2.4 
99543  Olfml3  Olfactomedin‐like 3  1.0  1.2  2.9  3.7  2.3 
27078  B9d1  B9 protein domain 1  1.0  1.0  2.3  3.1  2.2 
77889  Lbh  Limb‐bud and heart  1.0  1.4  3.2  3.8  2.6 
17534  Mrc2  Mannose receptor, C type 2  1.0  0.9  3.0  3.6  3.1 
72080  2010317E24Rik  RIKEN cDNA 2010317E24 gene  1.0  1.1  3.2  4.1  2.2 
17218  Mcm5 
Minichromosome maintenance deficient 5, cell division 
cycle 46 (S. cerevisiae)  1.0  1.5  3.5  4.4  2.4 
209027  Pycr1  Pyrroline‐5‐carboxylate reductase 1  1.0  1.4  4.3  4.9  2.8 
20377  Sfrp1  Secreted frizzled‐related protein 1  1.0  1.6  3.9  5.5  3.0 
66929  Asf1b  ASF1 anti‐silencing function 1 homolog B (S. cerevisiae)  1.0  1.7  4.1  4.9  3.0 
66570  Cenpm  Centromere protein M  1.0  1.8  4.9  5.6  3.2 
14962  Cfb  Complement factor B  1.0  2.1  3.6  5.5  2.7 
53867  Col5a3  Collagen, type V, alpha 3  1.0  2.5  5.4  4.6  2.6 
*16852  Lgals1  Lectin, galactose binding, soluble 1  1.0  2.4  5.4  5.0  2.8 
19216  Ptger1  Prostaglandin E receptor 1 (subtype EP1)  1.0  1.7  5.2  5.8  4.0 
71878  2310007D09Rik  RIKEN cDNA 2310007D09 gene  1.0  2.3  4.3  4.9  2.5 
12822  Col18a1  Collagen, type XVIII, alpha 1  1.0  2.5  4.5  5.5  3.4 
12831  Col5a1  Collagen, type V, alpha 1  1.0  2.0  4.6  5.9  3.3 
17216  Mcm2 
Minichromosome maintenance deficient 2 mitotin (S. 
cerevisiae)  1.0  2.1  4.2  5.1  2.9 
54124  Cks1b  CDC28 protein kinase 1b  1.0  2.8  4.6  5.4  3.2 
20204  Prrx2  Paired related homeobox 2  1.0  3.3  5.3  6.4  2.9 
272551  Gins2  GINS complex subunit 2 (Psf2 homolog)  1.0  2.1  5.9  6.5  3.5 
107995  Cdc20  Cell division cycle 20 homolog (S. cerevisiae)  1.0  2.1  5.4  7.5  4.5 
70218  3000004C01Rik  RIKEN cDNA 3000004C01 gene  1.0  1.4  5.7  7.0  4.3 
20256  Clec11a  C‐type lectin domain family 11, member a  1.0  1.3  3.7  5.8  3.4 
12843  Col1a2  Collagen, type I, alpha 2  1.0  1.0  3.5  5.8  3.7 
20307  Ccl8  Chemokine (C‐C motif) ligand 8  1.0  2.7  5.8  12.1  7.6 
12842  Col1a1  Collagen, type I, alpha 1  1.0  1.4  6.6  9.0  6.4 
12534  Cdc2a  Cell division cycle 2 homolog A (S. pombe)  1.0  1.3  8.3  9.9  5.3 
14793  Cdca3  Cell division cycle associated 3  1.0  1.3  6.4  8.0  3.9 
11799  Birc5  Baculoviral IAP repeat‐containing 5  1.0  1.2  6.0  7.0  3.7 
21877  Tk1  Thymidine kinase 1  1.0  1.1  5.9  7.2  3.4 
12442  Ccnb2  Cyclin B2  1.0  0.9  5.1  6.9  2.9 
59288  Dynactin 5  1.0  0.9  4.2  5.6  2.8 
20877  Aurkb  Aurora kinase B  1.0  0.9  3.3  4.1  2.3 
20878  Aurka  Aurora kinase A  1.0  1.2  3.9  4.8  3.2 
52276  Cdca8  Cell division cycle associated 8  1.0  1.2  3.6  4.4  2.7 
17865  Mybl2  Myeloblastosis oncogene‐like 2  1.0  1.1  3.4  3.8  2.2 
110033  Kif22  Kinesin family member 22  1.0  1.1  2.9  3.4  1.8 
17121  Mxd3  Max dimerization protein 3  1.0  0.9  2.8  3.1  2.1 
16580  Kifc1  Kinesin family member C1  1.0  1.3  3.3  2.7  2.3 
106795  Tcf19  Transcription factor 19  1.0  1.3  3.3  3.6  2.3 
12759  Clu  Clusterin  1.0  1.3  3.2  3.1  2.5 
269224  Pask  PAS domain containing serine/threonine kinase  1.0  1.2  3.9  3.8  2.5 
68298  Ncapd2  Non‐SMC condensin I complex, subunit D2  1.0  0.8  2.9  2.9  1.9 
68588  Cthrc1  Collagen triple helix repeat containing 1  1.0  0.7  3.8  4.4  1.8 
12832  Col5a2  Collagen, type V, alpha 2  1.0  1.2  3.8  4.2  2.0 
20377  Sfrp1  Secreted frizzled‐related protein 1  1.0  1.3  4.4  5.8  2.2 
*Denotes realtime validation. 
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A.2 SUPPLEMENTARY TABLES:  UNPRODUCTIVE REPAIR GENE SIGNATURE 
Table 4. Unproductive Repair Gene Signature (Node 278) 
Fold Change Retive to Control (0) 
LLID  Symbol  Name  0  3  6  9 
20753  Sprr1a  Small proline‐rich protein 1A  1.0  2.0  44.0  72.6 
20210  Saa3  Serum amyloid A 3  1.0  5.7  32.6  39.3 
17394  Mmp8  Matrix metallopeptidase 8  1.0  1.7  2.2  11.7 
17381  Mmp12  Matrix metallopeptidase 12  1.0  0.9  3.0  6.7 
17392  Mmp3  Matrix metallopeptidase 3  1.0  0.8  3.6  7.8 
12661  Chl1  Cell adhesion molecule with homology to L1CAM  1.0  1.0  2.4  10.2 
231293  C130090K23Rik  RIKEN cDNA C130090K23 gene  1.0  1.0  2.4  12.7 
74175  Crct1  Cysteine‐rich C‐terminal 1  1.0  1.0  2.1  37.9 
78593  Nrip3  Nuclear receptor interacting protein 3  1.0  1.3  6.9  8.8 
21923*  TNC  Tenascin C  1.0  0.9  6.5  8.6 
20306  Ccl7  Chemokine (C‐C motif) ligand 7  1.0  1.8  8.9  8.2 
85031  Pla1a  Phospholipase A1 member A  1.0  1.8  7.0  11.8 
21825  Thbs1  Thrombospondin 1  1.0  2.0  6.7  8.6 
21816  Tgm1  Transglutaminase 1, K polypeptide  1.0  2.5  9.3  10.0 
18405  Orm1  Orosomucoid 1  1.0  2.8  6.8  8.5 
77522  D630002J15Rik  RIKEN cDNA D630002J15 gene  1.0  2.5  5.5  6.6 
20296  Ccl2  Chemokine (C‐C motif) ligand 2  1.0  2.0  5.4  5.6 
20717  Serine (or cysteine) peptidase inhibitor, clade A, member 3M  1.0  1.7  5.2  7.9 
15945  Cxcl10  Chemokine (C‐X‐C motif) ligand 10  1.0  2.1  5.3  8.5 
12740  Cldn4  Claudin 4  1.0  2.7  5.9  18.2 
20716  Serine (or cysteine) peptidase inhibitor, clade A, member 3N  1.0  2.5  10.3  16.6 
21857  Timp1  Tissue inhibitor of metalloproteinase 1  1.0  2.7  17.7  21.2 
68891  Cd177  CD177 antigen  1.0  11.2  21.9  29.1 
11839*  AREG  Amphiregulin  1.0  5.7  13.7  12.9 
23886  Gdf15  Growth differentiation factor 15  1.0  7.5  14.5  14.0 
12575  12575 Cyclin‐dependent kinase inhibitor 1A (P21)  1.0  5.7  9.1  10.2 
76507  Abp1  Amiloride binding protein 1 (amine oxidase, copper‐containing)  1.0  4.8  5.6  4.7 
56742  Psrc1  Proline/serine‐rich coiled‐coil 1  1.0  4.1  5.7  6.4 
20310  Cxcl2  Chemokine (C‐X‐C motif) ligand 2  1.0  3.1  5.5  8.3 
12534  Cdc2a  Cell division cycle 2 homolog A (S. pombe)  1.0  3.0  6.4  6.8 
20307  Ccl8  Chemokine (C‐C motif) ligand 8  1.0  4.5  6.9  8.0 
17750  Mt2  Metallothionein 2  1.0  3.9  10.8  13.5 
20730  Spink3  Serine peptidase inhibitor, Kazal type 3  1.0  6.5  17.6  3.7 
14120  Fbp2  Fructose bisphosphatase 2  1.0  1.1  4.2  4.9 
16668  Krt18  Keratin 18  1.0  1.6  4.3  6.1 
66166  S100a14  S100 calcium binding protein A14  1.0  1.7  4.4  5.5 
17869  Myc  Myelocytomatosis oncogene  1.0  1.9  4.4  5.1 
69908  Rab3b  RAB3B, member RAS oncogene family  1.0  2.4  4.9  4.3 
21950  Tnfsf9  Tumor necrosis factor (ligand) superfamily, member 9  1.0  2.4  4.7  4.2 
16156  Il11  Interleukin 11  1.0  1.6  4.5  3.9 
100952  Emilin1  Elastin microfibril interfacer 1  1.0  1.6  3.7  3.8 
13929  Amz2  Archaelysin family metallopeptidase 2  1.0  1.7  3.7  3.7 
13121  Cyp51  Cytochrome P450, family 51  1.0  1.3  2.6  3.1 
51797  Ctps  Cytidine 5'‐triphosphate synthase  1.0  1.3  2.8  3.6 
16782  Lamc2  Laminin, gamma 2  1.0  1.4  2.9  3.7 
76905  Lrg1  Leucine‐rich alpha‐2‐glycoprotein 1  1.0  2.9  6.0  6.5 
20293  Ccl12  Chemokine (C‐C motif) ligand 12  1.0  2.5  5.2  5.6 
12450  Ccng1  Cyclin G1  1.0  2.8  5.4  6.4 
11847  Arg2  Arginase type II  1.0  2.5  4.1  5.5 
12842  Col1a1  Collagen, type I, alpha 1  1.0  1.9  3.8  4.8 
103988  Gck  Glucokinase  1.0  2.0  4.5  5.2 
16691  Krt8  Keratin 8  1.0  2.0  4.6  5.4 
55948  Sfn  Stratifin  1.0  2.5  5.8  6.4 
27279*  Tnfrsf12a  Tumor necrosis factor receptor superfamily, member 12a  1.0  2.5  6.5  6.8 
12642  Ch25h  Cholesterol 25‐hydroxylase  1.0  2.5  7.4  5.8 
20295  Ccl17  Chemokine (C‐C motif) ligand 17  1.0  2.0  7.5  5.3 
14825  Cxcl1  Chemokine (C‐X‐C motif) ligand 1  1.0  2.7  5.3  5.1 
14620  Gjb3  Gap junction protein, beta 3  1.0  2.2  5.2  6.3 
20297  Ccl20  Chemokine (C‐C motif) ligand 20  1.0  2.0  5.3  5.7 
19734  Rgs16  Regulator of G‐protein signaling 16  1.0  1.8  6.1  4.6 
66929  Asf1b  ASF1 anti‐silencing function 1 homolog B (S. cerevisiae)  1.0  1.9  5.3  4.2 
54124  Cks1b  CDC28 protein kinase 1b  1.0  2.2  5.0  4.0 
272551  Gins2  GINS complex subunit 2 (Psf2 homolog)  1.0  2.3  6.2  4.9 
21877  Tk1  Thymidine kinase 1  1.0  2.1  5.5  5.2 
14793  Cdca3  Cell division cycle associated 3  1.0  1.9  5.1  5.8 
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70835  Prss22  Protease, serine, 22  1.0  2.1  5.2  4.8 
11799  Birc5  Baculoviral IAP repeat‐containing 5  1.0  2.2  5.1  5.6 
70218  3000004C01Rik  RIKEN cDNA 3000004C01 gene  1.0  2.6  4.5  5.3 
107995  Cdc20  Cell division cycle 20 homolog (S. cerevisiae)  1.0  2.4  3.9  4.9 
20878  Aurka  Aurora kinase A  1.0  2.0  3.9  4.6 
12442  Ccnb2  Cyclin B2  1.0  1.8  3.9  5.3 
72391  Cdkn3  Cyclin‐dependent kinase inhibitor 3  1.0  1.5  4.0  6.6 
74041  4632434I11Rik  RIKEN cDNA 4632434I11 gene  1.0  1.3  4.0  6.5 
16644  Kng1  Kininogen 1  1.0  1.6  3.1  6.5 
56710  Dbc1  Deleted in bladder cancer 1 (human)  1.0  1.5  2.9  6.4 
71934  Car13  Carbonic anhydrase 13  1.0  1.5  3.0  5.0 
14187  Aldo‐keto reductase family 1, member B8  1.0  1.2  2.6  4.8 
16426  Itih3  Inter‐alpha trypsin inhibitor, heavy chain 3  1.0  1.4  2.7  4.7 
171180  Syt12  Synaptotagmin XII  1.0  1.6  3.3  4.6 
20754  Sprr1b  Small proline‐rich protein 1B  1.0  1.5  3.2  4.5 
53867  Col5a3  Collagen, type V, alpha 3  1.0  1.5  3.0  3.8 
240913  Adamts4 
A disintegrin‐like and metallopeptidase (reprolysin type) with thrombospondin type 
1 motif, 4  1.0  1.4  3.0  4.0 
14066  F3  Coagulation factor III  1.0  1.7  3.3  4.0 
384009  Glipr2  GLI pathogenesis‐related 2  1.0  1.9  3.5  3.8 
60411  Cenpk  Centromere protein K  1.0  1.5  3.5  4.2 
70645  Oip5  Opa interacting protein 5  1.0  1.6  3.3  3.6 
66198  Them5  Thioesterase superfamily member 5  1.0  2.3  3.7  7.7 
14229  Fkbp5  FK506 binding protein 5  1.0  2.2  3.0  5.7 
11486  Ada  Adenosine deaminase  1.0  1.8  2.8  6.0 
16948  Lox  Lysyl oxidase  1.0  1.8  3.1  6.2 
20288  Msr1  Macrophage scavenger receptor 1  1.0  1.5  2.4  4.7 
69863  1810054D07Rik  RIKEN cDNA 1810054D07 gene  1.0  1.4  2.4  5.2 
14130  Fcgr2b  Fc receptor, IgG, low affinity IIb  1.0  0.9  2.3  5.4 
51944  D2Ertd750e  DNA segment, Chr 2, ERATO Doi 750, expressed  1.0  1.0  2.2  5.3 
12630  Cfi  Complement component factor i  1.0  1.3  2.9  8.4 
72119  Tpx2  TPX2, microtubule‐associated protein homolog (Xenopus laevis)  1.0  1.2  3.1  5.3 
70466  Ckap2l  Cytoskeleton associated protein 2‐like  1.0  1.1  2.5  4.5 
76131  Depdc1a  DEP domain containing 1a  1.0  1.0  2.8  4.6 
55985  Cxcl13  Chemokine (C‐X‐C motif) ligand 13  1.0  1.4  2.8  7.7 
13717  Eln  Elastin  1.0  2.1  4.8  8.9 
66442  Spc25  SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae)  1.0  1.0  2.6  2.9 
108907  Nusap1  Nucleolar and spindle associated protein 1  1.0  0.9  2.2  2.8 
21789  Tfpi2  Tissue factor pathway inhibitor 2  1.0  0.9  2.3  3.0 
70385  Ccdc99  Coiled‐coil domain containing 99  1.0  0.9  2.1  3.1 
192200  Wfdc12  WAP four‐disulfide core domain 12  1.0  0.6  2.0  4.5 
79201  Tnfrsf23  Tumor necrosis factor receptor superfamily, member 23  1.0  1.1  2.7  5.5 
19417  Rasgrf1  RAS protein‐specific guanine nucleotide‐releasing factor 1  1.0  1.1  3.3  4.6 
13123  Cyp7b1  Cytochrome P450, family 7, subfamily b, polypeptide 1  1.0  0.9  3.2  4.8 
11752  Anxa8  Annexin A8  1.0  1.1  3.7  5.3 
52033  Pbk  PDZ binding kinase  1.0  1.6  5.6  4.8 
12448  Ccne2  Cyclin E2  1.0  1.0  3.8  2.9 
18973  Pole  Polymerase (DNA directed), epsilon  1.0  0.9  3.3  3.6 
17219  Mcm6  Minichromosome maintenance deficient 6 (MIS5 homolog, S. pombe) (S. cerevisiae)  1.0  1.1  2.9  3.2 
15366  Hmmr  Hyaluronan mediated motility receptor (RHAMM)  1.0  1.2  3.0  4.5 
110033  Kif22  Kinesin family member 22  1.0  1.2  2.8  3.8 
13605  Ect2  Ect2 oncogene  1.0  1.1  2.4  4.0 
23921  Sh2b2  SH2B adaptor protein 2  1.0  1.9  2.7  3.6 
69028  Mitd1  MIT, microtubule interacting and transport, domain containing 1  1.0  1.4  2.3  3.7 
57266  Cxcl14  Chemokine (C‐X‐C motif) ligand 14  1.0  1.4  2.7  4.6 
18802  Plcd4  Phospholipase C, delta 4  1.0  1.7  2.7  3.9 
57875  Angptl4  Angiopoietin‐like 4  1.0  2.5  3.2  3.4 
12428  Ccna2  Cyclin A2  1.0  1.4  4.1  4.7 
19366  Rad54l  RAD54 like (S. cerevisiae)  1.0  1.5  4.2  3.9 
26886  Cenph  Centromere protein H  1.0  1.2  3.9  4.2 
12544  Cdc45l  Cell division cycle 45 homolog (S. cerevisiae)‐like  1.0  1.5  3.6  3.2 
20135  Rrm2  Ribonucleotide reductase M2  1.0  1.5  3.3  2.6 
22171  Tyms  Thymidylate synthase  1.0  1.2  3.3  2.6 
16772  Lama1  Laminin, alpha 1  1.0  1.0  2.4  3.5 
78354  2210407C18Rik  RIKEN cDNA 2210407C18 gene  1.0  1.0  2.5  4.0 
12267  C3ar1  Complement component 3a receptor 1  1.0  1.2  2.0  4.9 
54159  Ear5  Eosinophil‐associated, ribonuclease A family, member 5  1.0  1.2  2.0  4.1 
85031  Pla1a  Phospholipase A1 member A  1.0  1.2  2.0  4.1 
18491  Pappa  Pregnancy‐associated plasma protein A  1.0  1.3  1.9  4.3 
18491  Pappa  Pregnancy‐associated plasma protein A  1.0  0.9  1.4  3.9 
11846  Arg1  Arginase 1, liver  1.0  1.2  1.6  5.5 
17167  Marco  Macrophage receptor with collagenous structure  1.0  1.1  1.2  6.0 
68774  Ms4a6d  Membrane‐spanning 4‐domains, subfamily A, member 6D  1.0  1.3  1.9  4.7 
14727  Gp49a  Glycoprotein 49 A  1.0  1.2  1.7  4.4 
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12768  Ccr1  Chemokine (C‐C motif) receptor 1  1.0  1.4  2.3  5.5 
13038  Ctsk  Cathepsin K  1.0  1.4  2.1  5.3 
216725  Adamts2 
A disintegrin‐like and metallopeptidase (reprolysin type) with thrombospondin type 
1 motif, 2  1.0  1.5  1.9  4.5 
18212  Ntrk2  Neurotrophic tyrosine kinase, receptor, type 2  1.0  1.2  4.6  2.8 
17865  Mybl2  Myeloblastosis oncogene‐like 2  1.0  1.6  3.8  3.1 
106795  Tcf19  Transcription factor 19  1.0  1.7  3.8  3.4 
16000  Igf1  Insulin‐like growth factor 1  1.0  1.4  3.3  3.6 
66311  2610036L11Rik  RIKEN cDNA 2610036L11 gene  1.0  1.9  3.5  3.5 
16852*  Lgals1  Lectin, galactose binding, soluble 1  1.0  2.0  3.8  3.3 
66570  Cenpm  Centromere protein M  1.0  2.0  3.8  3.6 
17218  Mcm5  Minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae)  1.0  1.9  4.4  2.8 
19216  Ptger1  Prostaglandin E receptor 1 (subtype EP1)  1.0  2.0  3.9  2.1 
17216  Mcm2  Minichromosome maintenance deficient 2 mitotin (S. cerevisiae)  1.0  1.8  4.0  2.5 
14121  Fbp1  Fructose bisphosphatase 1  1.0  2.1  3.9  2.1 
269224  Pask  PAS domain containing serine/threonine kinase  1.0  2.3  4.7  4.3 
67951  Tubb6  Tubulin, beta 6  1.0  2.0  4.5  3.9 
110749  Chaf1b  Chromatin assembly factor 1, subunit B (p60)  1.0  1.7  3.7  2.6 
20877  Aurkb  Aurora kinase B  1.0  1.7  3.0  3.3 
69784  1500009L16Rik  RIKEN cDNA 1500009L16 gene  1.0  1.9  2.9  3.8 
76835  RIKEN cDNA 2900052L18 gene  1.0  1.7  2.4  3.6 
18791*  Plat  Plasminogen activator, tissue  1.0  1.9  3.6  3.5 
67177  Cdt1  Chromatin licensing and DNA replication factor 1  1.0  1.8  3.1  3.0 
15484  Hsd11b2  Hydroxysteroid 11‐beta dehydrogenase 2  1.0  1.9  3.2  2.9 
268930  Pkmyt1  Protein kinase, membrane associated tyrosine/threonine 1  1.0  1.5  2.5  2.2 
209027  Pycr1  Pyrroline‐5‐carboxylate reductase 1  1.0  1.6  2.6  2.3 
21915  Dtymk  Deoxythymidylate kinase  1.0  1.8  2.7  2.5 
17220  Mcm7  Minichromosome maintenance deficient 7 (S. cerevisiae)  1.0  1.7  3.0  2.4 
72151  Rfc5  Replication factor C (activator 1) 5  1.0  1.9  3.4  2.8 
18102  Nme1  Non‐metastatic cells 1, protein (NM23A) expressed in  1.0  2.0  3.3  2.9 
56454  Aldh18a1  Aldehyde dehydrogenase 18 family, member A1  1.0  1.8  2.7  2.7 
72512  Tmem173  Transmembrane protein 173  1.0  1.7  2.9  2.9 
214425  Cilp  Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase  1.0  1.6  2.8  3.1 
14156  Fen1  Flap structure specific endonuclease 1  1.0  1.7  2.8  2.8 
12831  Col5a1  Collagen, type V, alpha 1  1.0  1.7  2.5  3.0 
20204  Prrx2  Paired related homeobox 2  1.0  1.6  2.7  3.2 
19288  Ptx3  Pentraxin related gene  1.0  1.4  2.5  2.3 
234199  Fgl1  Fibrinogen‐like protein 1  1.0  1.4  2.7  2.6 
14086  Fscn1  Fascin homolog 1, actin bundling protein (Strongylocentrotus purpuratus)  1.0  1.5  2.5  2.5 
66183  1110032A04Rik  RIKEN cDNA 1110032A04 gene  1.0  1.9  2.7  2.7 
12822  Col18a1  Collagen, type XVIII, alpha 1  1.0  2.0  2.9  2.5 
14705  Bscl2  Bernardinelli‐Seip congenital lipodystrophy 2 homolog (human)  1.0  1.8  2.2  2.2 
56264  Carboxypeptidase X 1 (M14 family)  1.0  1.7  2.0  2.3 
68678  Smtnl1  Smoothelin‐like 1  1.0  1.8  2.2  2.8 
23795  Agr2  Anterior gradient 2 (Xenopus laevis)  1.0  1.4  2.8  3.1 
71860  Wdr16  WD repeat domain 16  1.0  1.7  2.5  3.0 
20377  Sfrp1  Secreted frizzled‐related protein 1  1.0  2.1  2.4  3.0 
12332  Capg  Capping protein (actin filament), gelsolin‐like  1.0  2.2  2.7  3.5 
51800  Bok  Bcl‐2‐related ovarian killer protein  1.0  2.3  3.4  3.6 
12833  Col6a1  Collagen, type VI, alpha 1  1.0  1.8  2.7  2.8 
12843  Col1a2  Collagen, type I, alpha 2  1.0  1.6  2.2  2.9 
104009  Qsox1  Quiescin Q6 sulfhydryl oxidase 1  1.0  2.1  2.9  3.4 
22351  Vill  Villin‐like  1.0  1.9  2.4  2.9 
16669  Krt19  Keratin 19  1.0  2.1  2.7  3.1 
14226  Fkbp1b  FK506 binding protein 1b  1.0  2.5  2.8  3.8 
170706  Tmem37  Transmembrane protein 37  1.0  2.3  2.8  4.1 
20377  Sfrp1  Secreted frizzled‐related protein 1  1.0  2.2  2.7  3.9 
16580  Kifc1  Kinesin family member C1  1.0  2.1  2.9  2.6 
12447  Ccne1  Cyclin E1  1.0  1.7  2.4  2.3 
78906  9130017N09Rik  RIKEN cDNA 9130017N09 gene  1.0  2.0  2.5  2.5 
66422  2410015N17Rik  RIKEN cDNA 2410015N17 gene  1.0  2.0  3.0  2.6 
12070  Ngfrap1  Nerve growth factor receptor (TNFRSF16) associated protein 1  1.0  2.1  2.8  2.6 
16176  Il1b  Interleukin 1 beta  1.0  2.2  2.3  2.6 
14972  Histocompatibility 2, K1, K region  1.0  1.8  2.2  1.9 
18971  Pold1  Polymerase (DNA directed), delta 1, catalytic subunit  1.0  1.9  2.5  1.4 
77889  Lbh  Limb‐bud and heart  1.0  1.8  2.7  1.4 
217847  Serpina10 
Serine (or cysteine) peptidase inhibitor, clade A (alpha‐1 antiproteinase, antitrypsin), 
member 10  1.0  1.9  3.1  1.6 
27273  Pdk4  Pyruvate dehydrogenase kinase, isoenzyme 4  1.0  1.9  2.8  2.5 
52276  Cdca8  Cell division cycle associated 8  1.0  1.7  3.0  3.0 
68298  Ncapd2  Non‐SMC condensin I complex, subunit D2  1.0  1.6  2.7  3.1 
66336  Cenpp  Centromere protein P  1.0  1.3  2.5  2.5 
15201  Hells  Helicase, lymphoid specific  1.0  1.1  2.5  2.2 
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67141  Fbxo5  F‐box protein 5  1.0  1.2  2.3  2.3 
23834  Cdc6  Cell division cycle 6 homolog (S. cerevisiae)  1.0  1.1  2.7  2.2 
27357  Gyg  Glycogenin  1.0  1.2  2.4  2.2 
13361  Dhfr  Dihydrofolate reductase  1.0  1.5  2.9  2.3 
67196  Ube2t  Ubiquitin‐conjugating enzyme E2T (putative)  1.0  1.9  3.1  2.5 
76843  Dtl  Denticleless homolog (Drosophila)  1.0  1.7  2.7  2.3 
17067  Ly6c1  Lymphocyte antigen 6 complex, locus C1  1.0  1.8  3.1  3.0 
17215  Mcm3  Minichromosome maintenance deficient 3 (S. cerevisiae)  1.0  1.1  2.4  2.1 
26557  Homer2  Homer homolog 2 (Drosophila)  1.0  1.3  2.6  2.4 
319554  Idi1  Isopentenyl‐diphosphate delta isomerase  1.0  1.3  2.5  2.2 
13346  Des  Desmin  1.0  1.5  2.1  1.5 
13653  Egr1  Early growth response 1  1.0  1.6  2.8  1.6 
11468  Actg2  Actin, gamma 2, smooth muscle, enteric  1.0  1.7  2.6  1.5 
67711  Nsmce1  Non‐SMC element 1 homolog (S. cerevisiae)  1.0  1.7  2.1  1.6 
66548  Adamtsl5  ADAMTS‐like 5  1.0  1.7  2.3  1.5 
19342  RAB4B, member RAS oncogene family  1.0  1.9  2.0  1.8 
11490  Adam15  A disintegrin and metallopeptidase domain 15 (metargidin)  1.0  1.7  2.1  1.9 
103733  Tubg1  Tubulin, gamma 1  1.0  1.7  2.2  1.8 
110074  Dut  Deoxyuridine triphosphatase  1.0  1.9  2.5  2.0 
20382  Sfrs2  Splicing factor, arginine/serine‐rich 2 (SC‐35)  1.0  1.7  2.3  1.9 
108115  Slco4a1  Solute carrier organic anion transporter family, member 4a1  1.0  2.2  3.1  2.3 
15200  Hbegf  Heparin‐binding EGF‐like growth factor  1.0  2.0  3.2  2.3 
11535  Adm  Adrenomedullin  1.0  2.1  3.1  2.2 
16007  Cyr61  Cysteine rich protein 61  1.0  1.9  2.8  1.9 
12817  Col13a1  Collagen, type XIII, alpha 1  1.0  1.9  3.0  1.8 
16404  Itga7  Integrin alpha 7  1.0  1.9  3.1  1.7 
12406  Serpinh1  Serine (or cysteine) peptidase inhibitor, clade H, member 1  1.0  1.8  2.3  1.3 
76574  Mfsd2  Major facilitator superfamily domain containing 2  1.0  1.5  2.1  1.4 
75495  1700010A17Rik  RIKEN cDNA 1700010A17 gene  1.0  1.9  2.0  1.2 
14613  Gja5  Gap junction membrane channel protein alpha 5  1.0  1.6  2.3  1.3 
54525  Syt7  Synaptotagmin VII  1.0  1.5  2.3  1.2 
223646  Naprt1  Nicotinate phosphoribosyltransferase domain containing 1  1.0  1.6  2.1  1.6 
67169  Nradd  Neurotrophin receptor associated death domain  1.0  1.7  2.2  1.6 
18218  Dusp8  Dual specificity phosphatase 8  1.0  2.0  2.4  1.4 
13710  Elf3  E74‐like factor 3  1.0  2.0  1.9  1.2 
18011  Neurl  Neuralized‐like homolog (Drosophila)  1.0  2.4  2.6  2.3 
20256  Clec11a  C‐type lectin domain family 11, member a  1.0  2.2  2.6  2.1 
71780  Isyna1  Myo‐inositol 1‐phosphate synthase A1  1.0  2.3  2.5  1.8 
18111  Neuronatin  1.0  2.1  2.1  1.8 
114663  Impa2  Inositol (myo)‐1(or 4)‐monophosphatase 2  1.0  1.9  2.6  2.1 
12580  Cdkn2c  Cyclin‐dependent kinase inhibitor 2C (p18, inhibits CDK4)  1.0  1.8  2.6  2.0 
17766  Nudt1  Nudix (nucleoside diphosphate linked moiety X)‐type motif 1  1.0  1.8  2.3  1.9 
22256  Ung  Uracil DNA glycosylase  1.0  1.7  2.3  1.7 
11806  Apoa1  Apolipoprotein A‐I  1.0  1.8  2.8  1.4 
20941  Svs4  Seminal vesicle secretory protein 4  1.0  1.5  1.9  2.2 
20308  Ccl9  Chemokine (C‐C motif) ligand 9  1.0  2.4  3.1  5.2 
29870  Gtse1  G two S phase expressed protein 1  1.0  3.3  4.8  6.0 
20698  Sphk1  Sphingosine kinase 1  1.0  2.8  3.1  4.3 
18793*  Plaur  Plasminogen activator, urokinase receptor  1.0  2.5  3.1  3.4 
94242  Tinagl  Tubulointerstitial nephritis antigen‐like  1.0  2.5  4.2  3.5 
20361  Sema7a 
Sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, 
(semaphorin) 7A  1.0  2.5  3.8  3.7 
116903  Calcb  Calcitonin‐related polypeptide, beta  1.0  2.6  3.1  3.2 
59083  Fetub  Fetuin beta  1.0  2.9  3.2  4.3 
26366  Ceacam10  CEA‐related cell adhesion molecule 10  1.0  3.3  2.7  4.3 
19152  Prtn3  Proteinase 3  1.0  3.7  3.4  4.8 
17071  Ly6f  Lymphocyte antigen 6 complex, locus F  1.0  2.8  2.6  4.6 
17474  Clec4d  C‐type lectin domain family 4, member d  1.0  2.9  2.1  3.9 
12765  Il8rb  Interleukin 8 receptor, beta  1.0  3.0  2.4  4.6 
58203  Zbp1  Z‐DNA binding protein 1  1.0  2.7  2.9  3.3 
17314  Mgmt  O‐6‐methylguanine‐DNA methyltransferase  1.0  2.8  3.2  3.1 
11910  Atf3  Activating transcription factor 3  1.0  3.2  4.5  3.5 
27280  Phlda3  Pleckstrin homology‐like domain, family A, member 3  1.0  3.2  4.0  3.4 
18406  Orm2  Orosomucoid 2  1.0  4.7  4.9  4.3 
74747  Ddit4  DNA‐damage‐inducible transcript 4  1.0  3.7  2.7  2.8 
77914  Krtap17‐1  Keratin associated protein 17‐1  1.0  3.6  3.2  2.6 
223921  Aaas  Achalasia, adrenocortical insufficiency, alacrimia  1.0  2.7  3.3  2.9 
12609  Cebpd  CCAAT/enhancer binding protein (C/EBP), delta  1.0  3.3  4.0  2.5 
76770  2010005H15Rik  RIKEN cDNA 2010005H15 gene  1.0  6.4  2.7  7.4 
20202  S100a9  S100 calcium binding protein A9 (calgranulin B)  1.0  5.9  2.8  5.1 
20201  S100a8  S100 calcium binding protein A8 (calgranulin A)  1.0  6.1  2.6  5.1 
*Denotes realtime validation. 
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A.3 SUPPLEMENTARY FIGURES 
Figure 24.  Epithelial repair is associated with matrix remodeling leading to restoration of steady-state levels 
and distribution.   
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Figure 24 Continued. 
CCSP, TNC, and α-SMA were immuno-localized on formalin fixed and cryo-preserved lung tissue isolated from 
(A-D) Control mice and (E-H) 1, (I-L) 3, (M-P) 5, and (Q-T) 30 days after naphthalene injury.  Pseudo-colored 
images of DAPI (Grey) merged with CCSP (A, E, I, M, Q; Magenta), TNC (B, F, J, N, R; Green), or α-SMA (C, G, 
K, O, S; Red).  (D, H, L, P, T) 4-color merged images of tissue from Control, 1, 3, 5, and 30 days post injury.  
Images are representative of the proximal airway epithelium at 400X. 
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APPENDIX B 
SUPPLEMENTARY MATERIALS (CHAPTER 3) 
B.1 SUPPLEMENTARY TABLES 
Table 5. CCSP independent and LPS responsive alterations to gene expression. 
         Wild‐type Fold‐Change*  CCSP‐/‐ Fold Change* 
Row  Acc Num  Name  C  1.5  6  12  C  1.5  6  12 
1  AK015155  RIKEN cDNA 4930415O20 gene  1.0  3.1  6.1  2.6  1.0  2.2  4.6  2.9 
2  NM_133712  Kallikrein related‐peptidase 10  1.0  2.9  5.9  1.9  1.0  2.6  2.9  1.9 
3  AK016757  Ankyrin repeat domain 45  1.0  1.2  3.1  2.5  1.0  1.1  1.5  1.2 
4  BB022508  Gap junction membrane channel protein alpha 5  1.0  1.5  2.7  1.6  1.0  2.1  3.0  1.4 
5  NM_011331  Chemokine (C‐C motif) ligand 12  1.0  3.1  3.8  1.6  1.0  2.5  2.5  1.1 
6  NM_146963  Olfactory receptor 45  1.0  1.5  2.1  1.0  1.0  0.7  2.0  1.4 
7  NM_133362  Erythroid differentiation regulator 1  1.0  1.6  2.7  1.3  1.0  1.5  2.3  0.9 
8  NM_022435  Trans‐acting transcription factor 5  1.0  1.2  2.2  1.5  1.0  1.8  3.2  1.1 
9  AK002567  Metallothionein 2  1.0  1.0  1.7  0.5  1.0  1.6  2.7  1.1 
10  NM_145357  cDNA sequence BC023105  1.0  0.7  2.3  0.8  1.0  1.2  2.1  1.4 
11  NM_008331 
Interferon‐induced protein with tetratricopeptide 
repeats 1 
1.0  0.8  2.7  1.5  1.0  1.4  1.3  1.6 
12  NM_008599  Chemokine (C‐X‐C motif) ligand 9  1.0  1.4  2.5  1.5  1.0  1.6  1.2  2.0 
13  BB185036  Transcribed locus  1.0  2.1  2.6  1.5  1.0  1.9  0.7  1.8 
14  AF285585  Ring finger protein 17  1.0  2.1  3.4  4.9  1.0  1.6  0.8  1.5 
15  Z31361  Vasoactive intestinal polypeptide  1.0  1.8  3.5  1.8  1.0  1.0  0.5  1.1 
16  BB383444  Mitogen‐activated protein kinase 10  1.0  1.3  2.6  0.7  1.0  2.2  0.6  2.4 
17  NM_024273  RIKEN cDNA 4930455C21 gene  1.0  2.2  3.3  1.5  1.0  0.8  0.5  0.5 
18  NM_009216  Somatostatin receptor 1  1.0  3.6  5.4  4.0  1.0  0.8  0.6  0.4 
19  NM_146309  Olfactory receptor 1337  1.0  1.4  2.6  2.2  1.0  0.5  1.0  0.7 
20  NM_145847  Vomeronasal 1 receptor, J3  1.0  1.9  3.2  2.9  1.0  0.7  0.9  0.7 
21  BC067397  Reduced expression 2  1.0  1.1  1.4  1.0  1.0  0.5  0.7  0.6 
22  NM_145489  Expressed sequence AI661453  1.0  1.0  1.9  0.9  1.0  1.0  1.0  0.8 
23  AK147634  RAB GTPase activating protein 1‐like  1.0  1.4  2.9  2.5  1.0  1.0  1.0  1.0 
24  NM_016874 
Deformed epidermal autoregulatory factor 1 
(Drosophila) 
1.0  1.5  1.7  2.2  1.0  1.0  1.3  1.1 
25  NM_011199  Parathyroid hormone receptor 1  1.0  1.4  2.8  3.0  1.0  1.3  2.1  1.4 
26  NM_016707  B‐cell CLL/lymphoma 11A (zinc finger protein)  1.0  1.3  2.4  3.4  1.0  0.9  1.9  1.3 
27  AF072758 
Solute carrier family 27 (fatty acid transporter), member 
3 
1.0  1.3  2.3  3.5  1.0  0.8  1.6  1.1 
28  BC052169  Tetraspanin 18  1.0  1.3  3.1  2.0  1.0  0.6  2.2  0.8 
29  NM_016749  Myosin binding protein H  1.0  3.7  8.4  8.2  1.0  1.1  2.9  1.4 
30  BC026978  IQ motif containing C  1.0  0.9  1.3  0.7  1.0  1.5  1.5  1.3 
31  NM_145462  DNA segment, Chr 14, ERATO Doi 500, expressed  1.0  1.0  1.4  1.2  1.0  2.1  2.4  1.9 
32  BF464708  RIKEN cDNA 9230110C19 gene  1.0  1.0  1.8  1.0  1.0  1.1  1.8  1.6 
33  AK015120  Mus musculus, clone IMAGE:4483401, mRNA  1.0  1.4  1.8  0.7  1.0  0.7  1.0  1.1 
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34  AK086813 
0 day neonate lung cDNA, RIKEN full‐length enriched 
library, clone:E030002K04 product:hypothetical protein, 
full insert sequence 
1.0  1.4  1.8  1.2  1.0  0.8  1.7  1.3 
35  NM_080845  Formiminotransferase cyclodeaminase  1.0  1.3  1.1  0.9  1.0  1.5  2.1  1.7 
36  NM_172728  CAMP responsive element binding protein 5  1.0  1.6  1.3  1.0  1.0  2.6  2.9  1.9 
37  NM_007870  Deoxyribonuclease 1‐like 3  1.0  1.1  1.4  1.0  1.0  1.5  1.7  1.5 
38  AK021377  Transcribed locus  1.0  1.5  1.7  1.2  1.0  1.2  1.5  1.1 
39  M97635  Transcription factor 12  1.0  1.2  1.3  1.0  1.0  1.1  1.5  1.0 
40  BC024471  HEAT repeat containing 1  1.0  1.1  1.6  1.0  1.0  1.0  1.1  1.1 
41  AK017052  Transcribed locus  1.0  1.0  1.7  1.4  1.0  1.1  1.0  0.6 
42  NM_053231  Vomeronasal 1 receptor, C1  1.0  0.9  1.8  0.9  1.0  1.2  1.2  0.8 
43  BB479526  Transcribed locus  1.0  1.1  1.4  0.4  1.0  1.0  0.9  0.8 
44  AK039104  Ring finger protein 190  1.0  0.8  1.3  0.9  1.0  1.6  1.5  1.2 
45  BF456094  Transcribed locus  1.0  0.8  1.2  1.0  1.0  0.9  0.7  1.0 
46  NM_134236  Vomeronasal 1 receptor, H11  1.0  1.0  1.4  1.5  1.0  1.5  0.7  1.3 
47  NM_026094  ATPase, class I, type 8B, member 3  1.0  1.7  1.5  1.4  1.0  1.8  1.1  0.5 
48  NM_011521  Syndecan 4  1.0  1.4  1.3  1.2  1.0  2.0  1.4  0.7 
49  NM_080436  Retinol dehydrogenase 9  1.0  1.6  1.2  1.6  1.0  1.5  1.2  1.1 
50  BB069382  Transcribed locus  1.0  1.6  1.7  1.6  1.0  1.2  0.4  0.7 
51  BB546359  Adenylate kinase 5  1.0  1.6  1.9  2.1  1.0  0.9  0.9  0.5 
52  NM_008398  Integrin alpha 7  1.0  1.7  1.7  1.5  1.0  1.0  1.2  0.7 
53  NM_013640  Proteasome (prosome, macropain) subunit, beta type 10  1.0  1.2  1.9  1.4  1.0  1.0  2.1  0.9 
54  NM_009046 
Avian reticuloendotheliosis viral (v‐rel) oncogene related 
B 
1.0  1.7  1.9  1.5  1.0  1.3  1.7  1.0 
55  NM_146004  CDNA sequence BC024997  1.0  0.9  1.2  1.5  1.0  0.8  2.2  0.9 
56  D83147  Sine oculis‐related homeobox 2 homolog (Drosophila)  1.0  1.3  1.5  1.3  1.0  1.1  2.9  0.7 
57  NM_009921  Cathelicidin antimicrobial peptide  1.0  1.7  2.0  3.3  1.0  1.4  0.8  1.5 
58  NM_011904  Tolloid‐like 2  1.0  2.0  2.1  3.6  1.0  1.7  1.3  1.1 
59  NM_080438  Glycine receptor, alpha 3 subunit  1.0  3.4  1.8  2.6  1.0  1.5  1.1  1.5 
60  NM_008260  Forkhead box A3  1.0  1.0  0.7  1.1  1.0  2.0  1.2  0.9 
61  NM_008620  Guanylate nucleotide binding protein 4  1.0  1.6  1.6  2.1  1.0  2.2  1.3  1.6 
62  AI586049  Glutamate‐cysteine ligase, catalytic subunit  1.0  1.8  1.3  1.8  1.0  2.8  1.0  1.7 
63  NM_007921  Arginyl aminopeptidase (aminopeptidase B)  1.0  3.0  1.9  1.7  1.0  2.1  1.2  1.3 
64  NM_011498  Basic helix‐loop‐helix domain containing, class B2  1.0  2.0  1.6  1.3  1.0  2.0  1.2  1.2 
65  NM_010168  Coagulation factor II  1.0  2.5  2.7  1.6  1.0  1.4  1.1  0.6 
66  NM_013521  Formyl peptide receptor 1  1.0  3.1  1.9  1.7  1.0  2.5  1.2  1.1 
67  AK004006  Cartilage intermediate layer protein 2  1.0  3.6  1.7  1.3  1.0  1.8  1.4  1.1 
68  BE981214  RIKEN cDNA C130039O16 gene  1.0  1.3  1.4  0.8  1.0  2.6  1.6  1.7 
69  X82786  Antigen identified by monoclonal antibody Ki 67  1.0  1.3  1.4  0.9  1.0  1.9  1.6  1.4 
70  NM_007609  Caspase 4, apoptosis‐related cysteine peptidase  1.0  2.1  1.6  1.4  1.0  1.8  1.2  1.4 
71  BB091104  Transcribed locus  1.0  4.3  2.2  2.2  1.0  1.4  0.8  0.9 
72  NM_011905  Toll‐like receptor 2  1.0  5.5  3.3  2.5  1.0  3.2  1.6  1.4 
73  NM_033075  DNA segment, Chr 17, human D6S56E 5  1.0  4.9  5.5  2.7  1.0  3.4  2.0  1.6 
74  NM_011684  Vomeronasal 1 receptor, A2  1.0  2.4  1.0  1.6  1.0  4.4  2.2  1.4 
75  NM_007707  Suppressor of cytokine signaling 3  1.0  3.8  1.5  1.2  1.0  4.6  1.9  0.9 
76  X02333  Colony stimulating factor 2 (granulocyte‐macrophage)  1.0  3.7  2.5  1.8  1.0  4.0  2.1  1.1 
77  NM_013693  Tumor necrosis factor  1.0  6.0  3.2  2.1  1.0  3.4  1.8  1.1 
78  NM_009856  CD83 antigen  1.0  7.1  2.4  1.6  1.0  4.6  1.2  0.7 
79  NM_008361  Interleukin 1 beta  1.0  15.3  5.9  2.7  1.0  10.1  4.3  3.5 
80  NM_009396  Tumor necrosis factor, alpha‐induced protein 2  1.0  10.5  2.7  1.7  1.0  10.9  3.3  1.8 
81  NM_021274  Chemokine (C‐X‐C motif) ligand 10  1.0  9.7  7.4  1.6  1.0  10.6  3.3  1.6 
82  NM_016960†  Chemokine (C‐C motif) ligand 20  1.0  122.1  5.4  3.5  1.0  82.3  5.1  2.6 
83  NM_008176†  Chemokine (C‐X‐C motif) ligand 1  1.0  89.6  12.0  4.2  1.0  94.9  19.4  5.1 
84  NM_009140†  Chemokine (C‐X‐C motif) ligand 2  1.0  211.9  31.9  4.6  1.0  282.8  47.9  4.9 
85  NM_011315†  Serum amyloid A 3  1.0  15.4  63.8  36.7  1.0  12.3  62.5  42.6 
*Fold‐Change calculated relative to control. †Valdation of at least one timepoint, p‐value <0.1 (Realtime PCR).  C:  Control, 1.5:  1.5 hours post LPS, 
 6: 6 hours post LPS, 12: 12 hours post LPS. 
 
147 
 
Table 6. CCSP dependent and LPS responsive alterations to gene expression. 
         Fold‐Change* 
Row  Acc Num  Name  C  1.5  6  12 
1  NM_009141  Chemokine (C‐X‐C motif) ligand 5  2.9  1.1  1.7  1.2 
2  NM_011337  Chemokine (C‐C motif) ligand 3  1.1  0.8  0.6  0.6 
3  NM_009841  CD14 antigen  1.1  1.3  1.4  1.1 
4  NM_009890  Cholesterol 25‐hydroxylase  1.4  1.2  1.2  1.3 
5  NM_031168  Interleukin 6  1.1  1.4  1.3  1.2 
6  NM_025416  Thioesterase superfamily member 5  1.3  1.9  2.1  2.0 
7  NM_030701  G protein‐coupled receptor 109A  1.2  1.1  1.4  0.9 
8  X80332  RAB20, member RAS oncogene family  1.3  1.3  1.4  1.2 
9  NM_153408 
Lung‐inducible neuralized‐related C3HC4 RING domain 
protein 
1.3  1.3  1.8  1.0 
10  NM_019948  C‐type lectin domain family 4, member e  1.0  1.5  0.7  1.5 
11  NM_007972  Coagulation factor X  1.2  1.1  1.1  1.2 
12  NM_145209  2'‐5' oligoadenylate synthetase‐like 1  0.9  1.6  1.2  1.6 
13  NM_011332  Chemokine (C‐C motif) ligand 17  0.6  1.2  1.6  1.3 
14  NM_011314  Serum amyloid A 2  0.2  1.0  0.5  1.3 
15  AK009605  NADPH oxidase organizer 1  1.7  1.3  1.5  1.3 
16  NM_010766  Macrophage receptor with collagenous structure  1.5  1.6  0.7  0.9 
17  NM_008198  Complement factor B  1.3  0.8  0.6  0.8 
18  AK015290  Coiled‐coil domain containing 116  1.3  1.5  1.3  1.3 
19  NM_145594  Fibrinogen‐like protein 1  1.8  1.6  1.2  2.2 
20  NM_007705†  Cold inducible RNA binding protein  4.0  1.2  2.1  1.6 
21  AK007714  Fas apoptotic inhibitory molecule 3  2.6  1.1  1.5  0.5 
22  NM_028807  RIKEN cDNA 1200009I06 gene  1.7  1.1  1.4  0.7 
23  AK020278  RIKEN cDNA 9130211I03 gene  1.8  1.4  1.5  0.7 
24  NM_153074  Leucine rich repeat containing 25  1.3  1.3  1.9  0.8 
25  BC018416 
Serine (or cysteine) peptidase inhibitor, clade A (alpha‐1 
antiproteinase, antitrypsin), member 10 
1.4  1.3  1.9  2.5 
26  NM_016850  Interferon regulatory factor 7  1.3  1.9  1.2  1.6 
27  NM_029796  Leucine‐rich alpha‐2‐glycoprotein 1  1.3  1.6  1.9  1.3 
28  NM_011593  Tissue inhibitor of metalloproteinase 1  1.2  1.0  1.4  1.5 
29  U89889  Hemopexin  1.7  1.1  1.5  1.8 
30  NM_054037‡  Secretoglobin, family 3A, member 1  3.1  1.7  1.1  0.7 
31  AK007956  RIKEN cDNA 1810065E05 gene  1.4  1.6  1.2  1.4 
32  AI426026  Developing brain homeobox 1  2.6  1.9  2.0  2.0 
33  NM_029733  RIKEN cDNA 2010005H15 gene  1.4  1.1  2.7  2.5 
34  NM_013650  S100 calcium binding protein A8 (calgranulin A)  1.0  0.9  1.8  1.2 
35  NM_023124  Histocompatibility 2, K1, K region  2.1  3.0  2.0  3.6 
36  NM_010391  Histocompatibility 2, Q region locus 10  1.3  1.4  2.6  1.5 
37  AK007169  Predicted gene, EG665024  1.4  1.6  2.5  1.7 
38  NM_033175  Small proline rich‐like 1  1.1  1.5  1.8  1.6 
39  NM_021406  Triggering receptor expressed on myeloid cells 1  1.0  1.1  2.1  2.1 
40  AK020597  RIKEN cDNA 9530047P18 gene  1.6  1.7  2.3  1.3 
41  AK014899  RIKEN cDNA 4921515G04 gene  1.5  1.4  1.7  1.4 
42  AK008234  Glucosaminyl (N‐acetyl) transferase 3, mucin type  1.6  2.1  1.7  1.6 
43  NM_023835  Tripartite motif protein 12  0.9  1.5  1.8  1.6 
44  BY598616  Transcribed locus  0.9  1.1  2.1  1.5 
45  BB102105  Pogo transposable element with ZNF domain  0.9  1.0  1.5  1.7 
46  BB232450  Retinoblastoma 1  0.7  12.9  1.0  1.8 
47  AK006226  Cytokine‐dependent hematopoietic cell linker  0.3  2.7  0.9  2.4 
48  AV271377  RIKEN cDNA 1700008F21 gene  0.6  2.7  0.9  1.3 
49  AK010743  Developmental pluripotency associated 2  1.2  3.6  0.8  1.3 
50  AV253409  RIKEN cDNA A730032A03 gene  1.9  2.9  3.5  2.0 
51  BC024515  Gastrin releasing peptide  1.7  1.7  3.2  2.7 
52  BC010324  Immunoglobulin heavy chain (J558 family)  2.6  1.8  3.0  2.9 
53  J00544‡  Immunoglobulin joining chain  5.3  2.7  1.7  3.3 
54  BC010327  Immunoglobulin heavy chain 6 (heavy chain of IgM)  9.2  2.7  2.0  5.2 
*Fold‐Change calculated relative Wild‐type, †Validation of at least one timepoint, p‐value <0.1 (Realtime).  
‡Previously validated using S1‐nuclease protection. C:control, 1.5:  1.5 hours post LPS, 6: 6 hours post LPS, 12: 12 hours post LPS. 
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B.2 SUPPLEMENTARY FIGURES 
Figure 25.  CCSP does not directly regulate the macrophage response to LPS. 
(A) Raw264.7 macrophages were exposed to 2.5, 25, and 250ng/ml LPS for 1.0 (black), 2,0 (dark grey), 
3.0 (light grey), and 4.0 hours (white).  Cell free supernatant was collected by centrifugation at 300g for 5 minutes.  
TNF-α protein abundance was measured using an ELISA as described in materials and methods. Using this dose  
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Figure 25 Continued. 
response and time-course the 25ng/ml dose of LPS and 2 hour exposure time for subsequent experiments was 
chosen.  (B and C)  WT and CCSP-/- lavage were physically and biochemically fractionated to enrich for CCSP 
according to a previously published protocol by Gupta and colleagues196.  Briefly, WT and CCSP-/- lavage was 
centrifuged at 225,000 g (HS = highspeed) to remove surfactant aggregates.  Further biochemical enrichment for 
CCSP was conducted using a perchloric acid precipitation procedure (PPT).  CCSP enrichment was quantified by 
gel electrophoresis, silver staining, and MS identification (Data not shown).  CCSP-/- lavage was also fractionated 
for use as a negative control.  Two experiments were conducted to test the direct affects of CCSP on the macrophage 
response.  Experiment one (B) tested whether CCSP interacts with macrophages to alter the response to LPS.  
Raw264.7 macrophages were incubated overnight with WT and CCSP-/- HS (Black), WT and CCSP-/- PPT (dark 
grey), or albumin (protein control, light grey) at 12.5ug/ml.  The next morning cells were washed once with PBS and 
stimulated with LPS at 25ng/ml for 2.0hours.  Raw264.7 cells that were not incubated with fractionated protein were 
used as a control (white).  Cell free supernatant was collected by centrifugation at 300g for 5 minutes.  TNF-α 
protein abundance was measured using an ELISA as described in materials and methods.  WT fractionated protein 
did not affect macrophage responsiveness when compared to KO protein.  Experiment two (C), tested whether the 
fractionated proteins could attenuate the activity of LPS.  WT and CCSP-/- HS (Black), WT and CCSP-/- PPT (dark 
grey), or albumin (protein control, light grey) at 12.5 ug/ml were incubated with LPS for 30 minutes at room 
temperature and then added to Raw264.7 cells for 2 hours.  As a control LPS not pre-incubated with protein 
fractionates was used (white).  Cell free supernatant was collected by centrifugation at 300g for 5 minutes.  TNF-α 
protein abundance was measured using an ELISA as described in materials and methods.  Surprisingly, all extracts 
reduced the responsiveness of macrophages to LPS.  However, albumin attenuated the response to a similar level, 
arguing that this affects was due to non-specific interaction of protein with LPS.  Cumulatively, these results argue 
that CCSP does not directly regulate macrophage responsiveness to LPS. (Asterisk denotes unpaired student’s t-test 
p-value<0.05). 
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ABBREVIATIONS 
Table 7.  List of Abbreviations. 
 
2D-DIGE Two dimensional-difference gel electrophoresis 
AC Adenocarcinoma 
AKP2 Alkaline phosphatase, liver/bone/kidney 
ALI Air liquid interface 
ALI* Acute lung injury 
ANXA1 Annexin A1 
APC Adenomatosis polyposis coli 
ARDS Acute respiratory distress syndrome 
AREG Amphiregulin 
ASF Airway surface fluid 
AT1I Alveolar type 1 cell 
AT2 Alveolar type 2 cll 
BADJ Bronchoalveolar duct junction 
BAL Bronchoalveolar lavage 
BALF Bronchoalveolar lavage fluid 
BASC Bronchoalveolar stem cell 
Bmi1 Bmi1 polycomb ring finger oncogene 
BMP Bone morphogenetic protein 
BrdU 5-bromo-2-deoxyuridine 
CATNNB1 catenin (cadherin associated protein), beta 1 
CCSP Clara cell secretory protein 
CCSP-/- Homozygous knock-out for CCSP 
CD133 Prominin 1 
CD14 CD14 antigen 
CD31 Platelet/endothelial cell adhesion molecule 1 
CD34 CD34 antigen 
CD45 Protein tyrosine phosphatase, receptor type, C 
CF Cystic fibrosis 
CFTR Cystic fibrosis transmembrane conductance regulator 
CGRP Calcitonin gene-related peptide 
CLD Chronic Lung Disease 
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CldU 5-Chlor-2-deoxyuridine 
CRE Cre recombinase 
DAPI 4',6-diamidino-2-phenylindole 
ECM Extracellular matrix 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
EMTU Epithelial mesenchymal trophic unit 
ERRFI1 ERBB receptor feedback inhibitor 1 
GATA-6 GATA binding protein 6 
GCV Ganciclovir 
HSV-tk Herpes simplex virus-thymidine kinase 
IdU 5-Iodo-2-deoxyuridine 
IL-6 Interleukin 6 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene  
LCC Large cell carcinoma 
LGALS1 Lectin, galactose binding, soluble 1 
LPS Lipopolysaccharide 
MALDI-TOF Matrix-assisted laser desorption/ionization-Time of flight 
MMP-7 Matrix metallopeptidase 7 
MS Mass spectroscopy 
MUC5AB Mucin 5AB 
MUC5AC Mucin 5AC 
NEB Neuroepithelial body 
NFATc1 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
Nf-KB Nuclear factor kappa B 
Nkx2.1 Nk2 homeobox 1 
NSCLC Non-small cell lung cancer 
P38 Mitogen-activated protein kinase 14 
PCL Pericilliary layer 
PI3K Phosphatidylinositol 3-kinase 
PLAT Plasminogen activator, tissue 
PLAUR plasminogen activator, urokinase receptor 
PNEC Pulmonary neuroendocrine cell 
PTEN phosphatase and tensin homolog 
Sca-1 Lymphocyte antigen 6 complex, locus A 
SCC Squamous cell  carcinoma 
SCID Severe combined immunodeficiency 
SCLC Small cell lung cancer 
SP-C Surfactant protein C 
STAT-3 Signal transducer and activator of transcription 3 
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TIMP1 Tissue inhibitor of metalloproteinase 1 
TLR4 Toll-like receptor 4 
TNC Tenascin C 
TNFRSF12A Tumor necrosis factor receptor superfamily, member 12A 
TNF-α Tumor necrosis factor-alpha 
TWEAK Tumor necrosis factor-like weak inducer of apoptosis 
vCCSP Variant CCSP expressing cell (aka vClara) 
vClara Variant Clara cell (aka vCCSP) 
WNT wingless-related MMTV integration site 
WT Wildtype 
α-SMA actin, alpha 2, smooth muscle, aorta 
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